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ABSTRACT 
This thesis reviews the major aetiological and treatment 
literature on premenstrual syndrome and concludes that 
methodological inadequacies, particularly subject selection 
and retrospective measurement, leaves the area in 
considerable disarry. Thus the first aim of the experiment, 
was to examine the relationship between a single interview 
selection proceedure and the symptom data collected over time 
subsequent to this interview 
The second aim of the experiment was to use treatment 
expectations to oppose negative expectancy and so further 
examine the adequacy of subject selection procedures. 
The third aim of the experiment was to collect 
sufficient prospective data to be able to use frequency 
domain time series analysis (spectral analysis) as an 
alternative to visual and non-probablistic methods of 
determining cyclicity 
Forty two subjects who reported symptoms of premenstrual 
syndrome were recruited. The first interview, during the late 
luteal phase, was based upon the rating scales of Steiner et 
al. (1979). Daily mood and symptom data were collected for the 
next three or four menstrual cycles, at which time a second 
interview was held. Thirty subjects agreed to continue 
recording for additional treated cycles, at the conclusion of 
which a third interview was held. 
Groups constitued on the basis of self-reported severity 
do vary significantly with respect to prospectively recorded 
mood symptoms but not with respect tp physical symptoms nor 
incidence. The overlapping variance between the retrospective 
interview ratings of severity and prospectively recorded 
symptoms is small but best predicted by a simple Visual 
Analogue Scale rating of the previous months symptom 
severi ty. 
Placebo induced treatment expectations significantly 
reduced incidence, premenstrual aversive mood and physical 
symptoms. Repeated use of the interview questionniares do not 
show major overlapping variance and post-treatment ratings of 
symptom severity do not show a significant relationship with 
the symptom records collected during treatment. Again the 
rating of the previous month on a Visual Analogue Scale was 
the best predictor. 
The use of spectral analysis was successful in 
identifying both menstrual and non-menstrual cyclicity. Its 
use suggested three criteria for selecting subjects. They 
should have a menstrual length peak in both mood and physical 
symptom spectral density functions. These two series should 
show significant coherence over the range of significant 
menstrual period spectral density peaks. Finally these 
features should not be lost when placebo treatment is given. 
It was concluded that the use of the above criteria and 
the use of both conventional and spectral density methods 
would be likely to reduce the confusion and uncertainty 
within the area and be an appropriate means of evaluating 
potential treatments. 
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SECTION ONE - LITERATURE REVIEW 
CHAPTER ONE - CLINICAL MANIFESTATIONS 
1-1 INTRODUCTION 
The classic definition of premenstrual syndrome (PMS) is 
generally acknowledged to be Frank's (1931), 
"The group of Homen to whom I refer 
especially complain of a feeling of indescribable 
tension from ten to seven days preceding 
menstruation Rhich in most cases, continues until 
the time that the menstrual floR occurs. These 
patients complain of unrest, irritability, "like 
jumping out of their skins", and a desire to find 
relief by foolish and illconsidered actions. Their 
personal suffering is intense and manifests itself 
in many and sometimes reprehensible actions. Not 
only do they realize their ORn suffering but they 
feel conscience-stricken tORards their husbands and 
families, knowing Rell that they are unbearable in 
their attitudes and reactions. Within an hour or 
tHO after the onset of the menstrual floR complete 
relief from both physical and mental tension 
occurs"( p1 054) . 
Although clearly manifesting a sympathetic if slightly 
bemused outlook, this historic description of the syndrome, 
has precipitated a body of literature of large, and confused 
proportions. Almost all authors have developed a relatively 
idiosyncratic cluster of defining symptoms. In short there 
would appear almost no limits to the number of possible 
symptoms, particularly when one considers the linguistic 
licence used. In excess of 150 symptoms have been associated 
wi th the menstrual cycle (Moos, 1969), Recent reviews have 
reduced this list to 42 commonly reported or used symptoms 
( Rubi now 8. Roy-Bryne, 1984), (Table 1). 
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TABLE 1 -1 
COMMON SYMPTOMS OF PREMENSTRUAL SYNDROME 
AFFECTIVE AUTONOMIC 
sadness 
anxiety 
anger 
irritability 
labile mood 
COGNITIVE 
decreased concentration 
indecision 
paranoia 
"rejection sensitivity" 
suicidal ideation 
PAIN 
headache 
breast tenderness 
joint and muscle pain 
NEUROVEGETATIVE 
insomnia 
hypersomnia 
anorexia 
craving for certain foods 
fatigue 
lethagy 
agitation 
libido change 
nausea 
diarrhea 
palpitations 
sweating 
CNS 
clumsiness 
sei2ures 
di22iness 
vertigo 
paresthesia 
tremors 
FLUID/ELECTROLYTE 
bloating 
weight gain 
oliguria 
edema 
DERMATOLOGICAL 
acne 
greasy hair 
dry hair 
BEHAVIOURAL 
decreased motivation 
poor impulse control 
decreased efficiency 
social isolation 
From "Premenstrual Syndromes: Overview From a 
Met hodol ogi c Pe rs pec t i ve II by D. R. Rubinow and 
P. Roy-Bryne, 1984, American Journal of 
Psychiatry, !..!.1., P170. 
The adequacy with which authors report their diagnostic 
criteria, shows similar variation and vagueness. For example 
some authors merely state that subjects had PMS without 
describing it further (Dalton, 1984), while others at least 
provide some diagnostic information, even if the outcome 
might seem to refer to another orthogonal condition (Barr, 
1984) 
A recent trend is to identify a cyclic state rather than 
symptoms. This is commented on with respect to its 
association with the onset of menstruation (Osmun, Steiner, 8. 
Haskett, 1983). To this extent there would seem to be a 
consensus that PM~ is a cyclical disorder, manifested by a 
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considerable variety of both physic~l and psychological 
symptoms, that begins around ten days prior to menstruation 
and is resolved with the onset of bleeding (Reid & Yen, 1983) 
Two critical dimensions exist for PMS. Firstly 
symptomatic expression, and secondly the temporal constraints 
with respect to the menstrual cycle. It is proposed to 
examine recent literature separately for these two issues. 
1-2 SYMPTOMATIC EXPRESSION 
Moos (1968; 1969),made one of the first attempts to 
structure this literature. The resulting 47 item Menstrual 
Distress Questionnaire (MDQ), contains eight symptom 
c 1 us ters. These were 1 abell ed pai n, concent ra ti on, 
behavioural change, autonomic reactions, water retention, 
nega t i ve affect, arousal, and cont rol. 
The majority of these items relate to somatic changes 
with psychological symptoms being contained within only two 
categories. This reflects a bias towards total menstrual 
cycle phenomena, and thus dilutes its effectivness as ~ 
standardised rating device for the premenstruum. Other 
limitations include the absence of specific inclusion and 
exclusion criteria which limit the ability of the scale to 
translate changes in mood and behaviour into useful 
diagnostic categories, as well as inadequacies of Moos's 
normative sample since over half were taking oral 
contraceptives and nearly 10% were pregnant (Rubinow & 
Roy-Bryne, 1984). In view of Ruble's work on expectations 
(Ruble, 1977; Ruble 8. Brooks-Gunn, 1979), another limitation 
is the entirely negative wording of the scale, making it 
impossible to respond in a positive fashion. 
Despite its limitations it remains the most widely used 
instrument. Apart from an unproducti ve attempt by Kashi wagi, 
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McClure, and Wetzel (1976), it was all that was available 
until the late seventies. 
More recently, Steiner, Haskett, 8. Carroll (1980), 
responding to the success of Research Diagnostic Criteria 
(RDC) (Spitzer, Endicott, 8. Robins, 1978) for other 
psychiatric syndromes, combined the MDQ with the Multiple 
Affect Adjective Checklist (Zuckerman 8. Lubin, 1965), the 
State-Trait Anxiety Inventory (Spielberger, Gorsuch, 8. 
Lushene, 1970), several Visual Analogue Scales (Aitken 
( 1969); Maxwell (1978», the Hami 1 ton Depression scale 
(Hamilton, 1960), and the Carroll Depression Scale (Feinberg 
et a1., 1979), to produce RDC (table 1-2) and rating scales 
(appendix 2 and 3). 
They identified eight major mood and behavioural 
symptoms, of which five are required for a positive 
diagnosis. While a tightening of diagnostic procedures is 
desirable, they have effectively reversed Moos's (1968) under 
emphasis of psychological symptoms (Rubinow 8. Roy-Bryn~ 
1984). Somatic symptoms are only present in the rating 
scales. They also specifically excluded women with a 
psychiatric history in their sample and relegated such women 
to the status of having PHS secondary to such a disorder. The 
end result is certainly a more homogeneous group but at the 
cost of excluding many women with premenstrual complaints. 
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TABLE 1-2 
RESEARCH DIAGNOSTIC CRITERIA FOR P~EMENSTRUAL 
TENSION SYNDROME 
PRIMARY RECURRENT PREMENSTRUAL TENSION DISORDER 
This category is applied to female subjects in their 
fertile years who do not currently meet the criteria for any 
other psychiatric disorder. 
The psychological and behavioural symptoms included in 
this disorder freguently occur in association with physical 
premenstrual symptoms, ego painful or tender breasts, 
headaches, swelling of the abdomen, breasts or ankles, with 
water retention, weight gain, etc. These are not necessary 
for the psychiatric diagnosis. 
A through D are required. 
A) At least 5 of the following are required for definite 
and 4 for probable as part of a current episode. 
1. irri table, hosti Ie, angry, short-fused. 
2. tense, restless, jittery, upset, high-strung, unable 
to relax. 
3. decreased efficiency, fatigue. 
4. dysphoria, marked spontaneous emotional lability, 
crying. 
5. lowered motor coordination, clumsy, prone to accidents 
(cut finger, break dish etc.) 
6. distractable, confused, forgetful, difficulty in 
concentration, lowered judgement. 
7. change in eating habits (cravings, overeating etc.) 
8. marked change in libido 
B) overall disturbance is so severe that at least one of 
the following is present: 
1. serious impairment soci,ally, with family, at home, at 
school or work. 
2. sought or was refered for help from someone or took 
medication (especially tranquillizers and/or 
diuretics) at least once during a premenstrual period. 
C) premenstrual dysphoric symptoms for at least the six 
preceding menstrual cycles. 
D) Symptoms only during the premenstrual period with 
relief soon after the onset of menses. 
SECONDARY RECURRENT PREMENSTRUAL TENSION DISORDER 
This category is applied for subjects who meet the 
criteria A through D for Primary recurrent premenstrual 
tension disorder but at the same time meet the criteria for 
another psychiatric disorder. 
note. from" Premenstrual Tensi on Syndrome : The 
development of research diagnostic criteria and new 
rating scales" by M. Steiner, R. F. Haskett, and B. J. 
Carroll, 1980, Acta Psychiatrica Scandinavica, 
62, p185. 
The next attempt to structure the symptomatic picture 
was that of Abraham (1980). His major emphasis was the 
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identification of sub-groups based on clinical experience. 
Kerr's (1977) unsuccessful attempt to do this was criticised 
for being based on a presumed endocrinological substrate. 
Abraham (1980) delineated 5 symptomatic subgroups:-
(1) PHT-A. characterised chiefly by anxiety, irritability 
and nervous tension 
(2) PHT-C. by premenstrual increase in appetite, 
cravings for sweets, headaches, palpitations, 
fainting spells and fatigue 
(3) PHT-D. by depression, lethagy, confusion, wi thdrawal 
and suicidal ideation 
(4) PHT-H. by hyperhydration with consequent weight gain 
and oedema 
(5) PHT-P. by general aches and pai ns. 
Abraham (1980) is cri ti cal of Kerr's (1977) presumption 
of aetiology, but does the same using nutrition in place of 
endocrinology. The 19 item scale is not soundly constructed, 
and includes questionable constructs (Rubinow 8. Roy-Bryne, 
1984). Further, it has suffered poorly justified ad hoc 
mo d i f i cat ion. Beg i n i n gas are d u c e dan d r e - 0 r de red H D Q, PH T - P 
and 6 dysmenorrhea items have been deleted without rationale, 
and modifications to the HDQ food items (Abraham, 1980) are 
not justified until three years later (Abraham, 1983). 
Abraham has done little more than postulate another cause, 
and reduce the HDQ, with the likely consequence of decreased 
reliabili ty. 
The most recent development in this area is the 
Premenstrual Assessment Form (PAF), Halbreich, Endicott 8. 
Schact, 1982; Halbreich, Endicott, Schact 8. Nee, 1982; 
Halbreich 8. Endicott, 1982). These authors have developed a 
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95 item assessment device together with two alternate scoring 
systems unipolar and bipolar scales) and a classification 
schema. It is an attempt to provide descriptive clarity, 
measurement reliability and a valid classification system. It 
is the absence of these features which are responsible for 
the inconsistency in studies which attempt to relate 
biological changes to premenstrual changes (Ha1breich, 
Endicott, Schact, 8. Nee, 1982). They are also cri tical of 
previous attempts such as Steiner et a1., (1989) and 
Kashiwagi et a1., (1976) because these provided a specific 
definition of a single premenstrual syndrome and thus avoided 
the issue of classification. 
The arguments for classification are threefold 
(Ha1breich 8. Endicott, 1982). 
1). Differentiation aids investigative clarity with 
respect to patterns of change. 
2). Differentiation helps clarify relationships between 
change and other variables. 
3). Differentiation between affective and physical 
changes has already proved useful, (Kashi wagi et a1., 1976; 
Wetzel, Reich, McClure, 8. Wa1d 1975; Diamond, Rubinstein, 
Dunner, 8. Fieve 1976; Cu11berg, 1972). 
Ha1breich 8. Endicott (1982) favour a categorical rather 
than dimensional approach to classification (Maxwell 1972). 
Although this issue is peripheral to the current discussion, 
their conclusion that the advantage of the categorical 
approach is to facilitate the selection of subgroups of 
subjects, has a parallel with the disputed category of 
pseudodementia. In this sense they seem to be alluding to a 
treatment-diagnosis feedback process in which diagnosis is 
sha ped by t rea tment res ponse. Thi s pragma tic, at he oret i cal 
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approach to management has advantages and is an intermediate 
step in developing theoretical understanding. 
While accepting the need for subtyping, Halbreich & 
Endicott's (1982) evidence in support, is unconvincing. 
K ash i wag i eta 1., (1 976), Wet z e 1 eta 1., (1 975), and D i a mo n d 
et a!., (1976) suggest affecti ve symptoms may be PHS 
symptoms, but are more likely to be a substrate with 
premenstrual exacerbation. To this extent little has been 
added to Steiner et al.' s (1980) category of Secondary 
Recurrent Premenstrual Tension Disorder (table 1-2). Some 
support does come from Cullberg's (1972) findings that women 
without premenstrual irritability do as well on oestrogen 
dominant oral contraceptives as on placebo with respect to 
negative symptoms. 
For any classification system, two questions need to be 
answered. (1) how adequate is the questionnaire on which the 
classification system is built. (2) how adequate is the 
classification system itself. 
There is a need for a questionnaire which covers a broad 
but clear variety of symptoms, and is sensitive to change in 
severity (Halbreich, Endicott, Schact, & Nee, 1982) To 
achieve these aims the PAF differs from other procedures in 
four major ways, (1) individualised definition of the time 
period covered; (2) specificity of item definition; (3) 
broadness of coverage; and (4) focus on severity of change. 
To some extent these differences have been achieved, but 
not without difficulty. The major problems are (a) the 
predominance of sophisticated retrospective jUdgements 
required of subjects; (b) the contradiction in practice of 
aiming for broad coverage and item specificity without undue 
length; and (c) the method of selecting items. The first, a 
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largely methodological problem, will be examined in greater 
depth in Chapter 4. 
The second problem is illustrated by the question, 
"miss time at work because of premenstrual changes". To 
ensure coverage this requires other equally specific items 
relating to work performance. Instead they include the 
non-specific and vague question, "Have lowered performance, 
output, efficiency or ease in tasks at work, at home, or with 
hobbies etc". 
Finally, an initial pool of 200 items, generated from 
the Ii terature and suggestions of 40 female staff, was 
informally red uced, to 150, by delet i ng those items 
describing similar types of change. This was reduced to 95 
items using item frequency and intercorrelations generated by 
154 normal women recruited from research institute employees 
and student nurses. This assumes the only difference between 
PMS sufferers and normals is 'symptom severity. It is quite 
possible that a clinical sample would have resulted in 
different items being selected. 
A classification system with subtypes would have 
con sid era b 1 e uti 1 i t y. Ha 1 b rei c han dEn d i cot t· s (1 982) s ys t e m 
emphasises the categorical or typological approach (Fliess, 
1972), and has a dimensional parallel (Maxwell, 1972). The 
major strength of their typology is that it has no obvious 
aetiological basis. However, evidence in support of the 
typology is presented in the form of its ability to 
differentiate between sets of symptoms. This was the 
expectation that one set of symptoms will not occur in the 
presence of another set. Visual analysis of their table, they 
suggest, shows the degree of differentiation to be 
i mpressi ve. Certai nly anxi ety( nondepressed) and 
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irritability(nondepressed) discriminate quite well. However 
between 66-100% of subjects reaching the criteria for all 
categories (except anxiety(nondepressed», are also 
classified as suffering from general discomfort. An 
additional problem is again the use of normal subjects. That 
they provide a more exacting test (Halbreich & Endicott, 
1982) is debatable. Discriminant Function Analysis, on a 
clinical sample, would provide more impressive evidence. 
This typology still has potential. The absence of an 
obvious aetiological model is a major strength. However, the 
critical test of any system is its ability to predict 
treatment response. The lack of speculation about what could 
function as therapeutic agents for each subtype, makes this 
more difficult. 
Rubinow & Roy-Bryne (1984) suggest the PAF is the best 
way of selecting patients with similar symptom profiles. Its 
utility remains to be demonstrated with a clinical 
population. Despite this reservation, the PAF is the most 
promising, comprehensive, yet manageable device, currently 
available. 
1-3 PREVALENCE 
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Given the diagnostic difficulties discussed above, it is 
not surprising to find major discrepancies in the estimates 
of prevalence (table 1-3). For example, Sutherland and 
Stewart (1965) found only three percent of their healthy 
sample were not classified as suffering from some 
premenstrual discomfort. They used a general definition, 
based on cyclicity with a loose timing requirement. By 
restricting symptoms to swelling, irritability, and 
depression they were able to reduce incidence to 38.7%. This 
left 58% of their young subjects claiming some discomfit 
which was, in their view, of insufficient severity to be 
classified. 
1 1 
Prevalence estimates range from about 20% to almost 100% 
(Coppen & Kessel, 1963). It is difficult to partial out 
diagnostic variability, from variations in sample 
constitution. While under more ideal circumstances this 
latter variance would be of intrinsic interest, it adds to an 
already clouded picture. 
TABLE 1-3 
PREVALENCE OF PREMENSTRUAL SYNDROME 
Authors 
Bickers & Woods (1951) 
Rees (1953a) 
Lamb, Ulett, Masters 
% with PMS 
36 
44 
& Robinson (1953) 73 
Penni ngton (1957) 95 
Appleby (1960) 29 
Coppen & Kessel (1963) 25 
Sutherland & Stewart (1965) 39 
Clare (1981) 77 
Study Sample 
Factory Workers 
Normal Women 
Student Nurses 
Normal Women 
GP Attenders 
Community Survey 
Normal Women 
GP Attenders 
In essence, the prevalence of PMS, is unknown. 
Definitive statistics awaits the acceptance of more precise 
diagnostic procedures. 
1-4 ASSOCIATED PHENOMENA 
A considerable literature exists on the relationship 
between PMS and a variety of other conditions and behaviours, 
much of it confounded by methodological problems, The 
relationship between PMS and neurosis, and PMS and 
personality traits, is reviewed in chapter 3, The 
relationship between PMS and psychotic disorders, 
dysmenorrhea, ovulation and contraceptive medication, 
suicide, and atypical episodic behaviour such as criminal 
acts, will be reviewed because of the relevance to 
methodological issues raised in this thesis. The large 
literature seeking evidence for menstrually related changes 
in objectively measured aspects of functioning, such as 
cognitive processing, and sensory sensitivity changes has 
been well reviewed by Parlee (1973) and is not central to 
this thesis, 
1-4-1 PsYchotic Disorder. 
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There are a number of studies that support the view that 
many reccurent psychotic illnesses become acute or florid 
more often in the premenstrual phase than would be expected 
by chance (Smith, 1975), 
This literature has been developed, with particular 
respect to primary affective disorder (Kashiwagi et al., 1976; 
Diamond et a!., 1976 and Haskett, Steiner, 8. Carroll, 1984>, 
This has both theoretical and practical implications. The 
possibility that PHS may be a model for recurrent depressive 
conditions or that the reverse is possible, namely that 
endogenous depressive disorder may provide some understanding 
of PHS, is made explicit in Haskett et a!., (1984), Their 
results provide no support for such a connection. The PHS 
group did not have the expected endogenous depression 
responses to the Dexamethasone Suppression Test and cortisol 
secretion. 
The practical significance of the relationship between 
primary affective disorder and PHS is in the need to 
differentiate between PHS and premenstrual exacerbation of a 
preexisting condition. The importance of this discrimination 
is primarily methodological, particularly in the execution of 
treatment trials, Whilst not denying the phenomenological 
significance of premenstrual exacerbation, it seems 
reasonable to exclude such women for trials designed to 
clarify etiology. 
1-4-2 Dysmenorrhea 
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There is strong evidence for a clinical association 
between PHS and dysmenorrhea (Perl', 1958; Coppen, & Kessel, 
1963; Argonz, & Abi nzaro, 1950; Paulsen, 1961; Herzberg, & 
Coppen, 1970). However, they are differentially predicted by 
parity, increments in which are associated with increasing 
PHS and decreasing dysmenorrhea (Reid, & Yen, 1981). There is 
also evidence that PHS is associated with both ovulatory and 
anovulatory cycles, (Adamopoulus, Loraine, Lunn, Coppen, & 
Daly, 1972), whereas dysmenorrhea occurs wi th ovulatory 
cycles, (Reid, & Yen, 1981). It is clear from the attempts at 
defining PHS, reviewed above, and from the observations that 
the two disorders are frequently associated, that 
differentation is important in the selection of subjects. 
1-4-3 Oral Contraceptives 
Controversy exists with respect to the relationship 
between oral contraceptive use and PHS. Reid and Yen (1981) 
summarise the positive support for the use of these 
medications in treating PHS, as coming from uncontrolled 
studies (Hoos, 1968; Hears, & Grant, 1962; Herzberg, Johnson, 
& Brown 1970; Royal College of General Practi tioners, 1974; 
Kutner, & Brown, 1972; Hi Ison, & Sol veIl, 1962). These 
potentially confused PHS symptoms with those of dysmenorrehea 
(Perl' 1958; Coppen & Kessel 1963; Argonz & Abinzoro 1950; 
Paulsen 1961; Herzberg & Coppen 1970). For most symptoms, 
large increases can be found amongst oral contraceptive 
users, while at most only a small decrease in PHS has been 
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noted (Royal College of General Practitioners, 1974; Mears & 
Grant 1962; Grant 1975). 
Given the possible therapeutic status, and the 
interference to the basic hormonal substrate, subjects taking 
oral contraceptives should be excluded from trials. This does 
however potentially bias available subjects. 
1-4-4 Infrequent Behavioural Events 
Suicide and criminal acts such as violent offending have 
been frequently studied in relation to menstrual cycle phase. 
MacKinnon, MacKinnon and Thompson's (1959) study on 
completed suicide, found 89% occurred within days 15-23 of a 
standardised menstrual cycle. They also found deaths by 
natural causes (84%), and accidents (90%) to have higher than 
expected frequencies. Birtchnell and Floyd (1974) and Buckle, 
Linnane, and McConachy, (1965) have criticised the assumption 
of a standard menstrual cycle and suggest the critical luteal 
phase ought to be defined in relation to the next onset of 
bleeding. This is especially important given the evidence 
that emotional stress can delay (Lloyd, 1962) or preci pi tate 
the onset of bleeding (Benson, 1964). If the luteal phase is 
determined by using the 12-16 days preceding the next 
expected menstrual period, then no significant differences 
were found in cycle phase for 76 attempted suicides 
( Bi rtchnell & Floyd, 1974). Bi rtchnell and Floyd (1975), 
matched 107 female suicide attempters with 110 age controls, 
and found comparable proportions of premenstrual emotional 
disturbance. Mandell and Mandell (1967) studying suicide 
prevention in 87 subjects suggested that there were peaks in 
first, middle, and last sevenths of a standardised cycle. In 
-
addition to the problems of actual cycle length, it is at 
least possible that women only perceive being early, middle, 
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or late in the cycle, and so respond in this fashion, (Clare, 
1983 ) 
The major studies that are frequently cited with respect 
to cri mi nal acts are those of Morton, Addi ton, Addi son, Hunt, 
and Sullivan (1953), and Cooke (1945). The former is 
methodologically sounder than most, but fails to state either 
the definition of cycle phase, or the method of determination 
(Parlee, 1973). Cooke's study merely cites the Parisian 
Prefect of Police who stated that 84% of all crimes of 
violence are perpetrated during the premenstrual or early 
menstrual phase. 
Other infrequent behaviours that have been linked with 
the menstrual cycle include taking a child to a medical 
clinic (Dalton, 1966) and loss of control of an aircraft 
( Whi tehead, 1934) 
In essence the data linking infrequent but well defined 
behavioural events to the menstrual cycle are at best weak, 
and at worst unhelpful. Even if the association were clear 
cut, it does not logically follow, that women who have not 
emitted the behaviour are more likely to do so during a 
particular cycle phase (Parlee, 1973). Therefore, results 
reported in this literature, have no predictive power for the 
population at large. 
CHAPTER TWO - BIOCHEMICAL THEORIES 
2-1 INTRODUCTION 
Given the methodological difficulties to be discussed in 
chapter 4, it is not surprising to find this area of 
literature in considerable disarray. It is also not 
surprising to find authors commenting on the lack of 
definitive progress in the fifty or so years since Frank 
(1931) first suggested the existence of a biochemical 
substrate for the syndrome (eg. Lancet Edi tori aI, 1981). 
The biochemical literature contains three major 
vi ewpoi nts. PMS is one homogeneous di sorder, or a group of 
related syndromes, with menstrual cylicity in common, or 
alternatively, a disorder of centrally located biochemical 
processes, which act in concert with peripheral systems to 
produce a pathoplastic clinical picture (Reid & Yen, 1981) 
Independent of which of these directions of 
investigation result in the m6st useful data, there a~e 
methodological difficulties that have a marked clouding 
effect. Subject selection procedures, the population studied, 
the use of retrospective self-report, and the varying symptom 
clusters accepted, are likely to lead to an initial 
over-reporting of symptoms, and, as a consequence, to the 
overvaluing of both drug and placebo responses. 
A further complication in reviewing this literature is 
that most authors neglect to acknowledge interactions between 
the hormone systems or the relatively non-specific action of 
the various compounds used to alleviate symptoms and so 
provide evidence for the particular theory. 
In this chapter of the review it is planned to (1) 
overview hormonal changes in the normal menstrual cycle, (2) 
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give a brief overview of each of the competing biochemical 
aetiological theories. and (3) evaluate the evidence 
supporting these. 
2-2 HORMONAL CHANGES IN THE MENSTRUAL CYCLE 
Steiner and Carroll (1977) summarise the menstrual 
biochemical process as follows. 
"In response to a hypothalamic releasing 
factor, the anterior pituitary produces 
follicle-stimulating hormone (FSU) which stimulates 
the development of the ovarian follicles and causes 
constant estrogen secretion during this phase of 
the cycle. Estrogen secretion rises to a peak at 
mid-cycle when, through a hypothalamic feedback 
mechanism, a surge of lutenizing hormone (LU) 
occurs together with a peak of FSH release. 
Ovulation then occurs and the corpus luteum begins 
to secrete progesterone. This is termed the luteal 
phase of the cycle. If fertilisation of the ovary 
has not occured, then progesterone secretion begins 
to decrease about 6 days prior to menstruation. 
Estrogen secretion from the ovary also begins to 
fall at about the same time" (p 323). 
A variety of other hormone systems are reported as 
showing cyclical variation during the menstrual cycle. It is 
planned to review these briefly. 
In a normal menstrual cycle there is a greater 
variablility of prolactin (PRL) secretion, during the luteal 
phase than exists within the follicular phase (Steiner & 
Carroll, 1977; Carroll & Steiner, 1978). It is clear from 
these reviews that variablility exists between women and 
potentially within individuals across cycles. The literature 
they cite fails to discriminate between normal and deviant 
cycles. 
Adrenocorticotrophin hormone (ACTH) and cortisol show a 
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cyclical pattern of lower follicular levels, modest increases 
at ovulation and a small decrease premenstrually (Genazzani, 
Lemarchand-Beraud, Aubert, & Felber, 1975). Limited 
methodological sophistication, in this study, makes these 
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observations difficult to accept at face value. 
The mineralocorticoids, particularly aldosterone (ADS), 
has been studied quite intensively. A two fold increase in 
both ADS excretion in the urine and secretion rate has been 
reported (Reich, 1962; Gray, Strausfeld, Wantanabe, Sims, & 
Solomon, 1968; Schwatz & Abraham, 1975), ADS levels, in 
ovulatory cycles, reach a peak at about 9-10 days before 
menstruation and drop rapidly 6-7 days before bleeding begins 
(Katz & Romfh, 1972; Michelakis, Yoshida & Dormois, 1975). 
These changes were not found in annovulatory cycles. Other 
mineralocorticoids, such as desoxycorticosterone and 
corticosterone, follow a similar pattern (Schwart2 8. 
Abraham, 1975; Manlimos, Maroulis & Abraham, 1975). 
A similar pattern also exists for plasma angiotensin, in 
that there are significantly elevated levels in the luteal 
phase when compared to the follicular phase, (Sundsfjord & 
Aakvaag, 1970), This is thought to be a function of increased 
progesterone secretion, during the luteal phase, which leads 
to sodium loss through the kidneys, which leads in turn to 
increased secretion of renin and angiotensin, which in turn 
leads to an increased secretion of ADS (Steiner & Carroll, 
1977). The slightly lagged response in ADS to renin during 
the luteal phase supports this, (Katz & Romfh, 1972). as does 
the finding of no changes in plasma ADS levels or plasma 
renin activity in annovulatory cycles (Michelakis et. a1., 
1975), given that progesterone secretion does not rise during 
the luteal phase in such cycles. 
Androgens, oestrogen and PRL are reported to show 
mid-cycle peak levels (Judd & Yen, 1973; Abraham, 1974; 
Abraham & Chakmankj ian, 1973). 
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2-3 BIOCHEMICAL AETIOLOGICAL THOERIES 
The first biochemical theory suggested reduced renal 
excretion of estrogen was responsible for PMS (Frank, 1931). 
This is possibly the only theory which considers oestrogen in 
the absence of progesterone and as such is considered crude. 
The field has increased considerably in sophistication since 
this time but as noted above this has not resulted in an 
equivalent progress. The review which follows is not 
exhaustive but rather illustrative of such endeavours. 
2-3-1 Oestrogen/Progesterone Theories 
Theories in this area are of 4 general forms, (1) a 
relative deficit of progesterone, (2) a relative deficit of 
oestrogen, (3) an idiosyncratic sensitivity to oestrogen, (4) 
withdrawal of either progesterone or oestrogen (Steiner & 
Carroll, 1977). These posi tions postulate ei ther an oestrogen 
excess or progesterone deficit, the latter resulting in a 
relati ve oestrogen predomi nance, and are based on 
progesterone having a modifying effect upon oestrogen. 
Unopposed oestrogen results in fluid retention, breast 
enlargement and tenderness (Morton, 1959) and its 
accumulation in the limbic system causes the CNS 
manifestations of PMS (Backstrom & Mattsson, 1975). 
Support for this position comes from using progesterone 
to significantly alleviate symptoms (Dalton 1964), oestrogen 
injections producing similar symptoms (Morton, 1950), and 
studies which link raised oestrogen levels, low progesterone 
levels, and high ratios of oestrogen/progesterone with 
symptoms (Backstrom & Mattsson, 1975; Munday, Brush, & 
Taylor, 1977; 1981). However there have been many reports of 
adequate corpus luteal function in patients with PMS (Bickers 
& Woods, 1951; Lamb, Ulett, Masters, & Robinson, 1953; 
Andersch, Hahn, Wendestam, Ohman, & Abrahamsson, 1978i Gray, 
1941; Greenblatt, 1940) 
There is some evidence that premenstrual anxiety is 
associated with low progesterone or oestrogen alone 
(Backstrom & Carstensen, 1974; Backstrom & Mattsson, 1975). 
However insufficient detail makes interpretation difficult. 
It is possible that what makes the oestrogen/progesterone 
ratio significantly different between the experimental and 
control groups is a transient reduction in inter-subject 
variance. Subjects wi th premenstrual depression show no 
differences in plasma progesterone across phase and 
predictably show no improvement when treated with 
progesterone injections (Smith, 1975). Subjects who .have 
responded to progesterone injections, suffered from anxiety, 
hostility, and irritability (Steiner & Carroll, 1977). 
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It is possible that these subgroups do reflect 
differential changes in the oestrogen/progesterone ratio, 
however double blind trials ot progesterone have not ahown 
significant results (Sampson, 1979). It is not clear what 
type of patient Sampson was using, and it possible that the 
doses used were less than Dalton's recommendations, which are 
greater than required to achieve normal luteal levels (Reid 
& Yen, 1983). It is possible that pharmacologic doses of 
progesterone may have some unknown central effects (Reid & 
Yen, 1983). Thi s concl us i on seems ge ne rous. 
2-3-2 Vitamin Deficiency 
The original interest in vitamin B complex was 
stimUlated when a deficiency was found to impair oestrogen 
metabolism in rats. This was not confirmed in humans (Reid & 
Yen, 1981). Renewed support followed the di scovery t ha t 
vitamin B6 acts as a coenzyme (pyridoxal phosphate) in the 
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production of dopamine and serotonin (Dennerstein 8. Abraham, 
1982) and significant improvements in a double blind trial of 
depression associated with oral contraceptives (Adams, Rose, 
Folkhard, Wynn, Seed, 8. Strong 1973). It is speculated that 
oestrogen generates, by altering tissue distribution and 
inducing competitive hepatic enzymes, a relative deficiency 
of B6 and therefore dec reased serotoni n, and dopami ne, wi t h 
depression and increased prolactin (Rose, 1969; 1978; 
Andersch, Hahn, Wendestam, et al. 1978; Halbriech, Assael, 
Ben-David, 8. Bornstein, 1976; Benedek-Jaszmann 8. 
Hearn-Sturtevant, 1976). If B6 could augment dopamine 
production then this should result in beneficial effects, 
however no study has demonstrated a significant dopaminergic 
effect (Reid 8. Yen, 1981). This casts doubt upon the 
rationale for using B6 in the treatment of PMS. 
Uncontrolled trials, of B6, report positive results 
(Winston, 1969; Baumblatt 8. Winston, 1979; Kerr, 1977). 
However, a more controlled st~dy was negative, (Stokes 8. 
Mendels, 1972). 
2-3-3 Fluid Retention 
An enormous amount of interest has been directed towards 
looking for factors causing fluid retention and evaluating 
diu I" e tic s as t I" eat me n t s (R e i d 8. Yen, 1 981 ) . 
Early work suggested PMS was the result of cyclic, 
ovarian activity induced, increases in extracellular fluids 
(Greenhill 8. Freed, 1941). If this occurred in the brain, 
gastrointestinal tract, or labia, then headaches, distention, 
or pruritis, respectively, will occur. This reflects a 
simplistic veiw of PMS symptomatology. What amounts to random 
changes have been found where weight change has been used as 
an indirect measure of fluid balance (Reid & Yen, 1981). 
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Studies using more sophisticated techniques found no 
differences between follicular and luteal phases in either 
total exchangable sodi urn or body water (Andersch, Hahn, 
Andersson, & Isaksson 1978; Preece, Richards, Owen, & Hughes, 
1975). 
While it has been suggested that there is a relationship 
between the degree of premenstrual weight gain and the 
severi ty of symptoms (Bickers & Woods, 1951; Abramson & 
Torghele, 1961; Janowsky, Berens, & Davis, 1973), most 
authors have not been able to establish a pattern of weight 
gain, (Mattsson & Schoultz, 1974; Bruce, & Russel, 1962; nor 
find any relationship between degree of fluid retention and 
severi ty of PMS symptoms other than oedema (Appleby, 19613; 
Bruce & Russell, 1962; Gol ub, Menduke & Conley, 1965; Lamb, 
Ulett, Masters, & Robinson 1953). 
Controlled studies of diuretics failed to find 
significant improvement (Mattsson & Schoultz, 1974; Jordheim, 
1972; Andersch, Hahn, Andersson & Isaksson, 1978). 
The lack of support for fluid retention, has not 
deterred investigators and some of the more elaborate 
hormonal/neurotransmitter propositions involve this fluid 
retention concept. 
2-3-4 Renin-Anqiotensin-Aldosterone (RAA) Axis 
A close parallel between negative affect scores and body 
weight, lead Janowsky et a1. (1973), to speculate that the 
underlying mechanism could be the direct action of 
angiotensin. However, they confuse depression and 
irritability, and more recent studies suggest that RAA 
activity decreases at around 6 days preceeding menstruation, 
thus making its involvement unlikely, In addition, there is 
evidence for PMS in annovulatory cycles (Adamopoulous et al., 
1972). where RAA and progesterone levels are not variable 
(Steiner 8. Carroll. 1977). 
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The position is, indeed. more complex in that (1) both 
oestrogen and progesterone interact with the RAA axis, (2) 
both oestrogen and progesterone act independently with 
respect to fluid retention. (3) there is a relationship 
between dopamine and ADS excretion. and (4) stress or anxiety 
is known to enhance ADS excretion (Reid 8. Yen, 1981). 
At this stage, given the additional contentious nature 
of the fluid retention literature. the involvement of the RAA 
axis. remains inconclusive. 
2-3-5 Prolactin 
Self-observation, by Horrobin, following injection of 
PRL, first suggested the idea that it could playa major role 
in the premenstrual syndrome (Reid 8. Yen. 1981; Carroll 8. 
Steiner, 1978). More specifically. premenstrual depression 
may be the result of elevated PRL levels in conjunction with 
high oestrogen or progesterone dominance. ~nd premenst~ual 
irritability, elevated PRL levels with low progesterone 
(Carroll 8. Steiner, 1978). 
The major evidence cited in support of this position is 
the study by Benedek-Jaszmann & Hearn-Sturtevant (1976). 
However, these authors did not impressively demonstrate high 
PRL nor cyclic changes, nor did they adequately specify what 
psychological disturbances were suffered by their subjects. 
Further confusion results from the use of subjects recruited 
for an infertility clinic with annovulatory cycles and short 
luteal phases. 
Halbriech, et a!. (1976), are also cited as providing 
direct evidence for the PRL position (Steiner & Carroll, 
1978). However, these authors suggest that previous studies 
show no cyclical changes in PRL secretion and their findings 
were characterised by large individual variation. They also 
found no correlation between serum PRL and symptom rating 
scales, and stress related increases in serum PRL. 
The PRL hypothesis is also linked to the contentious 
fluid retention literature, on the basis of an association 
between premenstrually occuring oedema and dysphoria, and 
that it is the only hormone which leads to retention of 
water, sodium, and potassium (Steiner & Carroll, 1978). 
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Reid and Yen (1981) extend Steiner and Carroll's review 
and come to the opposite conclusion. Some recent studies have 
found elevated luteal phase PRL levels in PMS patients 
(Andersch, Hahn, Hendestam, et a1., 1978), whi Ie other 
fi ndi ngs have been equi vocal (Andersch, Abrahamsson, 
Hendestam, Ohman, & Hahn, 1979; Anderson, Larsen, Steentrup, 
Svendstrup & Nielsen, 1977). Controlled clinical trials of 
bromocriptine, a PRL suppressant, in the treatment of PMS has 
produced largely equi vocal or 'negati ve restil ts (Andersch, 
Hahn, Hendestam, et a1., 1978; Andersch, Hahn, Anderson et 
a1., 1978; Anderson, et a1., 1977; Graham, Hardi ng, Wi se & 
Berri man, 1978; Andersc h, et a1., 1979; Ghose & Coppen, 
1977) . 
A more recent review of controlled studies using 
bromocriptine, includes aditional studies (Andersch & Hahn, 
1982; Barwin, 1980; Elsner, Buster, Schindler, Nessim & 
Abraham, 1980; Kullander & Svanberg, 1979; Ylostalo, 
Kauppila, Puolakka, Ronnberg & Janne, 1982), but concludes 
that there is little support for bromocriptine as a treatment 
for PMS, beyond symptomatic relief (Andersch, 1983). 
In summary the elaborate theorising with respect to PRL 
has not resulted in much empirical support nor effective 
t rea t ment. That does not nec essari I y mean that PRL has no 
role in generating PHS symptoms but that methodological 
inadequacies are likely to have obscured its involvement. 
2-3-6 Endogenous Hormone Allergy 
A positive skin reaction to injection of steroids in 
women with severe PHS (in the absence of such an effect in 
normal controls) has lead to hypersensitivity to endogenous 
hormones or their metabolites being suggested as a possible 
cause of PHS (Zondek 8. Bromberg, 1945; 1947). Uncontrolled 
studies report an overall 80% success rate, (Henkle, 1951; 
1953; Rogers, 1962; Simmonds, 1956>' As skin reactivity is 
extremely sensitive to several extraneous variables (Henkle 
1949; 1951; Henkle 8. Scherp, 1955) such evidence is seen as 
insufficient (Reid 8. Yen, 1981). 
2-3-7 Neuropeptides 
A central and pituitary based cause of PHS, involving 
the neuropeptides beta-endorphin and alpha-melanocyte 
stimulating hormone, has been 'suggested (Reid 8. Yen, 1981) 
They cite some lower animal research to support this 
position. The central effects, in sensitive subjects, of 
these neuropeptides, and their ability to modify the action 
of neurotransmitters, may produce changes in mood and 
behaviour, as well as affecting the release of other 
pituitary hormones such as prolactin and vasopressin. 
Individual variation in peripheral hormone response to these 
events, could account for the heterogenous clinical 
manifestations observed in PHS (Peck, 1982) 
Beta-endorphin has a complex and interactive function, 
with raised levels being associated with, decreased 
luteinizing hormone, decreased prostaglandin E1, increased 
PRL which further decreases progesterone and leads to an 
25 
26 
increase in oestrogen/progesterone ratio, decreased dopamine 
which leads to an increase in ADS activity and consequent 
fluid retention, as does the increase in vasopressin activity 
with its associated rise in ACTH and ADS (Peck, 1982). An 
increase in b-endorphin is also associated with insulin 
release and consequent changes in blood sugar and appetite. 
This is plausibly complex. Naloxone, a beta-endorphin 
antagonist was given to 12 women in a double-blind trial over 
2 cycles (Peck, 1982). Both placebo and naloxone 
significantly reduced stress scores when compared to the 
baseline level of stress. However the placebo resulted in 
si gni f i cant 1 y greater improvement t han naloxone. Pec k 
speculates that naloxone could have had an aggravating effect 
and that this could be a result of excessive rebound to 
dopaminergic hyperfunction. She neither re-examines the data 
for a predominance of specific dopaminergic symptoms nor does 
she present enough detail for this to be deduced. 
It is not clear from either Peck's (1982) study or that 
of Reid & Yen (1981) what the relationship is between 
beta-endorphin and alpha-melanocyte stimulating hormone. It 
seems possible that if naloxone is a specific antagonist to 
b-endorphin then Peck's study is not an adequate test of the 
hypothesis. It is also possible that subject selection 
factors are again obscuring actual relationships. 
2-4 SUMMARY 
None of the above aetiological hypotheses, nor the 
pharmacological treatments derived from them, have survived 
double blind trials. The lack of methodological rigour and 
compatibility make it difficult to compare studies. In short 
1 itt 1 e pro g res s has bee n mad e sin c e F ran k' s (1 931 ) 
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identification of the syndrome (Lancet Editorial. 1981). 
CHAPTER 3 PSYCHOLOGICAL THEORIES AND TREATMENTS 
3 -1 I NTRODUC Tl ON 
Literature on psychological approaches to PMS is 
relatively sparse. What is available falls into two major 
groups: (1) Historical studies, that relate and implicitly 
explain the PHS on the basis of personality variables. (2) 
Those more recent studies which examine social attitudes and 
associated attributional processes. These two approaches, 
while being dealt with separately in this review, are 
strongly related since the second is a more sophisticated 
outgrowth of the first. A third, minor aspect of the current 
literature concerns evolutionary/sociobiological writing on 
the premenstrual syndrome. 
The role of psychological factors is often disputed. For 
example, some authors suggest that both psychological and 
psychosocial fac~ors account for a minor proportion of the 
variance (Rees, 1953a; James 8. Pollitt, 1974; Steiner 8. 
Carroll, 1977). Others suggest there is considerable evidence 
supporting the importance of psychological and enviromental 
factors (Dal ton, 1964; Coppen 8. Kessel, 1963j Janowsky, 
Gorney, 8. Kelley, 1966; Janowsky, Fann, 8. Davi s, 1971; 
Janowsky et a1., 1973). 
The point argued in this section of the review is that 
neither of these positions are adequate. This area, together 
with the biologically oriented literature, frequently fails 
to appreciate that correlation does not imply cause. In the 
rare occasions that this is acknowledged, predictably the 
evidence is for a moderate position of multiple cause. The 
other major confusion in this area is that frequently authors 
have focused upon total menstrual cycle related distress 
rather than the distress related specifically to the 
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premenstrual phase. 
3-2 PERSONALITY THEORIES 
Some of the earliest work in this area was from writers 
of an analytic orientation. As such, the manifestations of 
PMS were seen as reflecting intense unconscious conflicts 
concerning the female role (Deutsch, 1944; Benedek, 1952; 
Benedek.8. Rubenstein, 1939a; 1939b; Israel, 1938). More 
specifically, PMS is related to a lack of acceptance of 
menstrual function. Menstruation is used to express distress 
which results from other conflicts about enviromental 
situations, interpersonal difficulties, pregnancy and related 
issues. As such menstruation symbolises either a lost child 
or femi ni ni t y. 
There are many problems with the psychoanalytic model. 
One major problem for the theory is the central position 
given to menstruation, in that the bulk of the psychological 
symptoms occur before menstruation Rausch, Janowsky, Risch, 
Judd, 8. Huey, 1982). Thi s may be one of t he reasons for the 
menstrual/premenstrual confusion mentioned above. The other 
major problem, in common with other theoretical models is 
that of correlation vs causality, Pathology and aetiology 
have also been confused in this early work (Vei t, 1955), in 
that dynamic explanations are often just additional 
descriptions of current pathology. Examples of this are, 
dysfunctional mother/daughter relationships (Deutsch, 1944), 
dysfunctional father/daughter and husband/wife relationships 
( I srae 1, 1938), and di s t urbance in pre -pube rt al deve lopment, 
(Veit, 1955). 
Recent literature is less speculative. For example, high 
premenstrual tension scores are related to more disturbed 
family relationships, viewing the menarche and menses as 
stressors and sources of unhappiness, and feelings of being 
less adequate with respect to psychosocial and psychosexual 
roles (Paulson, 1961). 
Levitt and Lubin (1967), Paige (1971), May (1976), 
Fortin, Wittkower, and Kalz (1958) and Shainess (1961) are 
similar in that they each relate menstrual symptoms to 
outdated personality models and conclude descriptively about 
negative menstrual attitudes and their origins. 
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Suarez-Murias (1953) and Lamb et a1. (1953) differ from 
this trend. They indentify problems with such factors as 
marital status, emotionality, life stressors, maternal 
symptoms, preparation and attitude to menarche and 
menstruation, and abnormalities in psychosexual development. 
The real factors are personality type and the enviromental 
setting (Suarez-Murias, 1953). The latter point has been 
developed more fully within an attribution framework, the 
former in the literature looking at the neurotic personality. 
More recent literature his attempted to relate mehstrual 
and premenstrual complaints to neuroticism and a generalized 
psychosomatic complaining (Smith, 1975>' PMS has been found 
to have a higher prevalence in psychiatric patients than in 
normals (Rees, 1 953a). While there were no between-group 
differences on emotional instability or neurosis there was a 
positive correlation between neurotic constitution and PMS. 
Wha tis meant by these 1 abel sis unclear. Poor work rec ord 
was the only discriminably different item of all those listed 
for both emotional instability/neurosis and neurotic 
constitution. The positive correlation between severity of 
neurosis and severi ty of PMS, and between severe PMS and 
maladjustment, are similarly difficult to evaluate. 
In a futher study of 30 women with severe PHS, Rees 
(1953b) concluded that PHS is not primarily a form of 
neurosis, on the grounds that it almost always predates the 
neurosis and further, improvement in either condition is 
independent of the status of the other. 
A study of 500 normal women found symptoms such as 
irritability depression and tension were at a maximum 
premenstrually, and these symptoms together with headaches 
and swelling around the menstrual period were significantly 
associated with Haudsley Personality Inventory (HPI) 
neuroticism scores (Coppen & Kessel, 1963). These findings 
are difficult to evaluate. Of the correlations reported, the 
shared variance accounted for is low, ranging from 3.8% to 
6.6%. Another problem is that the correlations appear to be 
calculated without reference to where in the cycle symptoms 
occured. Thus it is not possible to clarify the combined 
relationship. An extension of this work to psychiatric 
patients (Coppen, 1965) found neurotics but not those with 
affective disorders or schi20~hrenia had, compared with 
controls, an increased frequency of irritability and 
depression premenstrually with menstrual pain and headaches. 
Coppen's conclusion of a strong association between PHS 
symptoms and HPI neuroticism is selective given most 
menstrual problems in psychiatric patients show this 
relationship. It is possible that menstrually related 
symptoms are epiphenomenal to the psychiatric disorder. This 
work has also been criticised because the HPI neuroticism 
scale contains questions a sufferer would answer positively 
as a result of having PHS, rather than these responses being 
a reflection of neuroticism (Smith, 1975). Coppen maintains 
the association remains after the removal of the offending 
items. 
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A later study (Kramp. 1968) does little to clarify the 
position. Of 131 women referred for psychiatric evaluation 
prior to an abortion, 52% of the 50% that suffered PHS are 
reported as having had a neurotic disposition in childhood or 
early youth. 
In summary, there is likely to be a group of women that 
are anxious and may have sex-role adjustment difficulties, 
and are statistically more likely to complain of premenstrual 
irritability (Smith, 1975). There are also many non-neurotic 
persons who suffer similarly. There are strong parallels with 
pain and alcohol research in that considerable effort has 
been expended in the identification of personality 
characteristics of both of these patient groups, and with 
similar lack of success. This is not suprising given the 
outdated personality models these researchers use. 
3-3 ATTRIBUTION THEORIES 
Parlee's (1973) review of the menstrual literature has 
had two direct consequences. tirstly the literature examining 
the personality characteristics of women with premenstrual 
distress has decreased in rate. Secondly there has been an 
increasing amount of theoretical and empirical work being 
done within a social psychological framework using 
attribution theory. It is proposed to examine these 
theoretical and empirical aspects separately. 
3-3-1 Theoretical Position 
The menstrually related literature is based upon an 
assumptive model that sees physiological processes as causes 
wi th psychosoci al phenomena as effects (Ruble, 1977; Parlee, 
1977; Sherif, 1980). As such it is both a physiologically 
reductionist and deterministic model. The literature is 
fraught with methodological problems and rare achievements of 
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experimental requirements. Hence a causative model is 
premature if not inaccurate. Menstrual processes could 
conceivably be a reason for distress not the cause. 
Performance deficits, beyond olfactory and tactile 
sensitivity, are poorly supported and there is little strong 
empirical evidence for the majority of women suffering severe 
cyclic changes on any parameter (Ruble & Brooks-Gunn, 1979). 
An alternative explanation is that the belief in a 
cyclic, hormonal, debilitating phenomenon is held by 
researchers and their subjects (Ruble & Brooks-Gunn, 1979; 
Parlee, 1974), and may in turn influence the existence of 
these symptoms. This risks medicalisation of a normal state 
(Lancet Editorial, 1983). 
Extreme posi tions are taken. The finding that women rate 
themselves and women in general similarly with respect to 
symptoms, has been used to suggest they are therefore 
reacting to or reflecting cultural stereotypes (Parlee, 
1974). It is possible that su~h reports indicate only that 
symptoms associated with the menstrual cycle are common 
knowledge across groups, rather than that the self-report 
reflects other than their own experience (Ruble & 
Brooks-Gunn, 1979). Another argument for the operation of 
cultural stereotypes is that males, over a 35 day period, 
show similar variation in mood and concentration 
difficulties, to women (Sherif, 1980). Given Sherif's sample 
did not suffer from PMS, the lack of difference is not 
surprising. 
Aside from these extreme positions, the important 
question is, how can the development and persistence of such 
biased or erroneous beliefs be explained. Ruble & Brooks-Gunn 
(1979) suggest attribution theory can do this and present a 
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cogent exposition of the possible mechanism. The diagnosis of 
premenstrual change involves the use of two subjective and 
ambiguous sets of information by either the subject or, with 
more difficulty (Irwin, Kammann, So Dixon, 1979), by an 
observer. These are symptoms and the phase of the cycle. 
Using these sets of information, the judge must decide if she 
feels or behaves differently during the premenstrual or 
menstrual phase of the cycle. This involves a considerable 
range of possible behaviours and a large span of time. It is 
likely that differential attention will occur and bias 
perceptions (Ruble So Brooks-Gunn, 1979). Evidence from the 
cognitive and social psychological literature supports the 
bias involvement in such tasks (Tversky So Kahneman, 1974). 
Ruble So Brooks-Gunn (1979) suggest negative beliefs 
about menstrual events may be acquired via three mechanisms. 
Firstly, if events share subjectively similar characteristics 
they can generate plausible, but fallacious causal 
connections (Nisbett So Wilson, 1977; Tversky So Kahnemah, 
1974). Secondly, distinctive events lead to focusing of 
attention, and so two temporally contiguous distinctive 
events frequently lead to illusory correlations (Chapman So 
Chapman, 1967; 1969). Thirdly, the joint occurrence of any 
two events is remembered best. Menstrual phenomena tend to be 
distinctive,and perceived negatively by a proportion of the 
population, as are negative moods and uncomfortable physical 
symptoms. It is therefore possible that some of the reported 
discomfort results from the negative expectations acquired in 
these ways. 
The strengthening of such negative beliefs and 
expectations, can happen in three ways (Ruble So Brooks-Gunn, 
1979). Firstly, distortion of evidence occurs to generate 
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maximum consistency, particularly if the data are ambiguous. 
Secondly, evidence for a belief tends to be detached from the 
belief itself, and thirdly the accessibility of evidence is 
at least in part a function of how the information is labeled 
and coded. 
In summary, Ruble & Brooks-Gunn (1979) are suggesting 
that at least some of the negative symptomatology surrounding 
the menstrual cycle is the result of socio/cultural beliefs 
genera ted by t he above mechani sms. Thi sis opposed tot he 
view that all such symptomatology is determined by the 
biological substrate. They do not deny these latter factors 
are important in generating individual differences, but 
suggest that they are insufficient on their own. 
3-3-2 Empirical support 
The proposed mechanisms of acquisition are supported in 
a study which found menstrually related phenomena were used 
to explain negative but not positive moods, even when the 
environment was described as unpleasant (Koeske & Koeske, 
1973). These findings are consistent with the first two 
acquisition propositions but, being cross-sectional, are 
unable to support the third. Their findings also support the 
proposition that evidence is distorted, as does the finding 
that similar behaviours are evaluated differently when they 
are associated with menstrual or premenstrual days compared 
with other times in the cycle (Ruble, 1977). 
It is possible that natural variation in cycle length 
leads to less awareness of the premenstruum. Oral 
contraceptive users, with regular cycles, made more menstrual 
cycle attributions for symptoms occuring premenstrually than 
non-users (Campos & Thurow, 1978). However, this is weakened 
by possible pharmacological effects and the failure to 
acertain if non users were in fact less able to predict the 
onset of menstruation. 
The lack of cyclicity in hysterectomised subjects 
(Beumont, Richards, & Gelder, 1975) is support for the 
attribution position (Osborn, 1981>. However, continuing 
symptoms have been found (Backstrom, Boyle, & Baird, 1981). 
strong support comes from stUdies which have attempted 
to conceal the purpose of the study and found few cyclic 
changes (Englander-Golden, Whitmore, & Dienstbier, 1978) or 
compared retrospective report and prospective tracking 
(Endicott & Halbreich, 1982) and found less evidence for 
cyclical changes in the latter instance. Futher indirect 
support comes from the high placebo rates reported in 
double-blind drug treatment trials. 
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In summary, the existence of a set of consistent and 
negative beliefs surrounding menstrually related phenomena is 
reasonably well supported, and no doubt contributes to biased 
reporting. The interesting que'stions remain. What proportion 
of the variance can be accounted for in this fashion? 
intervention is likely to succeed? 
What 
CHAPTER FOUR - METHODOLOGICAL PROBLEMS 
4-1 INTRODUCTION 
The major emphasis of the research reported in chapters 
five, six, and seven is to evaluate methodological changes 
designed to overcome problems that exist in this area. Some 
of these problems will be considered systematically in this 
section, as well as being mentioned elsewhere. 
Subject selection is reviewed in section 4-2. Some of 
the central methodological issues to the conventional 
diagnostic process were reviewed in chapter one, for example, 
heterogeneity of symptoms and negatively phrased questions. 
However the critical diagnostic aspect of PMS, the time 
dimension, creates specific problems for measurement 
strategy, and in the detection of cyclicity. These are 
reviewed in sections 4-3 and 4-4, respectively. 
4-2 SELECTION OF SUBJECTS 
Ideally, there is increasing use of more diverse 
populations of subjects as any area of research develops. 
This helps determine the generalisability of the conclusions 
reached. In the PHS literature this process has been 
distorted in two ways. 
Firstly, subjects· origin and characteristics are often 
so poorly described, that it is not possible to adequately 
interpret the results nor integrate them into a wider 
framework. For example, Barr (1984) gave no description of 
his 48 subjects, and also failed to report data of 12 
subjects in the active drug condition, and 18 in the placebo 
condition. Muse, Cetel, Futterman, and Yen (1984) reported 
race, edUcation, parity, but not age, of the 50 women who 
sought eval uati on and treatment. However, only 8 were used, 
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the remainder were dropped for reasons as diverse as having a 
psychotic profile or not being judged sufficiently dependable 
and motivated. No other details were provided. Dalton (1984), 
Similarly reported no details of subjects other than the fact 
that 31 volunteered to help in the study. 
Secondl y, many of the popul at ions s t udi ed are too 
extreme to be credible especially when the range of 
aetiological possibilites are considered. Rubinow and 
Roy-Bryne (1984) list some of the sources of subjects in 
studies which purport to address the question of menstrually 
related mood disorders ie., PMS clinics (Sampson, 1979), 
infertility clinics (Benedek-Jaszman & Hearn-Sturtevant, 
1976), women undergoing gynecological surgery (Beumont et 
a1., 1975), general practitioner patients with and without 
symptoms (Robinson, Huntington, & Wallace, 1977; Clare, 
1977), college students (Moos, 1968), normal women wi th no 
changes (Taylor, 1979; May, 1976) and normal women wi th 
symptoms but not requesting tr'eatment (0' Brien, Craven, 
Selby, & Symonds, 1979). 
PHS clinics are a reasonable source. Similarly a case 
can be made for using subjects showing symptoms while not 
receiving medical treatment, given the controversial nature 
of the disorder. However the use of an infertility clinic 
sample is indefensibile, given the likely presence of unusual 
stressors and possible hormonal substrate differences. 
Although admirable because of its attempt to avoid 
menstruation as a marker for cycle position (Osborn, 1981), 
Beumont et aI's., (1975) study on women undergoing 
hysterectomy, illustrates an unusually narrowly selected and 
potentially highly stressed group of subjects. 
The method of selecting subjects from within a 
population is rarely discussed. One aspect of this selection 
is the criteria for inclusion. Criteria such as menstrual 
regularity, mechanical methods of contraception, absence of 
psychiatric or physical disorder and absence of drug taking 
have been used (Steiner et aI., 1980. Steiner, Haskett, 
Carroll, Hayes, 8. Rubin, 1984; Steiner et aI., 1983). These 
are a minimum, but rarely specified requirement. 
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The second aspect to selecting within a population is 
how adequately do retrospective questionniares predict future 
symptom occurrence. This issue is reviewed in section 4-3. 
4-3 MEASUREMENT STRATEGIES 
One of the eariest reports expressing doubt about the 
adequacy of retrospective report is that of McCance, Luff, 
and Widdowson (1937). Disrepancies between data collected 
daily from 167 women, over 4-6 cycles, and preliminary 
questions, were" so frequent that they throw considerable 
doubt upon the value of any work on this subject based upon 
history or a questionnaire"(p576). This warriing has gon~ 
almost entirely unheeded until recently. Other evidence to 
support this contention comes from Abplanalp, Donnelley, and 
Rose (1979) who found the pattern of significant interphase 
differences reported on thrice monthly MDQ administrations, 
were not replicated in daily Profile Of Mood States records, 
at least with respect to negative affect. In a sample of 
college women (mean age 22 years), May (1976) found no 
relationship between subjects' mood changes assessed at three 
points during the menstrual cycle and their retrospective 
interview accounts. Golub (1976) similarly found no 
correlation between complaints of premenstrual symptoms and 
mood score obtained during the premenstrual phase. While 
present i ng no da t a, Sampson and Prescot t (1981> refe rred to 
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an unpublished paper by Sampson (1980) in which only 60% of 
cycles showed agreement between daily self-rating and 
retrospective rating. Brockway (1975) (cited in Abplanalp, 
Don nell e y, 8. R 0 s e , 1 9 79 ) me as u red sub j e c t s • d ail y rat i n g 
during two cycles for pain, water retention, and negative 
affect, and compared these wi th the retrospecti ve form of the 
HDQ. No relationship was found for pain or negative affect. 
The two month prospective use of Visual Analogue Scales for 
depression and anxiety confirmed self-diagnosis in only 8 of 
20 subjects (Rubinow, Roy-Bryne, Hoban, Gold, 8. Post, 1984) 
Endicott and Halbreich (1982) set out to directly test 
the degree of confirmation possible using daily ratings 
compared to the PAF. They were able to do this for 59% of 
their sample of 48 women. Within severity categories, they 
found confirmation rates varied from 42%, for subjects rated 
mild, to 87% for those categorised severe. Only 57% of 
subjects who rated themselves as having no symptoms had these 
ra t i ngs confi rmed. Three s ubj e'c ts were found to have mi 1 d 
levels of premenstrual change despite claiming no symptoms 
retrospectively. For those subjects claiming symptoms, the 
major reason for disconfirmation was high non-premenstrual 
scores. An additional mid cycle interview would not have 
helped as most of the 41% reported feeling well for a few 
days around mid-cycle followed by deterioration, with minimal 
premenstrual exacerbation. 
The only study to report successful prediction of PHS 
used the Steiner et al (1980) scales and related them to 
selected portions of one and a half cycles of daily ratings 
on the Profile of Hood States and an unspecified somatic 
symptom scale (Haskett, 8. Abplanalp, 1983). This study was 
highly selective, using only 24 out of 130 applicants and 
found that up to two or three cycles were needed to 
successfully schedule interviews in the follicular and late 
luteal phase. 
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With the exception of Abplanalp et al., (1979) and 
Rubinow, Roy-Bryne, Hoban et al., (1984), the major 
difficulty with most of these studies is that no data are 
presented to illustrate the conclusions drawn, nor are 
details provided of the prospective device used. It thus 
remains possible that the results are a function of a lack of 
overlap between the domains sampled with the different 
methods of collection, rather than the methods of collection 
themselves. Other difficulties are the preoccupation with 
mood data instead of the range of possible symptomatology. 
and the lack of a direct test regarding the predictive power 
of the retrospective interview when compared to prospectively 
collected data. 
Confirmation of interview data by prospectively 
collected data is one aspect ot this problem. Prospective 
studies frequently address the reliability of a retrospective 
instrument, when daily records have been kept between the 
first and second administration. Decreased scores have been 
found on the second retrospective test compared to first 
administration (Harrison, Endicott, Rabkin, & Nee, 1984; 
Endicott & Halbreich, 1982). The interpretation of such 
results highlights two problems. 
1. Dimensional v's categorical scales. Harrison et al. 
(1984) rated their 12.6% reduction in score as trivial. Using 
PAF diagnostic categories, Endicott and Halbreich (1982), 
however, found a decrease from 41 to 27 in the number of 
subjects reaching the criteria for major depressive syndrome. 
2. Expectation of constancy. Harrison et aI, (1984) 
suggest the decrease could have been the result of subjects 
correcting their retro~pective falsification of symptom 
severity or the psychological support provided in the 
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interim. Falsification is a perjorative term when compared 
with alternative explanations. It is possible that subjects 
are simply unable to respond accurately. The timing of 
interviews with respect to the menstrual cycle is not 
specified, but appears fixed and so independent of cycle 
length. Thus subjects are likely to be rating themselves at 
different points in the cycle. This is likely to induce 
change (Ruble 1977). Another possible explanation is that the 
severity of symptoms does fluctuate from month to month. This 
raises the issue, as does Endicott and Halbreich's (1982) 
paper of whether it is realistic to expect consistent levels 
of severity across cycles. One cycle of prospective data 
collection is inadequate to clarify these points. 
Overall there is reason to be suspicious of data 
collected entirely from retroipectively oriented 
questionnaires, particularly with respect to mood or 
emotional dimensions. The questions of how this applies to 
physical symptoms, how well such data predict subsequent 
daily scores, and the impact of viewing a larger number of 
cycles on the conlusions drawn, remain to be answered. It is 
also noted that prospective devices are unlikely to be 
entirely free from distortion (Ruble 1977), they reduce some 
inaccuracy, but are still influenced by stereotypic beliefs. 
4-4 CYCLICITY 
While symptom heterogeneity has been the subject of much 
discussion, the issue of cyclicity has been poorly discussed 
until very recently. The historical tradition has been simply 
to report a temporal association between the symptomatology 
and the menstrual cycle. This is inadequate on several 
grounds intrinsic to the concept of cyclicity. For the sake 
of clarity, at least three related but divisible aspects of 
cyclicity must be considered: (a) what period of time, with 
respect to the menstrual cycle, is defined as the 
premenstruum, and as such is the critical period for symptom 
occurrence; (b) what is the baseline against which these 
symptoms must be evaluated; (c) how many symptomatic cycles 
are needed to eliminate the hypothesis of chance 
fluctuations. 
4-4-1 Definition of Time Period 
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While it is accepted that considerable inter-subject 
variability does not invalidate the label PHS, the 
variability in defining the premenstruum is unhelpful. For 
example Kramp (1968) defines "premenstrual" as the last six 
days of the luteal phase and the first two days of 
menstruation while Taylor (1979) suggests that most symptoms 
are "perimenstrual". These are' illustrative of definitions 
that cause confusion, particularly with respect to 
dysmenorrhea. Halbreich, Endicott, & Schact's (1982) 
definition in the PAF takes a more idiographic position by 
suggesting in their instructions to subjects that the 
premenstrual period may range from one to fourteen days. They 
further suggest each woman should determine the duration of 
her premenstrual period using physical, behavioural and mood 
changes as guides. These are considered to be part of the 
premenstrual period if: (a) they appear or change during the 
premenstrual period (b) they do not exist in the same form 
or severity immediately prior to the premenstrual period; 
(c) they disappear or return to usual state during the full 
flow of menses. In other words they pass the responsibility 
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for defining the premenstruum to the subject and appear to 
allow the inclusion of symptoms after the onset of 
menstruation. While it is perhaps unreasonable to expect 
instantaneous relief from symptoms coincident with the onset 
of bleeding (as is implicit in some of Sutherland & 
Stewart's, 1968, objections to the term premenstrual tension) 
it has been suggested (Soule, 1960; Rei d & Yen, 1981) that 
similar symptoms can and do occur during menstruation and 
post-menstrually, particularly at mid cycle (Geiringer, 
1951>. 
Norris (1983) expands the temporal definition to include 
most of the above concerns; "we define the premenstrual 
syndrome (PMS) as a wide variety of adverse signs and 
symptoms that occur regularly in the same phase of each 
menstrual cycle, followed by a symptom-free phase in each 
cycle"(p509). The breadth and inclusiveness of this position 
creates problems, as does Steiner et aI's., (1980) suggestion 
that symptoms can only occur ~uring an unspecified 
premenstrual period with relief soon after menses. 
The little consensus that exists suggests, in the 
absence of a unifying cause, symptoms ocurring outside of an 
approximate ten day period immediately prior to menses should 
be excluded, if only for the sake of investigative clarity. 
While allowing 24-36 hours after the onset of menstruation 
for the subsidence of symptoms, it also is important to 
exclude those symptoms likely to be a direct result of 
bleeding such as dysmenorrhea. 
4-4-2 Baseline Measurement 
Most of the symptoms of PMS can and do occur for a 
variety of reasons at a variety of times independent of the 
menstrual cycle (Lancet Edi tori aI, 1981). Coppen and Kessel 
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(1963), Geiringer (1951), and Sampson and Jenner (1977), 
have shown women to be symptomatic at other times. This 
problem was responsible for the bulk of the disconfirmations 
in the Endicott and Halbreich's (1982) study. The 
interpretation of such data is almost inevitably in terms of 
premenstrual exacerbation of some underlying condition. While 
this is possible, the inverse has been rarely considered. 
Wilcoxon, Schrader and Sherif (1976) have suggested that 
stress is more related to symptoms than the menstrual cycle 
phase. While this is indirectly contradicted by the lack of 
consistent menstrual cycle phase related differences in 
plasma cortisol between sufferers and nonsufferers (Steiner, 
Haskett, Carroll, Hays, & Rubin, 1984), the possibility that 
the symptoms and the premenstrual phase of the menstrual 
cycle may be epiphenomenal is important. The number of cycles 
in which there is a significant degree of change in the 
premenstrual period, ie., consistent expression is seldom 
discussed. Steiner et a!.) (19813) state six cycles are 
needed, but not why. More frequently it is not discussed at 
all. In part this reflects an implicit assumption about the 
nature of the disorder, ie., a constant defect in the 
endocrinological, metabolic or psychological substrate which 
causes symptoms in the appropriate portion of the menstrual 
cycle. Other assumptions could be made about the aetiological 
substrate which would lead to different expectations about 
consistency over cycles. However, selecting only consistent 
subjects is reasonable. The advantages are the ability to 
evaluate treatments over a practical length of time, and some 
degree of homogeneity within the population being studied. 
This does not, however, overcome the problem of chance 
association between symptoms and the premenstrual phase. This 
is a major problem for studies which examine one cycle and 
only measure symptoms once during the premenstruum. 
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Other points raised by the concept of baseline are that 
of the measurement of change rather than absolute severity 
(Rubinow and Roy-Bryne, 1984; Halbreich, Endicott & Schacht, 
1982), how much variation is acceptable for exclusion as 
"normal" (Parlee 1973), and which other part of the cycle one 
uses as the contrast (see sec 4-4-1, for the range of 
possibilities which exist). 
4-4-3 Determination of Cyclicity 
Firstly, there is explicit reference in almost all 
definitions of premenstrual syndrome, to cyclicity and cycle 
phase, but few attempts exist that qualify this in any 
rigorous fashion. Secondly, there have rarely been 
ackowledgements (eg. Lancet Edi tori aI, 1981; Sampson 8. Jenner 
1977) that the symptoms can occur in response to stressors 
and so exist premenstrually by chance. These two 
methodological issues are to a degree inseparable, in that to 
establish the former, avoidance of the latter is a 
prerequisite. It is not sufficient merely to state the 
existence of cyclicity as a considerable number of authors 
have done (eg., Backstrom 8. Mattsson, 1975; Clare 1977; Osmun 
et a1. 1983). Nor is it sufficient to state the number of 
cycles in which symptoms have to occur (Steiner et a1. 1980). 
Authors who have attempted to quantify cyclicity are 
limited to those few studies of longitudinal design and true 
prospective daily recording. Such authors have used three 
techniques to achieve this. 
1. Di fference scores. 
o· Brien et a1., (1979) exemplify the use of difference 
scores, in an attempt to quantify cyclicity. The difference 
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between follicular and premenstrual score was used as a 
single indicator; a positive score indicating a symptomatic 
cycle. While this satisfies the requirment of detecting 
change rather than absolute level (Rubinow 8. Roy-Bryne, 1984) 
it raises the issue of establishing a baseline. A decrease 
from a euphoric mid-cycle state, to average mood during the 
premenstruum would, by this system be scored as a symptomatic 
cycle. Another issue is how to define a significant increase 
in difference. Steiner (personal communication, August 3, 
1983), in reference to twice monthly use of the premenstrual 
rating scale, suggests any difference is significant. This 
ignores the likely possibility of some random fluctuations 
and trivial variance (Parlee, 1973>' 
2. Phase scores as an independent variable 
Where group data has been of central interest, analysis 
of variance with repeated measures has been used, using phase 
as an independent variable. The advantage of this is to 
control for subject heterogeneity by reducing between group 
variance attributable to subjects (Keppel 1973). The 
disadvantage of this design is the risk of carryover 
effects, which if not of intrinsic interest, must be removed 
by counter-balancing for order. In menstrual cycle research, 
this creates problems. One of the only studies to even 
acknowledge this as a problem, was that of Sanders, Harner, 
Backstrom, and Bancroft (1983) who systematically varied the 
day of starting self recording to randomise the effects of 
repeated measures. By varying the first phase responded to 
this goes part way towards a solution, however Ii ttle can be 
done to vary the order in which cycle phases follow each 
other. The other limitation arises from the design being 
limited to group data. Given the difficulties involved with 
selecting a homogeneous group, a case is made for the 
analysis of the individual case. In this, analysis of 
variance ceases to be of value because of carryover effects 
and the strong possibility of autocorrelation. 
3.sine wave fitting. 
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The most sophisticated attempt at estabilishing 
cyclicity has used a least square regression technique to fit 
one sine wave to one cycle (Sampson S. Jenner, 1977). However, 
if some of the other methodological problems are dealt with 
by, for example, daily recording, then it is highly likely 
that the data will be autocorrelated (Jones, Vaught S. 
Heinrott, 1977) and that the pattern of cyclicity will be 
more complex than one simple frequency with fixed period and 
amplitude (Kruse S. Gottman, 1982>. If more than one cycle is 
examined then this latter point becomes more acute. These 
cycles are likely to be probabilistic, vaying in period and 
amplitude, rather than deterministic (Kruse S. Gottman 1982>. 
The direct result of this is that the degree of fit worsens 
over time. Assessing the degree of fit, also raises a 
problem. The least squares assumption, that the residuals 
are uncorrelated, is violated for a probabilistic process. 
Even moderate autocorrelation in the residuals can seriously 
bias the test of significance of the regression parameters 
(Glass, Hillson S. Gottman, 1975; Padia, 1975; Hibbs, 1974; 
Porges et al.. 1989; Horne, Yang S. Hare, 1982; Cook S. 
Campbell, 1979). It is reasonable to question the validity of 
statistical conclusions if a time series model is not at 
least considered (Gottman, 1981>. These three points reduce 
the utility of Sampson and Jenner's work. 
The number of cycles with negative symptoms in the 
premens t rual phas e, req ui red to overcome the probl em of 
random occurance, remains unspecified. If one assumes equal 
probabi lit y of symptoms or no s ympt oms, condi t i onal 
probabilities of symptoms given PMS (p=1. 0), and symptoms 
without PMS (p=0. 5), then, from a Bayesian view six cycles 
are needed to approach p=0.01. At best these assumptions are 
debatable, but they illustrate the problem. Some defence of 
the length of data collection is required, rather than the 
cavalier attitude that tends to prevail. 
4-5 SUMMARY 
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To summarise, the area is plagued with methodological 
problems, some of which it shares with other areas of 
research, such as sample representativeness, description of 
sample in terms that facilitate replication, definition of 
the syndrome, lack of controls, shortness of intervention 
phase, and lack of follow-up data. The major methodological 
limitations that are specific to PMS involve the issues of 
baseline, prospective recording of symptoms, determination of 
se ve ri t y, and cons is te nc y of s'ympt om expres si on. In ot he r 
words they include those aspects critically related to time 
as a dimension of the disorder, and the resulting 
implications for the type of data collected. 
SECTION TWO - THE EXPERIMENT 
CHAPTER FIVE - OVERVIEW OF THE EXPERIMENT 
5-1 INTRODUCTION 
The major issues in the PMS field are, (1) how best to 
identify subjects, (2) how best to collect accurate data, (3) 
how to decrease the infuence of negative expectation, and (4) 
the choice of the best form of analysis if prospective data 
have been collected. Once these issues have been adequately 
addressed, management regimes can be evaluated. 
5-2 SUBJECT IDENTIFICATION 
Of the available subject selection instruments, the 
St ei ne r s cal es (Ste i ner e t a1. 1980) we re us ed. These scales 
depend upon sophisticated retrospective judgments. The 
adequacy of this method of subject selection was compared 
with prospectively collected symptom data. 
5-3 METHOD OF DATA COLLECTION 
The disadvantages of retrospective data collection have 
been reviewed in chapter 4. In summary, some evidence 
suggests that diagnostic procedures based on retrospective 
self-report overestimate the condition (McCance et al. 1937; 
May, 1976; Abplanalp et a1. 1979; Sampson &. Prescott, 1981; 
Osborne, 1981; Halbreich, Endi cott, Schact &. Nee, 1982; 
Endicott &. Halbreich, 1982; Slade, 1984). Direct comparison 
between prospectively and retrospectively determined 
incidence and severity, is not possible, as the studies 
frequently present insufficient data. This comparison was one 
aim of the experiment. 
A direct consequence of this aim, was the need for a 
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prospective measurement device which satisfied the following 
requirements. (1) to be minimally intrusive, in contrast to 
studies using invasive (Sampson 8. Prescott, 1981>, or 
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i ntensi ve (Taylor, 1979) styles of prospecti ve data 
collection; (2) ease and rapi di ty of use, requi ri ng mi ni mal 
subject motivation; (3) to have bipolar mood scales (Mackay, 
1980), with positive and negative statments in contrast to 
devices that only present negatively worded statements for 
end 0 r s e me n t (S t e i n ere taL, 1 9 8 0; Moo s , 1 96 8); (4 ) t 0 h a ve 
alternating positive and negative poles to reduce response 
bias; (5) that cover a range of mood and physical symptoms. 
No existing questionnaire meets these requirements, but a 
combination of Visual Analogue Scales for mood (Aitken, 1969; 
Zea11y 8. Ai tken, 1969; Bond 8. Lader, 1974; Mackay, 1980), and 
discontinuous rating scales for physical symptoms, has this 
potential. 
A daily diary was constructed incorporating the above 
features (appendix 1), with instructions for the subject to 
rate the previous day. Additional information, such as 
weight, onset of menstruation, and any medication taken was 
also included. As such the diary had five parts: (1) a 
general introductory section for the recording of the 
subject's name, and weight, the date, and if any medication 
had been taken; (2) eight bipolar VAS scales designed to 
measure mood symptoms; (3) three yes/no questions concerning 
menstruation; (4) five physical symptom questions rated 
absent, mild, severe; (5) an open section for subjects to 
comment more generally. 
The dimensions contained within the symptom scales were 
derived from the general clinical manifestations literature 
and the clinical features contained within the RDC proposed 
by Steiner et a1., (1980) and the associated rating scales. 
There were some semantic differences between S~einer et al., 
(1980) and the daily questionnaire, because of the need for 
superordinate constructs that were able to subsume both 
negative and positive poles. 
Content validity of the physical symptom scales was 
determined by their overlap with existing scales. The mood 
VAS were cross-validated against the Multiple Affect 
Adjective Checklist (MAACL) (Zuckerman & Lubin, 1965), an 
established and valid mood questionnaire (Mackay, 1980). The 
results of this study are presented below. 
5-3-1 Mood VAS Validation. 
The critical validity questions are twofold, given the 
nature of the prospective nature of the experiment, namely 
(1) are the two questionnaires significantly correlated when 
gi ven at the same ti me? (2) are mood changes, measured by 
repeated use of both instruments over time, significantly 
correlated (Johnson & Hackman~ 1977)? 
Twenty two females (mean age = 31.1 years, sd = 10.9 
years) recruited from hospital staff and a counselling 
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centre, completed the mood VAS, and the MAACL, daily, rating 
the previous day, for a total of 625 days (mean = 28.4 days, 
sd = 5.1 days). Correlations for the 22 first pairs, the 22 
sets of repeated observations on the mood VAS, and MAACL, and 
all pairs, are presented in table 5-1. 
TABLE 5-1 
Means, standard deviations. and correlations between 
visual analogue mood scale scores and Multiple 
Affect Adjective Checklist scores 
Subject N mean SD Correlation Prob 
VAS MAACL VAS MAACL 
1 22 407 38. 7 94. 2 2. 41 -0. 5577 < 0. 01 
2 29 402 34. 1 54. 8 8. 13 -0.6505 < 0. 001 
3 29 395 40. 3 53. 2 0. 77 -0. 5895 < 0. 001 
4 29 491 38. 8 55.0 2. 06 -0.3748 < 0. 05 
5 7 351 30. 6 59. 3 10. 24 -0.7577 < 0. 02 
6 30 404 38. 3 47.8 2. 68 -0.8402 < 0.001 
7 30 378 38.5 52. 2 3. 05 -0.5742 <0.001 
8 31 530 35. 0 97.4 3. 60 -0.8512 <0.001 
9 31 409 40. 1 85.7 1. 34 -0. 7967 <0.001 
10 29 341 43. 4 47 4 3. 08 -0.6571 < 0. 001 
1 1 28 509 33. 8 50. 2 5. 83 -0.4709 < 0. 01 
12 30 465 38. 7 91.0 3, 15 -0. 5647 < 0. 001 
13 30 357 47. 1 51. 9 9. 53 -0. 7439 < 0. 001 
14 30 425 38. 8 77.3 3. 37 -0.8121 <0.001 
15 26 388 37.9 94. 5 5. 78 -0.6666 <0.001 
16 31 453 19 90. 6 8. 13 -0. 8217 < 0. 001 
17 30 446 32.2 90. 8 8. 35 -0.7921 < 0. 001 
18 31 486 38. 2 78.0 3. 52 -0. 4791 < 0. 01 
19 30 411 34.8 68.1 5. 44 -0.8941 <0.001 
20 31 390 37. 1 57. 1 6. 56 -0.5860 < 0. 001 
21 30 500 27. 2 94. 4 8. 61 -0. 8520 < 0. 001 
22 31 409 34. 9 46.1 3. 48 -0.1725 NS 
all 
cases 627 428 36. 4 87.7 7.81 -0. 5385 < 0. 001 
first 
'Pairs 22 417 36. 2 98. 2 8. 64 -0. 6091 < 0. 001 
These results, partIcularly those for fIrst paIrs for 
all subjects, supported the use of the mood VAS as a 
concurrently valid measuring device. 
5-4 NEGATIVE EXPECTATION 
Negative beliefs or expectations about symptoms does 
alter the perception of premenstrual events (Parlee, 1974; 
Beumont, Richards & Gelder, 1975; Koeske & Koeske, 1973; 
Rubl e, 1977; Englander Golden, Whi tmore & Di ens t bi er, 1978; 
Campos & Thurow, 1978; Rodi n, 1976; Ruble & Brooks -Gunn, 
1979; Abplanalp, Haskett & Rose, 1980; Sherif, 1980; Slade, 
1984). Removing the effect of these negative expectations is 
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difficult. PreviouslY suggested means of removal lack utility 
in a prospective study. It is possible to use of subjects 
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wi th PHS who undergo hysterectomy (Osborn, 1981). The absence 
of menstruation with an intact hormonal substrate allows the 
experimenter to systematically falsify feedback about cycle 
phase. The small numbers available, the debate over continued 
symptoms in this group (Backstrom et al., 1981; Beumont et 
a!., 1975), and possi ble confoundi ng induced by 
post-operative trauma, reduce the utility of this option. 
False assignment of premenstrual subjects to either 
intermenstrual or premenstrual groups, using electrodes 
placed upon the subjects head to convince them of the 
experimenter's ability to predict menstruation onset (Ruble, 
1977), is not suitable where data is collected daily over 
cycles. 
An alternative strategy is the use of a placebo 
treatment designed to counter the possible negative 
expectations. A placebo being any therapy used for its 
nonspecific psychological effect (Shapiro, 1968), One of the 
major reasons for using a plac~bo, is to eliminating bias on 
the part of the patient or observer (Beecher, 1955). There is 
inconclusive evidence to support the existence of a placebo 
effect for both pain and general mood (Ross, & Buckalew, 
1983), In part this is a result of the confusion between a 
change in behaviour compared with an untreated control (ie. 
placebo effect), and the response which automatically follows 
the administration of a placebo (ie" placebo response), 
Thi s semanti c confusi on, has led to the lack of use of 
untreated control groups, and hence to difficulties in 
interpretation. 
Placebo effects are known to be mediated by factors 
such as size, form, and colour of the placebo used (Jacobs, & 
Nordan, 1979; Buckalew, & Coffield, 1982a, 1982b). For these 
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reasons a capsule, of conventional si2e, would be most 
suitable. Directive suggestion has been indicated as a major 
ingredient of a placebo effect, with the placebo itself being 
a tangible focus, or a reason to believe (Buckalew, 1968, 
1972). Positive presentation, with the strong statement that 
the treatment is a novel approach, is likely to be needed in 
view of the predominately negative expectations generated by 
the popular press. 
5-5 STATISTICAL ANALYSIS 
The need for an adequate and robust technique is 
critical. The use of visual analysis and verbal desription is 
of low order, characterises an infant science (Gregson 1983) 
and is inaccurate (Sharpley, 1981>, The statistical 
techniques which have been used to analyse data from PMS 
studies all have limitations. These are; (1) problems 
discriminating mid cycle variability from premenstrual 
variation (O'Brien et a1., 1979); (2) sensitivity to 
autocorrelation (Gottman, 1981); (3) the ability to analyse 
only one cycle at a time (Sampson 8. Jenner, 1977); (4) the 
indirect nature of the determination of cyclicity 
A group of statistical techniques that is able to cope 
with autocorrelated data and probalilistic cycles is time 
series analysis. While parametric techniques in the time 
domain such as Box Jenkins autoregressive intergrated moving 
average (ARIMA) models (Box 8. Jenkins, 19713), have recently 
received an increasing share of attention within the 
psychological literature (eg. Hartmann et al. 19813; Jones et 
al. 1977; Cook 8. Campbell 1979; Ballard 1983), of particular 
relevance to PMS is analysis in the frequency domain 
( Spect ral Anaylsi s). Thi s has been used ina bi 01 ogi cal 
context (Luce, 19713), and to examine social interaction 
(Gottman, 1979), but has been used extensi vely in other 
disciplines such as engineering and econometrics (Jenkins & 
Watts 1968), to decompose variable phenomena into consituent 
frequencies. 
There are two advantages to decomposition in the 
frequency domain as opposed to the time domain (Porges et 
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a L, 1 98 e). Fir s t I y, est i ma t e s 0 f s p e c t r a Ide n sit y are 
approximately independent of frequency and so interpretation 
is easier than with other time series statistics such as 
sample autocovariance function. Secondly, wi th many physical 
problems, the spectrum or variance associated with various 
frequencies is of direct interest. For these reasons spectral 
technology seems to have some utility in the analysis of PMS. 
Gottman (1981) presents a cogent summary of the 
development and technical aspects of frequency domain 
analysis. What follows is a precis of that, together with 
additional literature where relevant. 
Bernoulli, in the eightee'nth century (Hawkins, 1970) 
suggested that a wide class of functions could be 
approximated using the sums of trigonometric functions. While 
this notion was rejected, Fourier, in his treatise The 
Analytic Theory of Heat (1822) used this technique to 
simulate data using the sums of sines and cosines, and 
estimating component frequencies, amplitudes and phase 
relationships. Fourier's work was in fact, partially in 
error. The resulting mathematical problems have taken over 
1ee years to overcome (Gottman 1981), 
The difficulties, were two fold. Firstly, there was the 
failure of the periodogram to be a reliable estimate within 
either the short or medium run, compared to the theoretical 
deri ved spectrum. Secondly, there was a conceptual 
difficulty, the solution of which underpins "our century's 
view of physical phenomena" (Gottmann, 1981. p182). Fourier 
and a number of those preceding and extending his work (such 
as Whittaker and Robinson (1924» aimed to discover 
deterministic patterns which were masked by white noise. The 
shift to a probabalistic view, the lack of an assumption of 
fixed frequencies, amplitudes and phases, has been critical. 
Yule, in 1921, (Gottman, 1981) suggested the terms 
psuedo-periodic or quasi-periodic were more appropriate than 
periodic in that the wave-like movements can be represented 
by a series of harmoni c terms, but not by a fi xed funct ion. 
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This progression in the history of the search for 
periodicity has moved from a position which ignored the 
external error component of a deterministic process, to 
models which conceptualise this error as masking white noise, 
through to viewing this error as an intrinsic part of the 
process. The end result of this process can be most clearly 
seen in the multi-component model of any time series, ie. a 
time series, Xt = trend + deterministic component + 
stochastic (probabalistic or nondeterministic) component + 
error (white noise). The aim of time series analysis, is to 
systematically remove these components, with the ultimate 
goal being specification of the stochastic element. This 
applies to both time and frequency domains and describes the 
general case. However, trend and the presence or absence of a 
deterministic component can be of intrinsic interest. 
Techniques of analysis have to deal with variability in 
menstrual cycle length as an intrinsic part of the 
phenomenon. Standardising cycle length involves making 
unjustified assumptions about the pacing of hormonal 
events(). An alternative is to restrict the analysis to one 
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cycle (Sampson & Jenner, 1977). thereby avoiding the problem 
of rapid attenuation of the fit which is almost certain given 
the strong possibility of the data being dominated by 
stochastic rather than deterministic cycles. It also ignores 
the possibility of chance occurance of symptoms within the 
premenstruum. This approach does fit within the historical 
framework (Gottmann, 1981). 
In summary, the major development within the Fourier 
methods has involved the modification of assumptions or 
models regarding the underlying process. It means the 
acceptance of the possibility of a stochastic or 
nondeterministic component rather than a deterministic 
component plus measurement error plus other noise. 
While the almost exclusive focus of this thesis is on 
frequency domain analysis. this is not meant to imply a 
separation between the frequency and time domains. Usually 
analysis in the two domains are treated as if they were 
unrelated (eg Kratchowi II. 1978 Horne eta!.. 1982; 
Dahlstrom. 1983). The current emphasis is a direct result of 
a primary interest in periodicity. 
The essence of frequency domain analysis is the spectral 
decomposition theorem. This states that the variance of any 
time series can be broken down. or represented by. the 
contributions of the statistically independent oscillations 
of different frequencies. The process by which this is 
achieved is the Fourier Transform. The locally available 
package (BMDP1 T. Di xon 1981> uses several algori thms. 
collectively known as the Fast Fourier Transform (FFT) to 
rapidly compute the fourier transform at a discrete set of 
frequencies. known as the fourier frequencies. or over-tone 
series (w=k/T. k=0.1.2 .... (T-1)/2l. Thus the spacing or 
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distance between independent frequencies is a function of the 
number of points in the series, and the range of frequencies 
is from zero to 0.5. The latter value, the Nyquist frequency 
(Gottmann, 1981) is the period of the fastest frequency able 
to be detected, which is the distance between two time 
points, ie f==0.5. This assumes equal spacing of observations, 
thereby implying the larger the number of observations, the 
finer will be the frequency grid. The fourier transforms are 
then used to compute the periodogram, which is then smoothed, 
using a weighted cosine function, to form the spectral 
density function. This smoothing or averaging process 
eliminates the instability of the periodogram. This smoothing 
is possible because the estimates of density are independent 
at neighbouring frequencies. The shape of the weighting 
function is one aspect of this stabilisation process, the 
other is the bandwidth or number of adjacent periodograms 
included in the smoothing procedure. Hider bandwidths provide 
more stable estimates but result in a loss of detail or 
resolution. As a consequence, this dilemma, Grenander's 
Uncertainty Principle (Priestly, 1981), is an important 
consideration in experimental design. 
To summarise, the end result is the spectral density 
function which measures the power or variance on these 
independent frequencies, namely the overtone series. Trends, 
or non-stationarity, are sho~n by peaks at f=0 (infinitely 
long cycles), deterministic cycles are shown by narrow peaks 
or line spectra, stochastic or probabalistic cycles by 
broader peaks, and white noise or random fluctuation by a 
horizontal line across all frequencies. 
The above describes the univariate case. Generalisation 
to the bivariate case involves two additional statistics. 
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They are (1) coherence, which is the best linear relationship 
between the two series at each frequency, and (2) phase, 
which decribes the temporal relationship between the two 
series, at each frequency. Coherence is interpretable 
provided at least some of the power or density is present at 
that frequency in both of the individual spectral density 
functions. If the coherence is high at a particular frequency 
but spectral density is low, the linear relationship is 
likely to be trivial. The converse is similarly not of 
interest, since coincidental peaks on the individual spectral 
density functions are likely to be a function of 
autocorrelation within each series rather than a reflection 
of a linear relationship between the series .. Phase is only 
interpretable if the coherence is significant, because the 
variance of the phase estimate increases dramatically as 
coherence approaches zero. The value of the phase estimate, 
divided by 2~f, is used to estimate the displacement 
existing between the two serie •. If this ratio is zero~ then 
the two series, at this frequency, are in phase and 
synchronous. The slope of the phase over the range of 
significant coherence, can (dividing by 2~) be used to 
examine the response time between the two series. A negative 
slope indicates the two series to be out of phase with the 
first series leading, and a positive slope suggests the 
second series leads. 
5-6 AIMS OF THE EXPERIMENT 
In light of the above, this study aimed to recruite a 
reasonably homogeneous sample of PMS sufferers, assess them 
with the retrospective Steiner at al., (1989) scales and two 
visual analogue severity scales, and prospectively collect 
symptom data over a sufficiently long period to enable 
spectral analysis to be used. Following this, to use a 
placebo preparation, to modify negative expectations. 
The specific aims were:-
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(1) to compare retrospective diagnosis, with 
prospectively determined incidence and severity, and compare 
di f fe rence, phase, and standard scores as ways of summar i si ng 
these data, while indirectly establishing cyclicity. 
(2) evaluate the use of a placebo as a means of altering 
negative expectancies. 
(3) investigate the use of time series analysis, as a 
means of analysing prospectively collected data. 
CHAPTER SIX - STUDY ONE 
6-1 INTRODUCTION 
The aim of the study reported in this chapter was to 
directly compare retrospectively and prospectively collected 
symptom records. The few studies that have addressed this 
issue have used questionnaires not specifically designed for 
PMS (Abplanal p et a1. 1979), have used normal women (May, 
1976), or have presented insufficient detail about the daily 
questionnaire and the method of analysis (Endicott & 
Halbreich, 1982>' Thus a direct comparison of retrospective 
initial self-evaluation, and subsequent incidence and 
severity of the disorder is needed. 
The aims were threefold. 
(1) To compare retrospective evaluation, using the 
Steiner scales (Steiner et a1. 1980), with prospectively 
determined incidence and severity. 
(2) Within this first aim, to compare the utility of 
conventional methods of determining cyclicity, such as 
difference scores, using cycle phase as an independent 
variable, and the use of standardised scores which enable 
comparisons across type of symptom. 
(3) To examine the ability of a combination of 
retrospective evaluation devices (specifically the Steiner 
scales and two visual analogue severity scales) to predict 
prospectively collected symptom records. 
6-2 METHOD 
Subjects 
Forty two women were finally involved in this study. 
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They were all of European origin, aged 25-46 years (mean ± 
sd, 35,06 ± 4,78 years), and were convinced they suffered 
from PHS. None had overt signs of physical illness apart from 
transient infections and minor allergies. Those with a 
psychiatric history or undergoing current and traumatic life 
experiences were not accepted. None took oestrogen 
preparations either during the period of observation or in 
the preceding 3 months, and all had a history of regular 
menstrual cyclicity, None had been pregnant during the last 
1.5 years, nor had lactated in the preceding 12 months. Body 
weights ranged from 84 to 169% of ideal (Hetropolitain Life 
Ins u ran c e , 1 9 5 9), (me a n ± s d , 1 0 9. 4 5 ± 1 5. 96), and 
their numbers of children ranged from 0 to 7 (mean ± sd, 
1. 67 ± 1. 49), 
In response to lectures, public notices, newspaper 
articles, and word of mouth, 58 women were initially 
recruited. Of these, three were excluded on the basis of 
taking various medications (despite questioning about this at 
initial telephone interview) two because of the presence of a 
major affective disorder, and one because of chronic physical 
i 11 he a 1 t h. 0 f the r e ma i n i n g 5 2 vol un tee r s , 1 0 fa i 1 edt 0 
complete recording for the required three months, one because 
she developed significant physical ill health, the remaining 
nine because of difficulties with completing the daily 
diaries on a regular basis. 
Procedure 
Subjects were interviewed during the luteal phase at 
which time retrospective rating scales were used to assess 
severity of current and past symptoms. They began prospective 
daily recording at the beginning of the next menstrual cycle, 
and continued for the next three cycles. The daily 
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questionnaire was completed each morning, rating the previous 
day. Once completed, subjects were asked to seal it in an 
envelope. These questionnaires and one early morning urine 
sample were collected weekly. 
Measures 
Interview: A 36 item self-rating scale (appendix 2). 
and 10 item observer rating scale (appendix 3) were used. 
(Steiner et a1.. 1980). These scales. covering the day of 
interview and the previous week. sample both physical and 
psychological symptoms. Two VAS (Mackay. 1980) were also 
used. to obtain severity ratings for both the preceding 
menstrual cycle and the preceding six cycles. 
Daily Diary: this instrument (appendix 1) had three 
major aspects:-
a) Moods were recorded on seven. bipolar 100mm VAS. 
with the following anchors; happy/unhappy. 
e xha us ted/ ene rget i c. se 1 fc onf i dent / hope 1 es s. tense / calm. 
friendly/hostile. confused/mentally alert. 
efficient/inefficient. Maximum negative mood was scored 0. 
and the seven scales were summed to give a daily mood score. 
Rationale for item selection. and concurrent validity with 
the MAACL (Zuckerman and Lubin. 1965) were presented in 
chapter five. An eighth VAS was used to rate increases or 
decreases in sexual interest. 
b) Physical symptoms. headaches, 
breast-tenderness, constipation. food cravings. bloated 
feelings) were recorded as absent (0). mild (1), or moderate 
to severe (2). These were summed dai ly to gi ve a physical 
symptom score. 
c) General information was also elicited such as 
whether menstruating, any pain associated with bleeding, 
weight, and if any medication had been taken. The latter was 
used as a check for contaminating drugs such as oral 
contraceptives, and for the existence of other than trivial 
health problems. 
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Ur i ne sampl es: Each woman colI ec ted an earl y morni ng 
sample of urine, once a week, for the estimation of 
pregnanediol excretion. Ovulation was assumed to have occured 
if in the 12 days preceding menstruation the 24hr 
pregnanediol output had exceeded 5 umol on a single 
occasion, or if in the same period the total excreted on two 
occasions, one week apart was) 7 umol (Metcalf, 1979) 
Independent variables 
In order to achieve the first aim, that of comparing 
Steiner retrospective evaluation with prospectively collected 
data, equal size groups were established using the mean of 
the two scores obtained on these scales at the interview. 
These were designated severe (group 1), moderate (group 2) 
and mi ld (group 3). The followl ng percentage cut off poi nts 
were used; group 1 ) 66%, 53% < group 2 < 66%, group 3 < 53%. 
The second aim required two further independent 
vari abIes. (1) Phase: The mi d-cycle phase was defi ned as 
being menstrual days 5-14, day 0 being the onset of menstrual 
bleedi ng. The Premenstrual phase was defi ned as the 5 days 
preceding the onset of bleeding. 
( 2) st andardi sed scores, wi t h mean = 5 and s t anda rd 
deviation = 1, were calculated to enable direct comparisons 
to be made between the types of symptoms (mode of 
expression) . 
The fifth independent variable was cycles, since 
recording extended over three months. 
66 
Dependent Variables 
In order to facilitate comparisons and focus upon change 
in severity rather than absolute level CRubinow & Roy-Bryne, 
1984) the following classes of summary scores, or dependent 
variables were used: 
a) Incidence. To exclude trivial change between the 
mid-cycle mean score and the premenstrual mean score, an 
arbitrary 10% change between the two phases was required. In 
order for PMS to be considered present in a cycle, a 
difference of 70 is required for daily mood scores, and a 
difference of 1 for daily physical symptom score. 
b) Severi ty i ndi ces. As noted, three methods of 
summarising the data were used to examine severity. All of 
these took scores from menstrual days 5-14 as a baseline and 
compared these to the 5 days preceding the onset of bleeding. 
These three methods were: 
1. difference scores. 
i. Mood. The difference between the mean daily 
mood score during the last 5 days of the 
menstrual cycle and the mean for days 5-14. 
ii. Physical symptoms. This was calculated in the 
same way as the mood difference score. 
2. phase scores. 
i. Mood. The mean score for the daily mood 
ratings of each period (mid-cycle, and 
premenstrual phase) was analysed. 
ii. Physical symptoms. This was calculated in the 
same fashion as mood phase score. 
3. Standardised scores. 
Both the mood and physical symptom mean scores 
were standardised ac~oss the 42 subjects (x=5, 
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sd=1), and di fference scores calculated as above. 
6-3 Results 
Out of the 126 cycles studied 2.4% (3 cycles) were 
annovulatory according to the criteria mentioned above 
(Metcalf, 1979) and urine samples were unavailable at times 
critical to the determination of cycle status in 3.9% (5 
cycles). The aim was to minimise rather than exclude 
annovulatroy cycles and thus these were included in the 
analysis. 
The results for this study will be presented in three 
sections. The first, using analysis of variance (ANOVA), will 
present results concerning the variability in prospectively 
determined incidence, in the light of group membership. The 
second will present an analysis of prospectively measured 
symptom severity (difference, phase, and standardised), in 
the light of group membership. The third section, using 
canonical correlation, will present results relevant to the 
predictive relationship betwee~ retrospective interview 
scores and prospectively measured symptoms. The eighth VAS, 
rating increase or decrease in sexual interest was not 
included in the daily total. Scores on this dimension were, 
with hindsight, considered to reflect change rather than 
absolute level, and therefore were inappropriate. All 
analyses were run on a Burroughs B6900, using BMDP (Dixon, 
1981) software. 
6-3-1 Incidence: 
In the first instance, incidence was determined 
separately for mood and physical symptoms. The analysis of 
variance of the number of cycles in which PMS was observed, 
suggests that there were no significant differences in 
incidence between groups, or between types of symptoms (table 
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6-1}. Mean i nci dence (SD) for mood and physi cal symptoms 
respecti vely, were 1.95 (1.0) and 2.07 (0. 99) cycles out of a 
possible 3. Group means (SD) were 2.14 (0.83), 2.25 (0.83), 
1.64 (1.17) respectively for groups 1 (severe), 2 (moderate), 
and 3 (mild) as rated on the Steiner scales. 
SOURCE 
group 
error 
mode 
Table 6-1 
ANOV A SUMMARY. Inc i denc e ove r three months, acros s 
groups and mode. 
SS df MS F P 
5.881 2 2.941 2. 22 NS 
51. 607 39 1. 323 
0. 298 1 0. 298 0. 53 NS 
mode*group 3. 167 2 1.583 2.80 NS 
error 22. 036 39 0. 565 
An alternative way of defining incidence is to collapse 
across symptom type, such that PMS is defined as existing 
within a cycle provided at least one type of symptom exceeds 
the criteria of 10% change. The analysis of variance in this 
case suggests there is no significant variation between 
groups (table 6-2). Mean i nci dence (SD) for groups 1 
(severe), 2 (moderate), 3 (mild), respectively were 2.5 
(0.5), 2.57 (0.62), and 2.21 (1.01). 
SOURCE 
group 
error 
Table 6-2 
ANOVA SUMMARY. Incidence over three months, across 
groups I colI apsed across mode. 
SS 
1. 476 
26.643 
df MS 
2 0.738 
39 0.638 
F P 
1.08 NS 
6-3-2 Severity 
A. Di fference scores 
i. Mood 
Analysi s of mood di fference scores, wi th group 
membe rs hi p and order (mont h 1, 2, and 3) as i nde pe ndent 
variables, suggests that while mood scores do not vary 
significantly across cycles, they do vary significantly 
across groups (table 6-3). There is no significant 
interaction between group membership and order. 
Table 6-3 
ANOVA SUMMARY. mood difference scores 
SOURCE 
group 
error 
group*cycle 
error 
SS df MS F P 
207327 2 103663 3.44 0.04 
1174955 39 
24087 
37661 
2 
4 
654536 78 
30127 
120431.44 
9415 1.22 
8391 
NS 
NS 
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Mean scores across groups show a decreasing trend in 
mood di fference scores from group 1 (severe), wi th a mean 
score (sd) of 173 (164), group 2 (moderate), with a mean (sd) 
of 109 (100), to group 3 (mild), with a mean (sd) of 77 (88). 
The decreasing trend in mean difference scores is consistent 
with decreasing retrospectively rated severity across groups. 
ii. Physical 
Analysis of variance (table 6-4) suggests that physical 
symptom difference scores are not significantly different 
between cycles (order main effect), nor across groups (group 
mai n effec t). The interact i on be t ween group membershi p and 
order approaches significance (p=0. 0506) suggesting that for 
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each group physical symptoms varies differentiy across 
cycles. Mean difference scores for each group across cycles 
suggest group 1 (severe) becomes less affected over the three 
cycles, wi th mean di fference scores (sd) of 1.96 (1.32), 2.15 
( 1.55), and 1.24 (1.50) respecti vely. Group 2 (moderate), 
increases in severity with scores of 1.87 (1.22), 2.23 
(1.65), and 2.15 (0.93), while group 3 (mild) fluctuates, 
wi th scores of 1.81 (1.79), 1.26 (1.27), and 1. 80 (1. 36) for 
cycle 1, 2, and 3 respecti vely. 
TABLE 6-4 
ANOV A SUMMARY. physical difference scores 
SOURCE 
groups 
error 
cycles 
group*cycle 
error 
B Phase scores 
i. Mood 
SS df 
5. 90 2 
168.14 39 
8. 48 2 
18. 85 4 
85. 29 78 
MS F P 
2.951 8.68 NS 
4. 311 
0. 202 8.18 NS 
2. 713 2. 48 8.05 
1.893 
Mood scores are significantly different across phases 
(table 6-5). Mean scores are in the expected di recti on, wi th 
lower mood in the premenstrual phase, phase 2 (mean score 
(sd) 339 (188», compared to 468 ('75) in phase 1 (mid-cycle>. 
The mean mood score (ad). collapsed across cycles and phases, 
for each group, 382 (148), 38'7 (94), and 438 (87) 
re spe cti vel y for groups 1, 2, and 3, a pproache s si gni f i cance 
(p=8. 8'7), and show the expected increasing trend, reflecting 
decreasing severi ty, from group 1 to group 3. There is no 
significant variation across cycles (order main effect). 
Table 6-5 
ANOVA SUMMARY mood scores by group, cycle and 
phase 
SOURCE SS df HS F P 
group 1155.9 2 577.9 2. 87 0. 07 
error 7850.7 39 201. 3 
cycle 3. 6 2 1. 8 0.06 NS 
cycle*group 203.3 4 50.8 1. 72 NS 
error 2035. 9 78 29. 6 
phase 9142.9 1 9124.6 63. 1 0. 00 
group*phase 1060.8 2 530. 4 3. 66 0. 03 
error 5649. 1 39 144.9 
phase*cycle 149. 2 2 74.6 1.77 NS 
group*phase*cycle 201. 7 4 50 4 1. 19 NS 
error 3294.5 78 42. 24 
Of the interactions, only groups*phases achieved 
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si gni fi cance. Mean scores show consi stency across groups for 
mean mid-cycle (phase 1) mood scores; 470 (93), 442 (57), and 
468 (68) for groups 1, 2, and 3 respecti vely. There was an 
increasing trend for mean premenstrual (phase 2) mood scores 
(sd), from group 1 (severe) to group 3 (mild); 294 (119), 332 
(93) and 391 (87) respecti vely for groups 1, 2, and 3. Thi s 
suggests that the group main effect from scores collapsed 
across phases is almost entirely a function of variation 
BC ross groups in premens t rual scores. Thi s hi ghl i ght s the 
advantage of phase scores over difference scores (table 6-3) 
where group variance significant but not able to be analysed 
according to phase. However the two sets of results are 
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consistent. 
ii Physical 
As for mood scores, the variation in scores between 
phases is significant (table 6-6) and mean scores again show 
a greater severity of symptoms premenstrually as opposed to 
mid-cycle, with mean scores (sd) being 0.32 (0.50), and 2.15 
(1.42) respectively. Similarly, variation in physical 
symptoms across cycles is not significant but, in contrast, 
scores do not vary significantly between groups despite an 
observable decrease in mean score from group 1 to group 3; 
mean score (sd) being 1.37 (1.46), 1.33 (1.40), and 1.02 
(1.34) respecti vely for groups 1, 2, and 3. 
Table 6-6 
ANOVA SUMMARY Physical symptom scores by groups 
cycles and phases 
SOURCE SS df MS F P 
group 6. 08 2 3. 04 1. 02 NS 
error 115.83 39 2. 97 
cycle 0. 83 2 0. 41 1 . 11 NS 
cycle*group 0. 33 4 0. 08 0. 22 NS 
error 29. 07 78 0. 37 
phase 210.29 1 210.29 99. 2 0. 00 
group*phase 2. 47 2 1. 24 0. 58 NS 
error 82. 67 39 2. 12 
phase*cycle 0. 45 2 0; 23 0. 41 NS 
group*cycle*phase 4.74 4 1 . 19 2. 13 NS 
error 43.46 78 0. 56 
None of the interactions achieve significance. Of 
interest, given the mood score anal ys is, was groups*phases. 
Mean scores ( s d) for phase 1 ( mi d-cycle) were 0. 46 (0.73), 
0.29 (0.35), and 0.22 (0.28) respecti vely for groups 1, 2, 
and 3. For phase 2 (premenstrual) the mean scores (sd) were 
2.28 (1.46), 2.38 (1.46), and 1.82 (1.49) respecti vely. The 
nonsignificant interaction reflects mid-cycle variation 
consistent wi th group severi ty, wi th group 1 havi ng more 
symptoms, and premenstrual variation which does not reflect 
group differences in severity. This again is consistent with 
difference scores (table 6-4) and shows the advantage of 
phase scores. 
C. STANDARDISED DIFFERENCE SCORES 
The standardised data showed no significant variation 
between groups, symptom type nor cycles. 
Table 6-7 
ANOVA SUMMARY standard scores across group. 
cycle and mode 
SOURCE 
group 
error 
cycle 
cycle*group 
error 
mode 
group*mode 
error 
cycle*mode 
group*cycle*mode 
error 
6-3-3 Interview data 
SS df MS F P 
8 58 6 6 2 4 2 9 3 31 . 5 9 N S 
1055197 39 
12592 2 
73317 4 
612856 78 
364 1 
71290 2 
490186 39 
9299 2 
4028 4 
220643 78 
27056 
6296 0.80 
18329 2.33 
7857 
364 0, 03 
35645 2.84 
12568 
46491.64 
1007 0.36 
2828 
NS 
NS 
NS 
NS 
NS 
NS 
Canonical correlation was used an alternative to 
analysis of variance, as a means of examining the 
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relationship between retrospective ratings of symptoms at 
interview, and the prospectively recorded symptoms. As such 
the predictor variables or first set, were scores on the 
interview measures; (1) self rating scale (SRS), (2) observer 
rating scale (ORS), (3) a VAS rating severity of symptoms of 
the previous 1 month (VAS1), and (4) a VAS rating severity 
over the previous 6 months (VAS6). Variables in the second or 
criterion set, were the mood and physical symptom difference 
scores for the three months of recording, making six 
variables in all. All analyses were carried out using BMDP6M 
(Dixon, 1981). 
Canonical Correlations 
Canoni cal correl at ions are presented in table 6 -8, along 
with eigenvalues associated with each pair of canonical 
variates. Only the first pair of canonical variates are 
significant. The two sets of variables overlap significantly, 
with the first pair of canonical variates accounting for 
45.6% of the variance involved: 
Table 6-8 
CANONICAL NUMBER OF BARTLETT'S TEST FOR 
EIGENVALUE CORRELATION EIGENVALUES REMAINING EIGENVALUES 
CHI-SQUARE DF PROB 
37.00 24 0.0438 
0.45574 0.67509 1 14. 19 15 0.5114 
0.16710 0. 40878 2 7.33 8 0.5015 
0.12614 0.35517 3 2. 27 3 0.5177 
0. 05882 0.24253 
To facilitate description of this first canonical 
correlation (Neufeld 1977), the correlation between it and 
the original variables are presented in table 6-9. 
The canonical variable loadings for the first set 
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were described primarily, by the 1 month visual analogue 
scale, and to a lesser degree by the two Steiner rating 
scales, The canonical variable loading for the second set, 
were best described by physical symptoms (cycle 2) and mood 
(cycle 2), and to a lesser extent by mood in both cycle 1 and 
3. 
Table 6-9 
Canonical variable loadings 
SET 1 
Canonical Correlation 
Self Rating Scale 
Observer Rating Scale 
Visual Analogue Scale (1 month) 
Visual Analogue Scale (6 months) 
SET 2 
Canonical Correlation 
mood symptoms, cycle 1 
physical symptoms, cycle 1 
mood symptoms, cycle 2 
physical symptoms, cycle 2 
mood symptoms, cycle 3 
physical symptoms, cycle 3 
Multiple correlations 
i. Within Sets 
1 
9, 591 
9. 532 
9, 923 
9. 288 
1 
9.338 
9, 142 
9, 623 
9, 894 
9, 319 
9.914 
There was a low multiple correlation between VAS1 and 
the other variables in set one (table 6-19). The strong 
linkage found in the first canonical correlation, between 
this variable and the second set, suggests it is measuring a 
different but useful dimension, compared to the other 
predictor variables. The strong relationship between the two 
steiner scales is expected in that they contain essentially 
the same items presented ina di fferent format) and ra te d by 
different people. However their involvement in the first 
canonical correlation linking the two sets is moderate. 
Table 6-10 
Squared Multiple Correlations for each variable 
in the first set with all other variables in 
the first set 
varlable R2 
self rating scale 0. 654 
observer rating scale 0.660 
visual analogue scale 1 month 0.182 
visual analogue scale 6month 0.204 
For variables within the second set, the multiple 
correlations (table 6-11), suggest there is a moderate 
relationship between the various symptom measures taken over 
time. This is consistent with the ANOVA results presented in 
the previous section. 
Table 6-11 
uared Multi e Correlations for each variable 
in the second set with others in the second set 
variable R2 
mood symptoms ( cycle 1) 0. 498 
physical symptoms ( cycle 1) 0.607 
mood symptoms ( cycle 2) 0.575 
physical symptoms ( cycle 2) 0. 508 
mood symptoms ( c yc 1 e 3) 0. 588 
physical symptoms ( c yc 1 e 3) 0. 464 
ii Between Sets 
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The multiple correlations between variables in the first 
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set and all variables in the second set (table 6-12), are 
consistent with the canonical correlations. The only multiple 
correlation to achieve significance was that associated with 
VAS1. 
Table 6-12 
Squared Multiple correlations for each variable in 
the first set with all variables in the second set 
variable R2 F df P 
self rating scale 0. 262 2.19 6 37 0, 089 
observer rating scale 0, 240 1. 94 6 37 0, 124 
visual analogue scale 1 month 0.408 4.26 6 37 0. 006 
vi sual analogue scale 6 month 0. 119 0. 83 6 37 0. 513 
The multiple correlations between variables in the 
second set with all variables in the first set (table 6-13), 
are also consistent with the information given by the first 
canonical correlation. The only significant correlations are 
mood and physical symptoms in cycle 2. The combined battery 
of interview scales are only able to predict one out of the 
three months, and this to a limited degree (25% and 31% of 
the criterion variance for mood and physical symptoms 
respecti vely) . 
Table 6-13 
uared Multi Ie correlations for each variable in 
the second set with all variables in the first set 
variable R2 F df P 
mood ( cycle 1) 0. 070 0. 73 4 39 0. 575 
physical symptom ( cycle 1 ) 0.074 0. 78 4 39 0. 546 
mood ( cycle 2) 0. 245 3. 17 4 39 0.024 
physical symptoms ( c yc 1 e 2) 0. 308 4. 35 4 39 0.005 
mood ( c yc 1 e 3) 0. 144 1. 64 4 39 0. 184 
physical symptoms ( c yc 1 e 3) 0. 002 0. 02 4 39 0. 999 
redundancy index. 
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An estimate of the proportion of the variance in one set 
that is related to variation in the other, namely the 
redundancy index, was obtained for the one significant 
canonical correlation. This index is 0.18 for the first set, 
and 0.10 for the second set. The overlap between the two sets 
of variables therefore accounts for only a minor proportion 
of the variation within each set. 
6-4 Discussion 
The low rate of annovulatory cycles avoids rather than 
confronts the controversy about the presence of PMS in such 
cycles. This however reflects a relatively homogeneous group. 
6-4-1 Incidence 
The lack of any significant variation, for any of the 
independent variables supports the hypothesis that 
retrospective rating is inadequate. However, groups were 
constituted on the basis of retrospective, self-reported 
severity of symptoms. This result may therefore be a function 
of inadequate assessment. 
It does however suggest that retrospective self-rated 
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severity is an inadequate guide to incidence. Consistency of 
symptoms is seldom reported, and appears to be inferred from 
severity. It is interesting that even using the most lenient 
criteria for a positive cycle, none of the groups showed 
totally consistent presence of PHS. This supports the point 
that treatment evaluation, using retrospective or prospective 
recording confined to one or two cycles, is likely to 
encounter problems. This could be overcome by selecting a 
subset of subjects with consistent symptom expression. 
6-4-2 Severity 
In the three approaches to quantifying severity, the 
lack of any significant cycle variation, suggests that the 
act of daily recording, does not, reduce symptom severity. 
This is in contrast to the self-monitering literature which 
suggests that it is decreased by self-recording. It may well 
be that the time scale for premenstrual symptoms is so long, 
that memory difficulties serves to reduce the effect of 
self-monitering, as well as inhibit the accuracy of 
retrospective self-report. 
Difference scores vary significantly across groups for 
mood scores but not for physical symptoms. It is not, 
however, possible to detect whether this variation in mood 
scores is due to mid-cycle or premenstrual variation. 
Phase scores show the expected pattern for both mood and 
physical symptoms. The differences between phases is 
significant and the mean scores are less severe at mid-cycle. 
The significant group variation for mood scores, but not 
physical symptoms, parallel the results for difference 
scores. The advantage of using phase as an independent 
variable lies in the group*phase interaction and the 
suggestion that the significant variation in mood scores is 
premenstrual rather than mid-cycle. 
st andardi sed scores are of 1 itt 1 e val ue. There was no 
significant variation for any of the independent variables. 
This contrasts to the significant variation found with other 
summary scores. 
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In summary, the null hypothesis for this study is 
supported for physical symptoms since there are no 
significant differences between groups in severity of these 
symptoms. This was not so for mood where significant 
differences existed. These were in the expected direction. 
The most useful style of summary score appears to be that 
which treats mid-cycle and premenstrual scores independently. 
6-4-3 Interview 
The results of the canonical correlation analysis 
suggests the following. 
(1) Hhile the first canonical correlation accounts for a 
significant proportion of the overlap variance (45.6%), the 
redundancy index suggests the degree of overlap is relatively 
small (18% for set one, and 113% for set two). The VASi was 
the most powerful predictor of subsequent symptoms followed 
by the two Steiner scales, The VAS6 was least predictive. 
(2) The low multiple correlation between VASi and the 
other variables in set 1, together with its strong linkage in 
the first canonical correlation, suggests it is measuring a 
different but useful dimension. Its simplicity confers an 
added advantage. The consistency of symptoms across months 
supports the lack of order effects found in the analysis of 
variance. 
(3) The multiple correlations between sets are 
consistent with the canonical correlation analysis in that 
only VAS1 correlates significantly with symptoms. 
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6-4-4 Summary 
Groups discriminated on the basis of retrospective 
self-reported symptom severity do vary significantly with 
respect to prospectively recorded mood symptoms, but not with 
respect to physical symptoms or incidence. Phase related 
symptom scores are the most useful type of summary score, 
although difference scores have the advantage of being 
expressed as a single number. 
The amount of overlapping variance between the 
retrospective ratings and prospectively recorded symptoms is 
small, but is best predicted by a simple VAS rating symptom 
severity over the previous month. 
CHAPTER SEVEN - STUDY TWO 
7-1 Introduction. 
The study reported in this chapter aimed to investigate 
negative expectancies, or beliefs, known to affect the 
perception of premenstrual events (Ruble & Brooks-Gunn, 
1979). Previous attempts to modify expectancies have 
limitations, especially for prospective trials. This study 
attempted to negate these beliefs, if they existed, by 
inducing treatment expectations by way of a placebo. A 
placebo effect is by definition nonspecific (Shapiro, 1968), 
but it may be used to reduce patient and observer bias 
(Beecher, 1955). This is usually in the context of evaluating 
an active treatment, but in this case the placebo effect is 
of primary interest, rather than a means of experimental 
control. 
The specific aims were threefold. 
(1) to evaluate the effect of a placebo on prospectively 
determined incidence and symptom severity. 
(2) to use the Steiner scales (Steiner et al., 1980) to 
compare retrospective evaluation before and after placebo, 
with prospective determined incidence and severity. 
(3) to examine the ability of the combination of 
retrospective evaluation devices, before and after placebo, 
to predict prospectively collected symptom records. 
(4) to examine the relationship between interview 
evaluations on the three occassions. 
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7-2 Method 
Subjects 
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Thirty subjects from the first study agreed to continue 
for an additional three months. Of the 12 who withdrew, 9 did 
so before begining this study. Reasons were: (a) medical, 
including a desire to take other medication (4 S' s); (b) 
daily recording too time consuming (3 S' s); (c) going on 
holiday (2 S' s). Two subjects recorded insufficient data, and 
one felt that the placebo medication was generating an 
unaccept abl e Ie vel of cons t i pa ti on. These wome n cont i nued to 
me e t the inc 1 us ion c r i t e ria de t ail e d for stu d y 1, and had 
very similar ages, weights and numbers of children; Age (mean 
± sd, 35.14 years ± 4.8 years), weight (mean percentage 
of ideal body weight, ± sd, 110.6% ± 16.18%), number of 
chi I d r e n (me an ± s d 1. 6 4 ± 1. 4 9) . 
Procedure and Measures 
Using the same measures as in the initial interview 
(interview 1), subjects were reinterviewedduring the luteal 
phase of the third cycle of study 1. This was labelled 
interview two. The daily measuring device was the same as 
that used in study 1. Eleven subjects were persuaded to delay 
begining the placebo treatment for one cycle, as an attempt 
to control for continued recording resulting in a significant 
reduction in incidence and severity of symptoms. Ideally, a 
randomly selected subgroup would have just recorded daily 
s ympt oms ove r t he three months to provi de t hi s cont roI. Thi s 
was not possible as the effort involved and the inability to 
seek treatment while recording, created some difficulties 
with subject compliance. The lack of significant variation 
across cycles found in study 1 made sudden improvement 
unlikely. 
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All subjects were interviewed again during the luteal 
phase of their sixth cycle, or seventh for those with the 
extra month's recording (interview 3). Additional information 
gathered at this final interview, were VAS scores, rating 
treatment effectiveness and severity of symptoms for the 
preceeding three treated cycles (appendix 4). 
A placebo capsule containing 0.1mg Priydoxine (5-10% of 
typical daily intake by diet (Birkbeck,1977», and 0.75g 
glucose, was taken daily on arising, from the begining of the 
fourth or fifth menstrual cycle. Subjects were told the trial 
was to test the theraputic effectiveness of a novel 
administration of Pyridoxine and Glucose. No information was 
given as to the specific composition of the mixture. Written 
consent forms were obtained from each subject (appendix 7). 
Independent Variables 
There we re four i ndepe nde nt variables, three as for 
stu d y 1, and the add i t ion a I va ria b 1 e, t rea t me n t . T rea t me n t 1 
was the three control cycles collected in study 1. Treatment 
2 was the three placebo treated cycles. The extra month of 
recording, for the seven subjects, was not included in the 
major analyses. The group variable was generated in the same 
manner as study 1, with three equal size severity 
classifications based on the two Steiner scales, with group 1 
(severe), group 2 (moderate), and group 3 (mi ld). Phase was 
defined as for study 1, with the mid-cycle contrast period, 
phase 1, being menstrual days 5 to 14, and phase 2, the 
premenstrual phase, ie., the last 5 days preceeding bleeding. 
The fourth variable, cycles, was the three menstrual months 
of rec ordi ng. 
Dependent Variables 
The same procedures were used to summarise scores for 
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this study as in study 1. Difference and phase scores used 
menstrual days 5 to 14 as a contrast to the 5 days preceeding 
bleeding. Standardised scores, however, were not used given 
their lack of utility in study 1. 
7-3 RESULTS 
Out of the 187 cycles studied, 2.2% (4 cycles) were 
annovulatory (Metcalf, 1979). Urine samples critical to the 
determination of ovulation, were not provided in 4.4% (8 
cycles). The aim was to minimise rather than exclude 
annovulatory cycles and thus these were included in the 
analysis. 
The results for this study will be presented in four 
sections. 
(1) results concerning variability in incidence in 
relation to the independent variables group and treatment. 
( 2) the a n a 1 ys i s 0 f s eve r i t yin res po n set 0 the 
independent vari abl es group and t re at ment, for mood and 
physical symptoms. 
(3) the changes in severi ty between the third, fourth 
and fifth month for the two groups of subjects who either 
began treatment, or continuing recording during the fourth 
month. 
(4) the analyses of the relati onshi ps between (a) 
interview one and interview two, (b) interview two, that 
preceeding treatment, and subsequent symptom scores, (c) 
interviews two and three, (d) interview three, following 
treatment and the prospective symptom records for the 
preceeding three months, (e) visual analogue ratings of 
premenstrual distress at interview three, with the symptom 
records from the three preceedi ng treated cycles, (f) vi sual 
analogue ratings of treatment effectiveness at interview 
three, wi th the symptoms from the treated cycles, (g) a 
combination of the treatment effectiveness and distress 
ratings, with the symptoms collected over the three treated 
months. 
7-3-1 Incidence 
Incidence was first calculated separately for mood and 
physical symptoms. 
An analysis of variance showed a significant treatment 
main effect, with incidence decreasing from a mean (sd) of 
1.96 (0.99), to 1.5 (1.02) in treated cycles. No significant 
difference between groups was present, wi th mean (sd) scores 
bei ng 1. 73 (0. 94), 1. 95 (0. 88), and 1. 53 (1. 13), for groups 
1, 2, and 3 respectively. Similarly, no significant 
difference was found between types of symptoms, with mean 
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(sd) incidence scores of 1.60 (1.01) cycles and 1.86 (1.03) 
cycles for psychological and physical modes respectively. The 
interaction between group and mode of expression was 
significant, with mean (ad) sc6res for psychological symptoms 
over groups 1, 2and3 being 1.95 (0.83), 1.80(0.95), 1.05 
(1.05) respectively, and 1.5 (1.10),2.1 (0.91),2.0 (1.03) 
respectively for physical symptoms. None of the other 
interactions achieved significance (table 7-1), 
Table 7-1 
ANOVA SUMMARY Incidence, over six months, across 
treatments, groups, and mode. 
SOURCE SS df MS F P 
group 3.617 2 1.808 1. 24 NS 
error 39. 350 27 1.457 
treatment 6. 533 1 6. 533 9. 56 0. 005 
error 18.450 27 0. 683 
mode 2. 133 1 2. 133 1. 72 NS 
mode*group 9.817 2 4. 908 3. 95 0. 031 
error 33. 550 27 1.243 
treatment*mode 0. 533 1 0. 533 1. 56 NS 
treatment*mode*group 1 . 717 2 0. 858 2. 51 NS 
error 9. 250 27 0.343 
Where incidence was determined positive if either 
psychological or physical symptoms achieved the 10% change 
criteria, the analysis of variance showed no significant 
effects (table 7-2). 
SOURCE 
group 
error 
treatment 
Table 7-2 
ANOVA SUMMARY Incidence over six months, across 
treatments and groups, collapsed across mode. 
SS df MS F P 
0. 900 2 0. 450 0.43 NS 
28.250 27 1. 046 
0.417 1 0.417 1 . 1 4 NS 
treatment*group 0. 233 2 0. 117 0.23 NS 
error 9. 850 27 0. 365 
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7-3-2 Severity 
A. Difference Scores 
i Mood 
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Analysis of mood difference scores with treatment, group 
and cycles (order) as independent variables, suggests that 
while mood scores do not differ significantly across cycles, 
they do vary significantly across treatments and with group 
membership (table7-3). None of the interactions were 
significant. 
Table 7-3 
ANOVA SUMMARY mood difference scores 
SOURCE SS df MS F P 
group 122903 2 61451 3. 48 0. 05 
error 476121 27 17634 
treatment 91035 91035 12. 31 0. 001 
treatment*group 21948 2 10974 1. 48 NS 
error 199729 27 7397 
cycle 1919 2 960 0. 11 NS 
cycle*group 23365 4 5841 0. 67 NS 
error 467784 54 8662 
treatment*cycle 8259 2 4129 0. 38 NS 
treatment*cycle*group 17450 4 4362 0. 40 NS 
error 585445 54 10841 
Placebo treatment resulted in a significant decrease in 
severity of mood difference score. Mean scores (sd) were, 113 
(110) for control cycles, and 68 (97) for the placebo cycles. 
It is not clear whether this reflects mid-cycle and/or 
premenstrual change. Analysis of phase scores will clarify 
this. 
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Mean scores (sd) for groups 1, 2, and 3, were 119 (132), 
97 (93), and 56 (89), respectively. The decreasing trend from 
group 1 to group 3 (severe to mild) is consistent with the 
results in study 1, and the hypothesis that retrospective 
reporting meaningfully relates to prospective recording of 
symptoms. The difficulty in interpreting difference scores 
makes it unclear whether this trend across groups reflects 
premenstrual and/or midcycle variation. 
ii. Physical 
The analysis of variance of physical symptom difference 
scores across treatments, groups and cycles is similar to 
that for mood difference scores, except there are no 
significant differences between groups (table 7-4). None of 
the interactions were significant 
Table 7-4 
ANOVA SUMMARY physical symptom difference scores 
SOURCE SS df MS F P 
group 9. 454 2 9. 2268 9.93 NS 
error 183. 999 27 6.8111 
treatment 9. 987 1 9. 9876 9. 82 9. 994 
treatment*group 2. 935 2 1.9176 1.99 NS 
error 27. 464 27 1 . 91 72 
cycle 1.747 2 9.8737 9.84 NS 
cycle*group 3. 771 4 9. 9428 9.99 NS 
error 56.411 54 1.9446 
treatment*cycle 9.239 2 9.1153 9.12 NS 
treatment*cycle*group 5. 862 4 1.4656 1. 48 NS 
error 53.419 54 9.9899 
Groups differing in retrospectively rated severity do 
not differ significantly in mean physical symptom difference 
scores. Similarly, no significant variation is found between 
cycles across or within treatments. 
Physical symptom difference scores were less severe 
under placebo. Mean scores (sd) were 1.83 (1.48) and 1.35 
(1.25) for control and placebo cycles respectively. Again it 
is unclear whethe~ mid cycle or premenstrual change is the 
source. 
B Phase Scores 
i. Mood 
Placebo treatment resulted in a significant increase in 
posi ti ve mood (table 7-5). Mean scores (sd) for control and 
placebo cycles were 408 (100), and 447 (98.6) respecti vely. 
The treatmeht*phase interaction is significant suggesting 
that treatment effects vary according to phase. Mean scores 
(sd) for control cycles were 464 (66.9), and 352 (98.1) for 
mid-cycle and premenstrual phases respectively, and 482 (78) 
412 (104) respecti vely for the placebo cycles. Rhi Ie 
placebo treatment does affect mood scores generally, this 
effect is not significant at mid-cycle compared with the 
effect upon premenstrual mood. None of the other treatment 
interactions were significant. 
Mood scores varied significantly with phase. Mean mood 
scores reflected lower mood premenstrually, with mean score 
(sd) of 382 (105), than at mid-cycle where the mean score 
(sd) was 473 (73.1). The treatment*phase interaction was 
discussed above. The phase*group interaction was significant 
and is discussed in conjunction with the group main effect. 
None of the other phase interactions were significant. 
Mood scores do not differ significantly between groups. 
However the group*phase is signi ficant. Mean scores (sd) for 
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mid-cycle were 479 (69), 459 (76), and 481 (73.1) for groups 
1, 2 and 3, res pee t i vel y. For the pre me n s t r u alp has e , the 
mean scores (sd) for groups 1, 2 and 3 were 358 (116), 363 
( 1 01 ), and 425 (84. 1 ). T his s u g g est s 1 itt 1 e mi d - c y c 1 e 
variation between groups but a positive increase in 
premenstrual mood from group 1 to group 3 (severe to mild). 
None of the other group interactions are significant. 
The lack of significant variation between cycles within 
treatments (treatment*cycle interaction), is of interest 
given the limitations of the design. There is a stable 
baseline prior to intervention with mean scores (sd) of 408 
(101), 408 (105), and 409 (97.6) for control cycles, and a 
clear increase at the beginning of treatment, with scores of 
431 (106), 449 (83.3) and 461 (103) respecti vely. The 
transition lends support to the conclusion that improvement 
is not a function of time alone. 
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Table 7-5 
ANOVA SUMMARY mood score by treatment, group, 
cycle and phase 
SOURCE SS df MS F P 
group 124550 2 62274 1 . 61 NS 
error 1045471 27 38721 
treatment 140857 1 140857 13. 80 0. 001 
treatment*group 11029 2 5514 0. 54 NS 
error 275492 27 10203 
cycle 14944 2 7472 2.65 NS 
cYcle*group 5171 4 1292 0. 46 NS 
error 152104 54 2816 
phase 742471 1 742471 83. 36 0, 001 
group*phase 66739 2 33369 3. 75 0.037 
error 240494 27 8907 
treatment*cycle 13035 2 6517 1. 86 NS 
treatment*cycle*group 9479 4 2369 0, 68 NS 
error 189051 54 3500 
treatment*phase 40343 1 40343 11 . 01 0.003 
treatment*group*phase 10193 2 5096 1. 39 NS 
error 98967 27 3665 
cycle*phase 1832 2 916 0.21 NS 
cycle*group*phase 12237 4 3059 0. 70 NS 
error 234769 54 4347 
treatment*cycle*phase 6042 2 3021 0. 60 NS 
treat*cycle*group*phase 12190 4 3047 0. 60 NS 
error 272863 54 5053 
ii. Physical Symptoms 
Placebo treatment resulted in significantly lower 
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physical symptom scores (less symptoms) 
condition (table 7-6). Mean scores (sd) 
in the .placebo 
we r e 1, 25 (1. 43) 
93 
for 
control cycles and 1.00 (1.23) for placebo. Treatment was 
also phase specific, with mid-cycle mean scores (sd) for 
control and placebo cycles respectively being B.35 (0.54) and 
0.33 (0.45). Premenstrually, again for control and placebo 
cycles respecti vely the mean scores (sd) were 2.15 (1.47) and 
1.68 (1.39). 
Physical symptom score was significantly more severe 
premenstrually than at mid-cycle (phase main effect). The 
mid-cycle mean score (sd) was 0.34 (0.49), with a 
pre me n s t r u a I s cor e 0 f 1. 91 (1. 45) . 
The lack of significant within-treatment variation 
between cycles in physical symptom scores, is of interest 
given the possiblity that recording itself may reduce 
severity. There was an increasing trend in severity prior to 
intervention with respective mean scores (sd) for the three 
control cycles of 1.19 (1.45),1.25 (1.51) and 1.32 (1.34). A 
sUbstantial decrease was evident during the first month of 
treatment, wi th a mean score (sd) of 1.08 (1.24). Subsequent 
mean scores (sd) for cycles five and six were 0.95 (1.22) and 
0.97 (1.26), The suggested trend lends support to the 
conclusion that improvement is not a function of time alone. 
In contrast to mood scores, there were no significant 
group or group interaction effects. 
Table 7-6 
ANOVA SUMMARY physical symptom scores across 
treatment, group, cycle and phase 
SOURCE SS df MS F P 
group 
error 
0.135 2 0.07 0.01 NS 
treat ment 
treatment*group 
error 
cycle 
cycle*group 
error 
157.565 27 
5.041 
5.544 
1 
2 
32.662 27 
0. 110 
0. 920 
2 
4 
19.40354 
phase 223. 098 1 
group*phase 0. 367 2 
error 89. 832 27 
treatment*cycle 0.828 2 
treatment*cycle*group 0.990 4 
error 21.318 54 
treatment*phase 4. 096 1 
treatment*group*phase 0.996 2 
error 13.872 27 
cycle*phase 0. 837 2 
cycle*group*phase 1.918 4 
error 28.971 54 
treatment*cycle*phase 0.093 2 
treat*cycle*group*phase 2. 379 4 
error 29.51754 
7-3-3 Fourth Control Month 
5.83 
5.04 
2.77 
1. 20 
4.17 0.051 
2. 29 NS 
0.05 
0.23 
0. 35 
0. 15 
0. 64 
223.10 67.05 
0.18 0.06 
3.32 
0.41 1.05 
0. 24 0. 63 
0. 39 
4.10 7.96 
0.49 0.97 
0.51 
0.41 0.78 
0. 48 0. 89 
0.53 
0.04 0.09 
0.59 
0. 54 
1.09 
NS 
NS 
0. 001 
NS 
NS 
NS 
0. 008 
NS 
NS 
NS 
NS 
NS 
Eleven subjects agreed to continue recording for an 
additional cycle. An analysis of variance for cycle 3 and 
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cycle 4 for mood symptoms (table 7-7) indicates there are no 
significant differences between cycles. Mean scores (sd) were 
411 (59.7) and 429 (67.0) for cycle 3 and 4 respectively. The 
significant difference between phases was expected given the 
significant phase main effect found in the ANOVA for mood 
scores in both control and placebo cycles. 
SOURCE 
cycles 
error 
phase 
error 
Table 7-7 
ANOVA SUMMARY mood scores across phase for cycles 
three and four (control subjects) 
SS df MS F P 
3636. 4 1 3636. 4 1. 77 NS 
20531.6 10 2053. 2 
160809. 1 1 160809.1 14. 80 0. 003 
1086613.9 10 10866.1 
cycles*phase 44. 13 1 44. 13 13, 132 NS 
error 19574.13 113 1957, 4 
Physical symptom scores similarly show no significant 
differences between cycles 3 and 4. Mean scores (sd) were 
1.27 (0.79) and 1.27 (1.24) for cycle 3 and 4 respectively. 
The significant difference between phases was again expected 
and not central to the aim of this analysis. 
SOURCE 
cycles 
error 
phase 
error 
Table 7-8 
ANOVA SUMMARY physical symptom scores across 
phase for cycles three and four (control subjects) 
SS df MS F P 
0.0003 1 0.0003 0.00 NS 
6. 0223 10 0. 6022 
38. 7657 1 38.7657 28. 22 0.001 
13.7368 10 1.3737 
cycles*phase 0. 4602 1 0. 4602 2. 50 NS 
error 1.8422 10 0.1842 
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A second set of analyses was carried out on the fourth 
cycle alone. The eleven control subjects were compared to the 
nineteen subjects who began placebo. Mood scores for this 
cycle (table 7-9) continued to show a significant difference 
between phases, but there were no significant differences 
between control and placebo s~bjects, nor ~ny strong evidence 
for a phase specific treatment effect. The treatment*phase 
interaction however showed a nonsignificant trend (p=0. 144) 
which is illustrated by the mean scores (sd). These were 488 
( 81), and 370 (93) for control subjects over phase 1 and 2 
respectively. and 453 (77) and 400 (123) for placebo treated 
subjects in phases 1 and 2 respectively. These differences 
were nonsignificant but in the expected direction. 
Table 7-9 
ANOVA SUMMARY mood scores across phase and 
treatment (month four) 
SOURCE 
treatment 
error 
phase 
phase*treatment 
error 
SS 
98 
346869 
1133763 
14819 
183777 
df MS 
1 98 
28 123888 
1 1133763 
1 
28 
1 4819 
6563 
F 
9.91 
15. 81 
2. 26 
p 
NS 
e. 131313 
NS 
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For cycle 4, physical symptom scores are similar to that 
for mood. A significant difference occured between phases, 
but neither treatment nor treatment*phase interaction was 
significant. Mean scores (sd) were 13.44 (13.85) and 2.11 
(1.75) for control subjects in phases 1 and 2 respectively, 
and 13.41 (13.44) and 1.65 (1.11) for placebo treated subj ects 
in phases 1 and 2 respectively. Again this nonsignificant 
difference is in the expected direction. 
SOURCE 
treatment 
error 
phase 
Table 7-113 
ANOVA SUMMARY physical symptom scores across 
phase and treatment (cycle 4) 
SS df MS F P 
8. 828 1 8. 828 e. 52 NS 
44.517 28 1. 589 
29.7132 1 29. 7132 44. 11 13.13131 
phase*treatment e. 6313 1 8. 6313 e. 94 NS 
error 18. 855 28 8. 674 
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7-3-4 Interview Data 
7-3-4-1 First and Second Interview 
The first and second interview scores were used, to 
examine the stability of such scores over time, The predictor 
variables or first set were scores on interview one; (1) self 
rating scale (SRS(1», (2) observer rating scale (ORS(n), 
(3) visual analogue scale 1 month (VAS1(1», and (4) visual 
analogue scale, 6 months (VAS6( 1», Variables in the second 
set, the criterion set, were score at interview two; (1) 
SRS( 2), (2) ORS( 2), (3) VAS1( 2), and (4) VAS6( 2). All 
analyses were run on BMDP6M (Dixon, 1981). 
i Canonical Correlation 
Canonical correlations are presented in table 7-11, 
along with eigenvalues associated with each pair of canonical 
variates. The two sets of variables show significant overlap 
at p<0.05. The first pair of canonical variates accounts for 
61.3% of the variance that is shared by the two sets of 
variables. The second pair accounts for 24.2%. The third pair 
of canonical variates are also significant but accounts for 
only 3.9%. In total. 89.4% of the overlap variance is 
described by the first two canonical correlations. 
Table 7-11 
CANONICAL NUMBER OF BARTLETT'S TEST FOR 
EIGENVALUE CORRELATION EIGENVALUES REMAINING EIGENVALUES 
CHI-SQUARE DF PROB 
55. 16 16 0. 0001 
0.61318 0. 78306 1 20. 50 9 0.0151 
0. 24224 0.49218 2 10.37 4 0. 0346 
0. 03890 0. 19723 3 1. 45 1 0.2288 
To facilitate description of the first two significant 
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canonical correlations (Neufeld 1977), the correlation 
between them and the original variables are presented in 
table 7-12. 
Table 7-12 
Canonical 
variable loadings 
SET 1 
Canonical Correlation 1 2 
SRS( 1 ) 0. 984 -0. 078 
ORS( 1 ) 0. 865 0. 330 
VAS1(1) 0. 279 -0.527 
VAS6( 1) 0. 409 -0. 378 
SET 2 
Canonical Correlation 1 2 
SRS( 2) 0. 777 -0. 258 
ORS( 2) 0.897 0. 392 
VAS1(2) 0. 475 -0. 387 
VAS6(2) 0. 543 -0. 429 
For the first canonical correlation the canonical 
variable loadings for both sets were described primarily by 
the Steiner scales. The canonical variable loadings for the 
other two variables in both sets were moderate. For the 
second canonical correlation, moderate negative correlations 
exist between the VAS scales in both sets, moderate positive 
correlations for the observer rating scale in both sets, and 
a minimal involvement for the self rating scale, again in 
both sets, Each of these canonical correlations are 
orthogonal, but given the nature of the two domains it is 
difficult to determine what features are represented in each 
of the correlations. What doe~Hia,p"fr(~N' is a consistency with 
Cl,I'\T[,RGURY 
N.Z. 
ratings on the Steiner scales. 
ii Multiple Correlations 
Within Sets 
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The squared multiple correlations for each variable in 
the first set with all other variables in the first set. has 
been presented and discussed in study 1. In summary, there 
was a strong relationship between the two Steiner scales and 
the total score, with low multiple correlations for the two 
VAS. 
The multiple correlations for variables in the second 
set (table 7-13) suggest a moderate interrelationship between 
these measures at second interview. 
Table 7-13 
uared Multi e Correlations for each variable in 
the second set with all others in the second set 
variable R2 
SRS( 2) 0.313 
ORS( 2) 0. 405 
VAS1(2) 0. 257 
VAS6(2) 0. 161 
Between Sets 
The multiple correlations for each variable in the first 
set with all variables in the second set, were consistent 
with the results of the canonical correlation analysis. Three 
of the four multiple correlations are significant (table 
7-14). 
Table 7-14 
Squared multiple correlations for each variable in 
the first set with all variables in the second set 
variable R2 F df P 
SRS( 1 ) 0. 600 13. 85 4 37 0. 001 
DRS( 1 ) 0. 501 9.28 4 37 0. 001 
VAS1( 1) 0. 152 1. 66 4 37 0. 180 
VAS6(1) 0. 254 3. 14 4 37 0. 025 
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The multiple correlations for variables in the 
second set with all variables in the first set, are also 
consistent with the information given in the two significant 
canonical correlations (table 7-15). 
Table 7-15 
Squared Multiple correlations for each variable in 
the second set with all variables in the first set 
variable R2 F df P 
SRS ( 2) 0. 423 6. 78 4 37 0. 001 
DRS ( 2) 0.539 10. 80 4 37 0. 001 
VAS1(2) 0. 301 3. 98 4 37 0. 009 
VAS6( 2) 0. 249 3. 07 4 37 0. 028 
iii. Red undanc y I nde x 
The first canonical correlation has a redundancy index 
of 0.30 for the first set, and 0.30 for the second set. The 
second canonical correlation has redundancy indices of 0.03 
and 0.03, for the first and second set respectively. The 
overlap between the two sets of variables accounts for only a 
moderate proportion of the variation within each set. 
i v. Summary 
These results suggest the two sets of interview data are 
strongly related. The first two canonical correlations 
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account for a sUbstantial proportion of the overlap variance 
(85.5%) , and the redundancy index for this suggests the 
degree of overlap is moderate (33% for both sets). The 
squared multiple correlations within and between sets, are 
consistent with the canonical correlations. 
7-3-4-2 Interview two and control cycles 
The aim of this analysis was to examine the relationship 
between the second interview's retrospective ratings, and the 
prospectively collected symptom data, collected for the 
previous three months. The first set of variables were 
SRS( 2), ORS( 2), VAS1 (2), VAS6( 2). The second set comprised 
the mood and physical difference scores for the three control 
cycles. 
i Canonical Correlations 
The two sets overlap significantly (table 7-16), wi th 
the first pair of canonical variates accounting for 54.7% of 
the overlap variance. 
Table 7-16 
CANONICAL NUMBER OF BARTLETT'S TEST FOR 
EIGENVALUE CORRELATION EIGENVALUES REMAINING EIGENVALUES 
CHI-SQUARE DF PROB 
44.84 24 0.006 
0.54652 0.73927 1 16.77 15 0. 333 
0. 36856 0. 60709 2 0.45 8 0.999 
0.01224 0.11064 3 0.01 3 0. 999 
0. 00025 0.01574 
The canonical variable loadings (table 7-17) for the 
first set were described primarily by VAS1 (2), and to a 
lesser degree by SRS( 2) and VAS6( 2). The canonical variable 
loadings for the second set were strongest for mood and 
physical symptoms in cycle 2 (as was found in study 1), but 
in contrast the correlations for the symptom ratings for 
cycles 1 and 3 were greater. 
Table 7-17 
SET 1 
Canonical Correlation 
SRS( 2) 
ORS( 2) 
VAS1(2) 
VAS6( 2) 
SET 2 
Canonical Correlation 
mood symptoms, cycle 1 
physical symptoms, cycle 1 
mood symptoms, cycle 2 
physical symptoms, cycle 2 
mood symptoms, cycle 3 
physical symptoms, cycle 3 
ii Multiple Correlations 
Between Sets 
Canonical 
variable loadings 
1 
B. 316 
13.681 
B. 9133 
13.624 
1 
0. 547 
0. 449 
0. 9135 
0.719 
0. 585 
0. 389 
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The multiple correlations between variables within the 
first set and all variables in the second set (table 7-18) 
are consistent with the results of the canonical correlation 
analysis. VAS1(2) is the strongest component of the canonical 
correlation, followed by the ORS(2). While loading moderately 
on the canonical correlation, VAS6( 2) fails to achieve 
significance, and SRS( 2) was unrelated. 
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Table 7-18 
Squared Multiple correlations for each variable in 
the first set with all variables in the second set 
variable R2 F p 
SRS( 2) 0.06S 0.41 6 3S 0.801 
ORS( 2) 0.4013.916 3S 0.010 
VAS1(2) 0.4675.116 3S 0.002 
VAS6( 2) 0.2421.876 3S 0.139 
The multiple correlations for second set variables with 
all variables in the first set (table 7-19) are also 
consistent with the canonical correlation. It appears that 
the combined battery of interview scales were able to 
retrospectively predict 3 out of the 6 symptom scores, with 
the amount of variance accounted for ranging from 27.4% to 
46. 4%. 
Table 7-19 
Squared Multiple corr~lations for ~ach variable in 
the second set with all variables in the first set 
variable R2 F ~f P 
mood ( cycle 1) 0.173 1. 94 4 37 0.124 
physical symptoms ( cycle 1) 0.274 3. 49 4 37 0.016 
mood ( cycl e 2) 0. 464 8. 00 4 37 0.001 
physical symptoms ( c yc 1 e 2) 0. 284 3. 68 4 37 0.012 
mood ( c yc 1 e 3) 0.188 2.13 4 37 0. 096 
-physical B ympt oms ( c yc 1 e 3) 0. 086 0.87 4 37 0.491 
iii Redundancy Index 
The redundancy index is 0.24 for the first set, and 0.21 
for the second set. The overlap between the two sets of 
variables therefore accounts for only a moderate proportion 
of the variation within each set. 
iv Summary 
These results suggest; (1) the first canonical 
correlation accounted for a moderate proportion of the 
overlap variance (54.6%>, (2) the redundancy index suggests 
the amount of overlap was not great. 
7-3-4-3 Second and Third Interview 
105 
These two sets of interview scores were examined with 
the expectation of no relationship. The treatment effect 
should be reflected if retrospective ratings are sensitive to 
actual events. 
i Canonical Correlation 
The two sets of variables are independent (table 7-20). 
Table 7-20 
CANONICAL NUMBER OF 
EIGENVALUE CORRELATION EIGENVALUES 
0.42881 0. 65483 1 
0.22787 0.47736 2 
0.09188 0. 30312 3 
0.01980 0. 14070 
ii Multiple Correlations 
Within Sets 
BARTLETT'S TEST FOR 
REMAINING EIGENVALUES 
CHI-SQUARE OF PROD 
22.91 16 0.1162 
9. 19 9 0. 4204 
2. 85 4 0.5830 
0. 49 1 0. 4840 
The multiple correlations for interview three (table 
7-21) show a similar pattern to interview one and two. The 
two Steiner scales have the highest correlations with total 
score, VAS1(3) next highest, and VAS6(3) a relatively low 
val ue. 
Table 7-21 
Squared Multiple Correlations for each variable in 
the second set with all others in the second set 
variable R2 
SRS(3) 0. 653 
ORS( 3) 0.674 
VAS1(3) 0. 393 
VAS6(3) 0. 201 
Between Sets 
Both of the multiple correlation analyses for between 
sets show no significant relationships, and are consistent 
with the canonical analysis (tables 7-22, & 7-23). 
Table 7-22 
Squared Multiple correlations for each variable in 
the first set with all variables in the second set 
variable R2 F df P 
SRS( 2) 0. 157 1 . 1 7 4 25 0.3489 
ORS( 2) 0. 201 1. 57 4 25 0.2125 
VAS1(2) 0. 240 1. 97 4 25 0.1294 
VAS6( 2) 0. 194 1. 51 4 25 0.2309 
Table 7-23 
Squared Multiple correlations for each variable in 
the second set with all variables in the first set. 
variable R2 F df P 
SRS(3) 0. 166 1. 24 4 25 0.3187 
ORS(3) 0. 295 2. 62 4 25 0. 0589 
VAS1(3) 0. 031 0. 20 4 25 0.9375 
VAS6(3) 0. 256 2. 15 4 25 0.1037 
iii Redundancy Index 
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Given the lack of significant overlap between these sets 
of variables this index is of little interest. For the first 
canonical correlation the index is 0.08 and 0.12 for the 
first and second sets. 
v Summary 
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There is little relationship between scores at second 
and third interview. This is the expected result given the 
already described significant treatment effect for the group 
as a whole. 
7-3-4-4 Interview Three and Placebo Cycles 
The third interview data were used in this analysis to 
examine the relationship between such data and prospectively 
collected symptom records. It is a replication of analysis 2, 
where the second interview data were related to the control 
cycles. 
i Canonical Correlations 
The two sets do not overlap significantly (table 7-24). 
Table 7-24 
CANONICAL NUMBER OF 
EIGENVALUE CORRELATION EIGENVALUES 
0.54380 0.73743 1 
0.33221 0. 57638 2 
0.10417 0. 32275 3 
0.03546 0. 18830 
ii Multiple Correlations 
Qithin Sets 
BARTLETT'S TEST FOR 
REMAINING EIGENVALUES 
CHI-SQUARE DF PROB 
31.37 24 0.1435 
12.92 1 5 0. 6083 
3.43 8 0. 9043 
0. 85 3 0. 8379 
The multiple correlations within the second set (table 
7-25), suggest there is moderate relationship between the 
various symptom measures taken over time, most particularly 
with physical symptoms in cycles 4 and 5. The degree of 
interrelationship is less than for control cycles, possibly 
because of a differential placebo response. 
Table 7-25 
Squared Multiple Correlations for each variable in 
the second set with all others in the second set 
variable R2 
mood symptoms ( c yc 1 e 4) 0. 198 
physical symptoms ( c yc 1 e 4) 0. 539 
mood symptoms ( c yc 1 e 5) 0. 334 
physical symptoms ( c yc 1 e 5) 0. 613 
mood symptoms ( c yc 1 e 6) 0. 215 
physical symptoms ( c yc 1 e 6) 0. 398 
Between Sets 
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The multiple correlations between first set variables 
and second set total score (table 7-26) are consistent with 
the the canonical correlations with the exception of VAS1( 3), 
which shows a significant multiple correlation with the 
second set, and accounts for 32.7% of such variance. 
Table 7-26 
Squared Multiple correlations for each variable in 
the first set with all variables in the second set 
variable R2 F df P 
SRS( 3) 0.258 1. 33 6 23 0.2871 
ORS( 3) 0. 181 0. 85 6 23 0. 5093 
VAS1(3) 0.478 3. 51 6 23 0.0224 
VAS6(3) 0. 327 1. 86 6 23 0. 1516 
The multiple correlations for each variable in the 
second set and first set total score are consistent with the 
canonical analysis. None were significant (table 7-27). 
Table 7-27 
Squared Multiple correlations for each variable in 
the second set with all variables in the first set. 
variable R2 F df P 
mood ( c yc 1 e 4) 0. 171 1. 29 4 25 0.3021 
physical symptoms ( c yc 1 e 4) 0.075 0. 51 4 25 0.7309 
mood ( c yc 1 e 5) 0.048 0. 32 4 25 0.8640 
physical symptoms ( c yc 1 e 5) 0. 154 1. 13 4 25 0.3635 
mood ( c yc 1 e 6) 0. 299 2. 67 4 25 0.0558 
physical symptoms ( c yc 1 e 6) 0. 133 0. 96 4 25 0.4465 
iii Redundancy Index 
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The redundancy index is 0.17 for the first set and 0.06 
for the second set. The overlap between the two sets of 
variables is a minor proportion of the variation within each 
set. 
iv Summary 
There is little relationship between the scores at 
interview three and placebo cycle symptom scores. Only 
VAS1(3) showed any significant multiple correlation with the 
combined symptom scores. There is less symptom consistency 
between cycles compared with the scores from control cycles. 
7-3-4-5 PMS Distress and Placebo Symptom Scores 
The third interview visual analogue scale ratings of 
Premenstrual Distress for the three placebo cycles (PD1, PD2, 
PD3 respectively), were the first set of variables in this 
analysis. The second set were the prospectively collected 
symptom scores for these cycles (cycle 4 to cycle 6). 
i Canonical Correlation 
The two sets overlap significantly (table 7-28). The 
first pair of canonical variates accounts for 51.4% of the 
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overlap variance. 
Table 7-28 
CANONICAL NUMBER OF BARTLETT'S TEST FOR 
EIGENVALUE CORRELATION EIGENVALUES REMAINING EIGENVALUES 
CHI-SQUARE OF PROB 
29. 99 1 8 0.0375 
0.51377 0.71678 1 12.69 10 0.2416 
0. 26990 0.51952 2 5. 14 4 0. 2733 
0.19276 0. 43905 
The canonical variable loadings (table 7-29) for the 
first set were described primarily by the ratings of distress 
for cycle 5. The canonical variable loadings for the second 
set were best described by a negative correlation with 
physical symptoms in cycle 5. 
Table 7-29 
Canonical 
variable loading~ 
SET 1 
Canonical Correlation 
P01 
P02 
P03 
SET 2 
Canonical Correlation 
mood symptoms, cycle 4 
physical symptoms, cycle 4 
mood symptoms, cycle 5 
physical symptoms, cycle 5 
mood symptoms, cycle 6 
physical symptoms, cycle 6 
1 
0. 027 
0. 990 
0. 115 
1 
0,383 
-0.024 
-0. 088 
-0. 720 
0. 200 
-0,314 
ii Multiple Correlations 
Within Sets 
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The multiple correlations within the first set 
suggest there is almost no relationship between 
retrospectively rated distress in these cycles (table 7-30). 
Table 7-30 
Squared Multiple Correlations for each variable in the 
first set with all other variables in the first set. 
variable R2 
PD1 0. 023 
PD2 0. 023 
PD3 0. 002 
Between Sets 
The multiple correlations between first set variables 
and total second set score (table 7-31) are consistent with 
the canonical correlation in that PD2 (cycle 5) features 
significantly. 
Table 7-31 
Squared multiple correlations for each variable in 
the first set with all variables in the second set 
variable R2 F df P 
PD1 0. 231 1 . 1 5 6 23 0.3500 
PD2 0.509 3. 97 6 23 0.0204 
PD3 0. 238 1. 20 6 23 0.3323 
The multiple correlations between each second set 
variable and all variables in the first set (table 7-32) are 
also consistent with the canonical correlation. The combined 
ratings of PMS distress at best predicts 29.7% of the 
variance of only one of the symptom measures (physical 
symptom scores, cycle 5). 
Table 7-32 
Squared multiple correlations for each variable in 
the second set with all variables in the first set. 
variable R2 F ~f P 
mood ( cycle 4) 0. 199 2. 15 3 26 0.1180 
physical symptoms ( cycle 4) 0. 035 0.31 3 26 0.8147 
mood ( cycle 5) 0.133 1. 33 3 26 0. 2872 
physical symptoms ( cycle 5) 0. 297 3. 67 3 26 0.0250 
mood ( cycle 6) 0.197 2.13 3 26 0.1210 
physical symptoms ( cycle 6) 0.123 1.22 3 26 0. 3240 
iii Redundancy Index 
The redundancy index suggests that the overlap is a 
minor proportion of the variance within each set (0.17 for 
the first set, and 0.07 for the second set). 
i v Summary 
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The first canonical correlation accounts for a 
significant proportion of the overlap variance (51.4%), but 
the redundancy indices suggest- the degree Of overlap is small 
(0.17 and, 0.07 respecti vely for set one and set two). 
Consistency within sets is low. The one significant canonical 
correlation links a narrow band of the total domains. 
7-3-4-6 Ratings of Treatment Effectiveness and Placebo 
Cycles 
The visual analogue scale ratings of treatment 
effectiveness for the three placebo cycles (TE1, TE2, TE3 
repectively) were the first domain. The second domain was the 
mood and physical symptom scores for those cycles. 
i Canonical Correlation 
The two sets do not show significant overlap (table 
7-33) . 
Table 7-33 
CANONICAL NUMBER OF 
EIGENVALUE CORRELATION EIGENVALUES 
0.53725 0.73298 1 
0. 24654 0. 49653 2 
0.03648 0.19100 
ii Multiple Correlations 
Within Sets 
BARTLETT'S TEST FOR 
REMAINING EIGENVALUES 
CHI-SQUARE DF PROB 
26.18 18 0.0957 
7.69 10 0.6595 
0. 89 4 0.9257 
As with PMS distress, the multiple correlations for 
treatment effectiveness ratings show little consistency 
across cycles (table 7-34), 
Table 7-34 
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Squared multiple correlations for each variable in the 
first set with all other variables in the first set. 
variable R2 
TE1 0. 113 
TE2 0.130 
TE3 0.201 
Between Sets 
The multiple correlations between first set variables 
and total score for the second set are consistent with the 
canonical correlation. None of the variables is significant 
( table 7 - 3 5). Onl y the rat i ng of treatment e ffecti veness for 
cycle 5 approaches significance. This is the same cycle 
represented in the canonical correlation in the previous 
analysis. 
Table 7-35 
Squared Multiple correlations for each variable in 
the first set with all variables in the second set 
variable R2 F df P 
TE1 0. 053 0. 21 6 23 0. 8863 
TE2 0. 436 2. 97 6 23 0.0532 
TE3 0. 306 1. 69 6 23 0.1970 
The multiple correlations for each second set 
variable with all first set variables are also consistent 
with the canonical analysis, with the exception of cycle 6 
mood, which is significant (table 7-36). Treatment 
effectiveness ratings do predict, but only one cycle's mood 
symptoms. 
Table 7-36 
Squared multiple correlations for each variable in 
the second set with all variables in the first set 
variable R2 F df P 
mood ( c yc 1 e 4) 0. 061 0. 56 3 26 0. 6447 
physical symptoms ( c yc 1 e 4) 0. 108 1. 05 3 26 0.3884 
mood ( c yc 1 e 5) 0. 149 1. 52 3 26 0. 2330 
physical symptoms ( c yc 1 e 5) 0. 075 0. 71 3 26 0.5561 
mood ( cycle 6) 0. 307 3. 85 3 26 0.0210 
physical symptoms ( c yc 1 e 6) 0. 032 0. 29 3 26 0.8357 
iii Redundancy Index 
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The redundancy index is 0.19 for the first set and 0.08 
for the second set. The overlap between the two sets of 
variables accounts for a minor proportion of the variation 
within each set. 
i v Summary 
There is no significant overlap between the domains of 
treatment effectiveness ratings and prospectively rated 
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symptoms. There is some predictive power within the first set 
of variables but only for cycle 6 mood. These ratings are 
therefore of limited value. 
7-3-4-7 Treatment Effectiveness and PMS Distress Ratings 
With Placebo Cycles 
The third interview VAS ratings of treatment 
effectiveness overall (TEOA) and premenstrual distress 
overall (PDOA) were the first set in this analysis. The 
second set comprised: - (1) mean mood difference score for 
placebo cycles (psyc4-6), (2) mean physical symptom 
difference score for placebo cycles (phys4-6), (3) mean 
standardized symptom score for placebo cycles (symp4-6). 
i Canonical Correlation 
The two sets do not show significant overlap(table 
7-37) . 
Table 7-37 
CANONICAL NUMBER OF 
EIGENVALUE CORRELATION E I G E 'N V A L U E S 
13.21852 0.46746 1 
13.16058 0.413072 
ii Multiple Correlation 
Within Sets 
BARTLETT'S TEST FOR 
REMAINING EIGENVALUES 
CHI-SQUARE DF PROB 
10. 96 6 0. 0896 
4. 55 2 0.1027 
The multiple correlations for variables within the first 
set suggest little relationship exists between treatment 
effectiveness ratings and ratings of PM distress (table 
7-38) . 
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Table 7-38 
Squared Multiple Correlations for each variable in the 
first set with all other variables in the first set. 
variable R2 
TEDA 0. 131 
PDDA 0. 1 31 
The multiple correlations for the variables within the 
second set suggest there is a strong relationship between the 
symptom measures (table 7-39), This strength of relationship 
is difficult to interpret as the standardised symptom scores 
(symp4-6) were a simple transformation of the mood and 
physical symptom scores. Including the standardised scores 
inflates the relationship between each of the variables and 
total score. Their major value is their function as the 
criterion. 
Table 7-39 
Squared Multiple Correlations for each variable in 
the second set with all others in the second set 
variable R2 
psyc4-6 0. 812 
phys4-6 0. 928 
symp4-6 0. 957 
Between Sets 
The multiple correlations for variables in the first 
set, wi th second set total scores (table 7-40), are 
consistent wit.h the canonical correlations. No overlap or 
predictability exists. 
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Table 7-40 
Squared Multiple correlations for each variable in 
the first set with all variables in the second set 
. 
variable R2 F df P 
TEOA 0.218 2. 42 3 26 0.1084 
PDOA 0. 169 1. 76 3 26 0.1917 
The multiple correlations for each second set variable 
with first set total scores (table 7-41) also reflects the 
canonical correlation, with no relationships evident. 
Table 7-41 
Squared Multiple correlations for each variable in 
the second set with all variables in the first set 
variable R2 F df P 
psyc4-6 0. 011 0. 16 2 27 0.8565 
phys4-6 0. 160 2.57 2 27 0. 0949 
symp4-6 0. 119 1. 82 2 27 0.1813 
iii Redundancy Index 
The redundancy index for the first canonical correlation 
was 0.13 and 0.01 for the first and second set respectively. 
For the second canonical correlation the index was 0.07 and 
0.09 for the first and second set respectively. 
iv Summary 
No relationship exists between retrospective ratings of 
both distress and treatment effectiveness and concurrent 
symptom scores. 
7-4 Discussion 
7-4-1 Method 
Methodological difficulties are plentiful in the study 
of PMS. The study reported in this chapter has taken the same 
steps as were taken in study 1 to minimize these 
difficulties. These include minimal intrusion into the lives 
of the subjects, inclusion criteria which required the 
absence of all but trivial health problems and life 
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stressors, and the measurement of relative change in severity 
of symptoms rather than absolute level. The continued low 
rate of annovulatory cycles avoids rather than confronts the 
controversy about the presence of PMS in such cycles. 
The design chosen was a variation of the traditional 
cross-over design where, rather than following the baseline 
period with both drug and placebo in random first position, 
19 women received placebo only. Some (11) continued recording 
for an additional month. This design was chosen for a number 
of reasons. Firstly, after 3 cycles of recording there was 
resistance to continued recording for another 3 cycles. 
Secondly, the strong possibility of asymmetrical transfer 
effects ( Millar 1983) makes the traditional cross-over 
design only useful if one carefully examines order effects. 
Thirdly, considerable between-subject variablility increases 
the risks involved with reducing the number of subjects. As a 
consequence the lack of order effects found within control 
and placebo cycles was crucial. The fourth cycle of control 
recording for the 11 subjects did not result in a significant 
difference between these subjects and those who had begun 
pI acebot rea t me nt. There were however, nons i gni f i cant trends 
in the expected direction. The lack of significant 
differences between cycles 3 and 4 for the control group 
suggests the additional month of recording does not have a 
significant effect. The most obvious problem was considerable 
variablity shown by subjects, which when combined with 
reduced numbers of subjects, reduced the size of any effects. 
This affects both the comparisons between cycles 3 and 4, and 
within cycle 4 between the control and placebo groups. 
Consequently, the credibility of the design and 
interpretation is dependent upon the lack of order effects 
within the total group. 
7-4-2 Results 
7-4-2-1 Incidence 
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For each symptom type incidence decreased significantly 
under placebo compared with baseline recording. The lack of 
significant variation attributable to group and symptom type 
parallels the results in study 1, and suffers the same 
interpretive problems since groups were constituted on the 
basis of symptom severity. The significant group*mode 
interaction differs from study 1. The decreasing trend across 
severity groups for psychological symptoms raises the 
possibility that treatment, when examined at group*mode 
level, differentially affected symptom type. This effect may 
have been lost in the examination of groups and mode because 
they were respectively collapsed across treatment and mode, 
and treatment and groups. 
Incidence is often calculated independent of which 
symptom type is present in the cycle. Defined this way, 
incidence showed no group or treatment effects. These results 
are similar to study 1 and again indicate that retrospective 
self-rating of severity is a poor indicator of incidence or 
consistency of symptom expression over months. Mean incidence 
is again less than every cycle. 
7-4-2-2 Severity 
The lack of variation across cycles (order effect) is 
similar to study 1. This applies to both approaches used to 
quantify severity. As previously noted, lack of order effects 
was critical to interpretation of treatment effects. Had 
order effects been present (particularly a downward trend 
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over cycles) a spurious treatment effect could have resulted. 
Difference scores for both psychological and physical 
symptoms showed a decline in severity under the treatment 
condition. Results for the other independent variables 
parallel study 1, with mood severity varying significantly 
and consistently with groups. It was unclear whether the 
treatment effect and the group effect for mood scores was the 
result of mid-cycle or premenstrual change. This was examined 
with phase scores. 
The phase score analysis shows mood to be higher during 
placebo than control cycles and to be lower premenstrually 
compared to mid-cycle. The absence of the significant 
variation in mood severity across groups is likely to be the 
result of collapsing across phase. The significant 
interaction between groups and phases supports this, and as 
with study 1 suggests that the source of variation is within 
the premenstrual rather than m~d-cycle sco~es. A similar 
situation exists with treatment. The significant interaction 
between treatment and phase, together with mean scores, 
suggests treatment has its effects upon premenstrual scores 
rather than at midcycle. This also applies to physical 
symptom scores where there was no significant variation 
across groups, mean scores were lower (less severe) under 
placebo and the effect was specific to the premenstrual 
phase. 
7-4-2-3 Interview Results 
Interviews one and two overlap to the extent of about 
30% of the total variance. Within this overlap they are quite 
strongly related but it is not clear which of the interview 
components contribute to this beyond the consistent 
appearance of the two Steiner scales. Given that this was a 
retest three months later, the lack of overlap is 
disappointing, but consistent with other studies (eg., 
Harrison et a1., 1984; Endicott & Ha1breich, 1982). 
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When compared with those symptoms in the cycles 
supposedly reflected in the ratings, interview 2 conclusions 
were similar to those of study 1. The VAS rating severity 
over the previous month was the most powerful predictor of 
overall symptom scores and showed a linkage to the symptoms 
in cycle 2. There was an increase in the amount of overlap 
and the degree to which this overlap is accounted for. To 
this extent the prospective recording may have improved the 
subjects· ability to comply. 
The comparison between the second and third interviews 
suggests they were independent or non-overlapping. This was 
as expected given the significant treatment effect. 
The comparison between interview three and placebo cycle 
symptoms suggested no signific~nt overlap, although again 
VAS1 was the best predictor. 
The ratings of Premenstrual distress for placebo cycles 
compared with symptom ratings for those months, show minor 
but significant overlap. Most of the linkage between these 
domains is negative and between distress ratings and symptoms 
on cycle 5. 
The ratings of treatment effectiveness show no 
significant overlap with the symptom ratings over the 
corresponding period of time. 
The ratings of both overall treatment effectiveness and 
overall distress also show no significant overlap with the 
symptom ratings over the corresponding period of time. 
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CHAPTER EIGHT - SPECTRAL ANALYSIS 
8-1 INTRODUCTION 
The purpose of this study was to explore the use of 
spectral analysis as a means of overcoming methodological 
problems associated with cyclicity in the diagnosis of PHS. 
The aims were as detailed below. 
1. To directly establish the presence or absence of 
cyclicity at the period equivalent to the menstrual cycle. 
Previous studies have established cyclicity by a variety of 
techniques, each varying in the degree of adequacy. 
Inadequate studies do not provide supporting evidence for the 
existence of cyclicity (eg., Backstrom 8. Hattsson, 1975), and 
measure symptoms during one fixed period in the cycle (eg. 
Graham, Harding, Wise, 8. Berriman, 1978). 
The use of the difference between follicular and 
premenstrual scores (0' Brien et al) is more acceptable. 
However interpretation is limited in that mid-cycle 
(follicular) variablity cannot be separated from premenstrual 
variation (chapter 6; Sampson and Prescott, 1981). A recent 
alternative procedure uses cycle phase as an independent 
variable and the presence of a phase main effect as evidence 
of cyclicity. The disadvantages of these approaches are the 
, 
need to analyse group data (Parlee, 1973; Kruse 8. Gottman, 
1982), and the impact of autocorrelation on levels of 
significance (Gottman, 1981). 
The most sophisticated alternative uses a fitted sine 
wave to describe prospectively collected data (Sampson 8. 
Jenner, 1977). This approach does not avoid all the 
difficulties. The assumption of deterministic rather than 
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stochastic variation is not a serious threat when examining 
one cycle. However serious reduction in goodness of fit is 
likely if more than one cycle is used. This is a problem if 
symptom expression is not expected to be constant over 
cycles, and several cycles are therefore collected to provide 
a stable baseline. Other unused techniques, such as fitting 
polynomials, involve similar problems. A further problem is, 
if one assumes deterministic cycles and constancy of 
expression, one must also ignore the possibility of 
non-menstrual stressors generating symptoms during the 
premenstrual phase. 
Spectral analysis (see Chapter 5) overcomes these 
problems and provides a method of directly assessing 
significant cyclicity. 
2. To provide another way of examining the issues of 
retrospective diagnosis and modifying negative expectations 
(chapters 6 & 7). A direct comparison of ANOVA and spectral 
analysis approaches is of inte'rest for two reasons. Firstly, 
analysis at the individual level prevents the loss of 
theoretical and practical significance induced by averaging 
across heterogenous subjects (Parlee, 1973; Kruse & Gottman, 
1982). Some empirical support exists for the advantages of 
time series analysis over analysis of variance (Ward et al., 
1983; Dahlstrom, 1983) 
3. To use Spectral analysis to investigate the existence 
of other cycles such as weekly, and the relationship between 
symptom types. Of particular interest was the distinction 
between psychological and physical symptoms. These two 
categories of symptoms are frequently treated differently. 
Some authors emphasise psychological symptoms (Wetzel et aI, 
1975; Haskett et aI, 1984), others emphasise physical 
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symptoms such as oedema and weight gain (Janowsky et al., 
1973) This dichotomy is also illustrated in Steiner et aI's 
(1980) approach where physical symptoms are included in the 
rating scales but not in the Research Diagnostic Criteria. 
Spectral analysis will be used as an exploratory method, 
where there are few grounds for ~ priori models 
(Jenkins & Watts, 1968). 
8-2 METHOD 
8-2-1 Introduction 
The data generated for study 2 were used in the analyses 
presented in this chapter. The subjects, procedure and 
instruments were the same as described in chapter 7. 
8-2-2 Analysis. 
For control and placebo cycles each subject's daily mood 
and physical symptom scores were analysed using BMDP1T 
(Dixon, 1981>. Files were visually examined in order to 
reject cycles with more than 5 days missing from the 
premenstruum, and then missing' values were replaced using the 
programme's default linear interpolation method. This was 
rare as most subjects either ceased recording or missed at 
most two or three points per cycle. Data preceeding the 
beginning of the first menstrual period were removed, as were 
any data from the incomplete cycles at the end of the study. 
Ihl.J 
Defaul t bandwi dths at 8, 3n ", and n 3 degrees of freedom (n 
bei ng the number of observati ons) were accepted, but 
1t3 • t generally 3n was ln erpreted as a compromise between 
resolution and stability. Log transformations of spectral 
density were plotted, as this results in equal length 
confidence intervals for all frequencies (Dixon, 1981>' The 
significance of peaks in log spectral density were assessed 
using the technique described in Kruse and Gottman (1982) and 
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Koopmans (1974). I n the bi variate analyses of mood and 
physical symptoms, the confidence intervals for coherence 
were calculated by the method suggested by Jenkins and Watts 
(1968). A critical level was established to ensure there was 
no overlap between the 95% confidence intervals around it and 
a coherence of 2ero. Coherence was interpreted provided it 
exceeded this critical level and there were significant peaks 
in the respective spectral density functions. Phase and slope 
of the phase plot were interpreted, provided coherence 
exceeded the critical level and there were significant peaks 
within both of the spectral density functions (Gottman, 1979; 
1981>. 
8-3 RESULTS 
8-3-1 Overview 
Spectral density analysis results will be presented in 
detail for one subject (54) as an illustration of an 
individual analysis. The rest of the results will be 
interpreted and presented acco~ding to the aims listed above. 
The raw data graphs and spectral density material for 
remaining subjects are presented in appendix 5 and 6. 
The actual menstrual cycle lengths, wi th means and 
standard deviations, are presented in table 8-1. The range of 
these values was between 23.3 and 34.6 days. Therefore, in 
interpreting the spectral density, peaks occurring within 
this range were accepted as being menstrual cycle congruent. 
subject c1 c2 
B1 24 22 
B2 27 26 
B4 25 24 
95 31 27 
97 33 25 
98 26 25 
19 27 29 
11 19 26 
14 25 23 
15 26 26 
16 23 25 
17 39 39 
18 28 31 
29 28 25 
21 24 23 
25 23 26 
29 24 23 
39 26 25 
32 26 24 
35 28 25 
36 27 26 
37 31 31 
38 22 22 
39 31 26 
44 24 26 
45 27 25 
46 29 24 
48 27 25 
49 28 33 
59 25 24 
Table 8-1 
Menstrual Cycle Length 
( days) 
c3 c4 c5 c6 c7 c8 mean 
cont c. 
25 26 23 23 23. 7 
25 28 24 26 26 26. B 
22 26 23 26 24 25 24. 3 
29 27 31 27 28 28. 5 
27 25 39 27 28.3 
26 27 27 25 27 25. 7 
28 29 24 29 28. 3 
28 27 24 29 24.3 
24 23 24 25 25 23. 8 
27 27 27 28 26. 3 
22 26 24 28 23. 3 
33 32 44 28 31. 9 
32 26 34 26 39. 3 
27 24 26 32 26. 7 
24 24 23 23 23 23.8 
25 23 23 25 24 24. 3 
25 25 26 25 24.9 
23 24 24 24 24 24. 5 
22 24 28 23 24. B 
39 32 28 29 31 27.7 
25 23 39 19 26. B 
39 31 31 31 31 39.8 
24 22 24 24 22. 7 
28 26 27 28 2B.3 
26 25 28 24 25. 3 
26 26 25 25 26 26. 9 
24 23 24 26 25 25.9 
26 39 26 27 24 27.B 
28 28 25 26 29.7 
24 25 25 26 24.3 
£1 = cycle one, £! = cycle two etc. 
s d mean 
cont c. plac c. 
1. 57 24. B 
1. BB 26.9 
1. 71 24. 5 
1.92 28. 7 
4.16 27.3 
9. 58 26. 5 
9.96 28.9 
4. 73 26. 7 
9. 96 24. 7 
B. 58 27.3 
1. 53 26.B 
2. 98 34.6 
2. 98 28. 7 
1. 53 27.3 
9. 59 23.9 
1.59 24.9 
1. 99 25. 3 
1. 29 24.9 
2.99 25.B 
2.52 39.9 
1.99 24.9 
9. 59 31.9 
1. 16 22. 7 
2. 52 27.9 
1. 16 25. 7 
9. B2 25. 3 
2. 71 25. 9 
2. 16 25. 7 
2.89 26. 3 
9.58 25. 3 
cont c. = control cycles. plac c. = placebo cycles. 
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s d 
plac c. 
1. 73 
1. 63 
1. 29 
2. B8 
2. 52 
2. 9B 
2.99 
2. 52 
9.58 
B. 58 
2. BB 
8. 33 
4. 62 
4. 16 
9. B9 
1. 99 
9. 58 
9.BB 
2.65 
1. 83 
5.57 
9.B9 
1. 16 
1. B9 
2.98 
9. 58 
1. 99 
1. 53 
1. 53 
9.58 
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8-3-2 A single subject analysis 
Daily mood scores (fig. 8-1) showed a decrease in mood 
or feelings of well being, around the onset of menstruation 
in most of the seven cycles. The exception was cycle 2 under 
placebo where the decrease was minimal and not clearly 
discriminable from mood scores reported for the rest of the 
cycle. It was also apparent that the mood disturbance 
continued or became more pronounced during the first one to 
three days of bleeding eg., the fourth control cycle (fig. 
8-1). A similar situation existed for physical symptoms with 
clear increases around the onset of menstruation and 
continuing for one to three days, with the exception of the 
second placebo cycle. 
The mood and physical symptom spectral densities for 
control cycles showed the same broad outlines (fig. 8-2). The 
significant peaks in both series were broad (9.3 to 102 days 
for mood and 14.5 to 102 days for physical symptoms (table 
8-2) but peak at 26 days. This' was within the range of 
menstrual values and was congruent with 34' s mean (sd) of 
24.3 (1.71) days actual menstrual cycle length. The coherence 
between mood and physi'cal symptoms (table 8-3) was 
significant over the range of 14.5 to 102 days with a peak at 
26 days. This fits with the significant peaks for both series 
in each of the spectral density functions. 
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Figure 8-1 
Mood and Physical Symptoms for Control and Placebo Cycles 
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Figure 8-2 
Spectral Density, Coherence, and Phase for Control 
and Placebo Cycles 
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For control cycles the phase at the peak frequency 
(f=0.0392) was -2.825 which suggests there was a 12 day delay 
at this frequency. This approximates half the cycle and was a 
consequence of the opposite directions in which increased 
severi ty was reflected for mood and physi cal symptoms. The 
slope of the phase plot over the range of significant 
coherence (table 8-3) was -0.2 which suggests that the input 
series (mood) leads but only by 0.03 days. 
For placebo cycles the spectral density functions showed 
similar but less well defined peaks in both the mood and 
physical symptom series (fig. 8-2). The range of significant 
cyclicity for mood (24 to 72 days) overlaped with menstrual 
values but the peak was displaced towards a longer period (36 
days) (table 8-2). This was probably a result of fewer data 
points (72 in placebo as opposed to 101 in control cycles) 
and therefore of no significance. The range of significant 
cyclicity for physical symptoms (9 to 72 days) (table 8-2) 
peaked at 24 days which was congruent with menstrual cycle 
values and the actual mean (sd) menstrual cycle length of 
24.5 (1.29) (table 8-1). The coherence between mood and 
physical symptoms was significant over the range of 23.9 to 
72 days (table 8-3). This fits with the significant peaks in 
the spectl'al density functions for each series. The phase at 
the peak frequency (f=0. 0278) was -2.980 and correspond to an 
aproximately 17 day delay. Again this was a consequence of 
the opposite directions in which an increase in symptom 
seve r it y was scored. The slope of the phas e ove r t he range of 
significant coherence was -3,6 which suggests mood leads by 
approximately 0.6 days. 
TABLE 8-2 
NUMBER OF DATA POINTS (T). BANDRIDTH (Bft), MEAN SPECTRAL DENSITY 
AND SIGNIFICANT CYCLICITY RITHIN SPECTRAL DENSITY ESTIMATES BY 
SUBJECT (S), TYPE OF CYCLE (C=CONTROL, P=PLACEBO), AND TYPE OF 
SYMPTOM (M=MOOD. P=PHYSICAL) 
S CYCLE" T Bit MEAN SP SUM OF PERIOD PEAK HI DF 
SYMPT DENSITY PEAK RANGE PEAK PENTR Q 
1 C/M 74 .8897 5689.9 139358 9.7- 78 25.9 343 112 
C/P .. .. 1.68 47.68 6. 5- 78 25. 9 396 168 
PItt tI II 3268. 8 28626 2. 1- 2. 5 2. 4 123 98 
PIP " " 1. 25 27.34 12 - 72 24 284 78 
2 C/M 89 .9824 14666 382879 12 - 85 42.5 365 98 
CIP " .. 1. 15 31.86 17 - 85 28 355 65 
P/M 108 .9673 19474.5 894849 17 -H14 25.9 578 98 
PIP .. tI 1. 49 48. 17 8 -194 25.9 452 168 
4 C/M 191 .9686 38925 1736259 9. 3-182 26 624 154 
C/P II " 9.84 15.89 14.5-192 26 265 79 
P/M 72 . 9694 31692 . 591999. 24 - 72 36 158 39 
PIP tI tI 9.84 28. 95 9. 9- 72 24 238 89 
5 C/M 123 . 9569 7873 . 356811. 8. 3-125 31. 3 634 219 
C/P .. .. 9.44 8, 13 11. 4- 63 31. 3 258 84 
II .. .. 
" 2.89 6.9- 6. 9 6.4 92 56 
PItt 83 . 9833 4845 . 55847. 12.0- 84 21. 0 159 98 
II tI .. 
" 40992. 5. 9- 8. 4 7.9 118 79 
PIP " II 9.46 9. 88 9. 3- 84 28.0 275 126 
7 C/M 93 .9737 8226. 181579. 11. 9- 95 31. 6 399 98 
CIP tI tI 9.75 15. 12 19.8- 95 31.6 281 79 
tI 
" 
It 
" 13.59 7.3- 15.8 11. 8 251 112 
P/M 88 .9875 6887. 144579. 19.9- 89 26.6 293 112 
PIP .. II 9.58 17.91 8.8- 89 26.6 429 126 
SIG 
.885 
.895 
.85 
.895 
.995 
.995 
.895 
.005 
.995 
.995 
.995 
.995 
.895 
.995 
.995 
.805 
.895 
.905 
.995 
.895 
.995 
.895 
.995 
Cont/-
1 31 
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8 C/M 84 .9833 8613. 298972. 12.9- 84 28. 9 338 98 .995 
C/P " " 2. 36 57.73 12.9- 84 28.9 342 98 .995 
P/M 195 .9667 2162. 93259. 8.1-195 26. 2 694 182 .995 
PIP " " 1. 18 56.99 14.9-195 26. 2 464 84 .995 
19 C/M 121 .9579 9465. 195789. 12. 1 - 29.2 15. 1 156 79 .995 
" " " " 138589. 5. 8- 8. 1 6. 7 295 98 .995 
C/P " " 1. 35 46.94 17.3-129 39. 2 477 98 . 995 
" " " " 19. 17 8. 1- 12. 1 8.9 195 79 .995 
P/M 83 . 9595 1848 . NO PEAKS 
PIP " " 1. 91 12. 71 21.9- 42. 9 28. 9 126 39 .995 
" " " " 12.96 12.9- 16. 8 14. 9 129 39 .995 
11 C/M 81 . 9864 23945 . 716719. 11. 6- 81 27.9 419 98 .995 
C/P " " 1. 93 41. 4 13.5- 81 49. 391 84 .995 
P/M 78 .9897 29355. 686911. 4. 6- 78 25. 9 472 238 .995 
PIP " " 9. 52 NO PEAKS 
14 C/M 98 .9714 7513. 216819. 14.9- 98 24. 5 494 98 .995 
C/P " " 2. 28 69. 22 16.3- 49 24. 5 369 79 .995 
P/M 78 .9897 3829. 81645. 7. 1- 39 13.9 299 149 .995 
PIP " " 1. 23 32. 25 11. 2- 78 25. 9 368 98 .995 
15 C/M 87 .9795 24234. 471419. 11. 9- 69 29. 3 272 112 .995 
C/P " " 1. 17 15. 21 17.6- 69 29. 3 181 79 .995 
P/H 89 .9625 25186. 536939. 13. 3- 89 49. 9 213 69 .995 
PIP " " 1. 16 22.69 13. 3- 89 49. 9 194 69 .995 
16 C/M 77 .9649 17246. 362995. 6. 4- 38 25. 6 219 119 .995 
C/P " " 9. 25 9.84 4. 5- 4. 8 4. 6 34 29 .95 
PI M 77 .9999 7779. 51329. 25.6- 77 38. 5 92 42 .995 
" " " " 68875. 7.9- 15. 4 12. 8 124 84 .995 
PIP " " 9. 99 9. 53 19.3- 77 25.6 89 56 .925 
" " " " 1. 93 3. 5- 4. 8 4. 9 155 98 .995 
17 C/M 199 .9799 8943. 153999. 14.9-109 25.9 239 98 .995 
C/P " " 1.07 23.99 29. 9-199 33. 3 344 79 .995 
Cont/-
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P/M 193 .9481 7865. 113858. 25.9-194 52.1 145 49 .995 
II .. .. 
" 63638. 6. 5- 9.5 7. " 81 69 .95 
PIP .. .. 9.69 23.23 29. 8-194 44. 335 59 .995 
18 elM 191 . 9686 969 . 21917. 8. 5-192 34. 397 168 .995 
.. II .. 
" 11916. 4. 4- 7.3 6.9 178 149 .925 
elP II II 1. 92 44.33 6.9-192 34. 696 238 .995 
P/M 82 . 9833 553 . 6333. 14.9- 84 28.9 158 84 .905 
II 
" 
.. 
" 5369. 4.2- 5.6 4.8 134 84 .995 
PIP .. " 9. 58 NO PEAKS 
29 elM 87 .9795 6922. 153269. 12.6- 88 29.3 319 98 .995 
.. II If II 56514. 6. 3- 8. 8 8.3 114 79 .995 
elP II II 9. 85 12.96 14. 6- 88 19. 3 214 84 .995 
II .. II .. 11. 33 5.2- 11. 9 8.8 187 149 .995 
P/M 81 . 9617 4969 . 79324. 13. 5- 81 29.2 142 69 .995 
PIP II II 1. 96 25. 54 13. 5- 81 27.9 249 126 .995 
21 elM 193 .9673 21823. 449939. 17. 3- 52 34.7 288 79 .995 
" 
.. 
" " 162789. 5. 8- 7.4 6. 5 194 79 .995 
elP II " 1. 56 27.20 17.3- 52 25.9 244 79 .995 
.. 
" " 
II 8.92 9.5- 11. 6 19.4 72 42 .995 
.. .. .. 
" 7.67 6. 5- 7.4 6.9 69 42 .995 
P/H 68 . 1929 7864 . 84614. 13.6- 68 34. 7 151 79 .995 
.. .. It It 64568. 6. 2 9. 7 7.6 115 79 .995 
PIP It .. 9. 11 9. 69 17. 3- 68 34. 7 76 56 .05 
.. It It It 1. 49 4.9- 11. 3 6. 8 176 126 .095 
25 elM 195 . 9667 6792 . 137479. 17.5-195 34.9 283 84 .995 
It It .. .. 38659. 19.5- 13 11. 6 89 42 .095 
elP II .. 1. 55 U.21 15,9- 53 26.3 363 84 .995 
PIli 71 .9972 5199. 198572. 9. 9- 72 18.9 297 112 .995 
PIP .. II 9. 49 5. 79 9. 9- 18 14.4 162 79 .995 
29 elM 78 .9897 5959. 156893. 7.8- 78 25.9 368 140 .995 
elP .. " 5. 13 162. 49 7.8- 78 25.9 444 149 .995 
Cont/-
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P/M 76 . 9921 H99 . 57727. 9. 5- 76 15.2 183 112 .995 
" 
It .. .. 53639. 4. 8- 7.6 6. 3 179 98 .905 
PIP " .. 1. 60 32. H 8. 5- 76 25. 3 284 126 .905 
39 C/M 197 .9648 7279. 96099. 9.8- 15. 4 13.5 184 79 .995 
C/P " .. 4.96 183. 53 15.4-197 27.0 518 98 .995 
P/M 79 .10ge 2486. 24884. 11. 7- 79 23. 3 149 84 .995 
.. .. .. .. 25599. 5.9- 8.8 6. 4 144 98 .905 
PIP .. .. 4.97 87.92 11. 7- 79 23. 3 399 84 .905 
32 C/M 78 .9641 8688. 83459. 25.9- 78 39 96 30 .905 
.. .. .. .. 123396 . 8.7- 15.6 11. 4 142 50 .905 
C/P " .. 1. 42 12.95 19. 4- 78 25.9 128 30 .905 
or .. 
" 
.. 22.25 7.8- 15.6 13.9 220 60 .905 
P/M 74 . 9933 7443 . 171909. 19.7- 75 25.0 322 98 .005 
PIP " .. 1. 86 53.19 6.3- 75 18.8 499 168 .095 
35 C/M 91 . 0769 4647 . 115499. 7.9- 91 19.1 348 182 .905 
C/P .. .. 1. 48 48.83 7.9- 91 39. 3 462 182 .995 
P/M 119 . 9588 4113 . 55993. 13.9- 69 29. 8 199 98 .995 
.. .. .. .. 45997 . 7.9- 11. 9 8. i3 156 112 .995 
PIP .. .. 9.98 32. 72 11. 9- 69 29.8 469 126 .995 
36 C/K 85 .9824 17839. 412790. 19.6- 85 21.2 324 112 .995 
.. tI .. .. 161469. 5. 3- 8.5 7.9 127 98 .95 
C/P II .. 1. 55 36. 99 10.6- 85 21. 2 334 112 .00S 
P/H 71 .0694 13394. 229978. 7.2- 36 23.9 171 126 .995 
PIP II II 0. 55 19.19 14. 4- 72 23.9 185 79 .99S 
37 C/M 129 .0692 15368. 849214. 19.9-139 32.5 995 234 .995 
C/P .. Of 3.65 297.81 19.9-139 32.5 1926 234 .995 
P/M 93 . 9737 13269 . 489876. 7.3- 95 23.8 S17 182 .995 
PIP It It 4.39 182.84 7.3- 95 23.8 584 182 .99S 
38 C/M 74 .9933 8922. 294453. 5. 3- 75 25.9 462 219 .995 
C/P .. .. 2. 59 84.97 5. 3- 75 25.9 475 219 .99S 
P/H 79 . 1999 4724. 137129. 3. 9- 79 35.9 496 2S2 .995 
Cont/-
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PIP It .. 1.77 58. 36 3.9- 79 17.5 462 252 .995 
39 elM 93 . 9737 16974 . 216449. 7.9- 15. 8 11. 8 179 98 .995 
elP " " 2. 45 51.76 15.8- 95 47 295 84 .995 
P/M 79 . 9875 11938 . NO PEAKS 
PIP .. .. 1.77 31.46 13. 3- 89 26. 6 248 84 .995 
44 elM 83 .9833 19666. 61769. 19. 5- 14 11. 2 81 56 .925 
.. .. It It 65629. 6.5- 8. 4 8.9 86 126 .925 
elP It " 5. 61 173.79 9. 3- 84 28.9 433 126 .995 
P/M 76 . 9921 9319 . 137159. 7.6- 15.2 19.8 296 84 .995 
PIP .. " 9.65 14. 95 9,5- 75 25, 3 322 112 .995 
45 elM 113 . 9614 9593 . 445292. 9.5-114 28. 5 659 168 .995 
elP .. " 1. 21 49. 52 9.5-114 28.5 571 168 .995 
P/M 74 .9933 9233. 271459. 8.3- 75 25.9 412 126 .995 
PIP It " 9. 76 13. 31 8.3- 75 25.9 247 126 .995 
46 elM 199 .9455 12669. 321534. 12.2-110 36. 6 254 99 .995 
elP It .. 2. 55 99.91 13.8-119 55 356 99 .005 
P/M 73 .9933 13393. 131739. 15.9- 75 37.5 139 79 .995 
It .. II .. 85219 . 8. 3- 12. 5 19.7 99 56 .995 
PIP .. .. 2.88 76. 96 9.4- 75 25.9 374 112 .995 
48 elM 116 .9427 3159. 45694. 29.2-117 58 145 49 .995 
" 
II 
" 
It 29587. 14.6- 23. 4 23. 4 71 49 ,925 
elP .. .. 9.28 8.72 13.9- 59 19.5 314 89 ,995 
PItt 76 . 9921 1919 . 23464. 8.4- 76 25. 3 171 126 .995 
PIP .. It 9.35 9.34 7.6- 76 25. 3 374 149 ,005 
49 elM 95 .9737 15999, 386289. 19. 6 95 23.8 369 126 .995 
elP It .. 1. 52 27. 51 9.5- 95 31. 6 253 149 .995 
.. .. .. .. 15.49 5,9- 7.9 5,9 142 112 .95 
.. II .. .. 13. 29 3, 7- 4. 8 4. 1 122 98 ,95 
P/M 78 .9897 11215. 275679. 9.8- 78 19.5 344 112 .995 
PIP .. .. 9. 33 4. 32 6.9- 11. 1 7.8 185 149 .925 
" 
.. 
.9641 9. 33 4.44 15. 6- 78 39 136 59 .995 
Cont/-
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56 C/M 86 . 0875 1118 . 11 U5. 16.6- 80 40 143 76 .065 
C/P .. .. 0. 32 2.63 16.6- 80 40 113 70 .665 
.. .. 
" " 2.66 4. 7- 6.7 5.7 112 84 .625 
Pili 73 . 0933 808 . 9235. 12.5- 75 25.0 166 84 .605 
PIP .. .. 0. 51 9. 28 3.9- 15 8. 3 253 210 .625 
Table 8..,3 
COHERENCE AND PHASE RELATIONSHIPS RITHIN SPECTRAL DENSITY ESTIHATES 
BY SUBJECTS, AND TYPE OF CYCLE (C=CONTROL, P=PLACEBO). 
S CYCLE PERIOD RANGE PEAK PHASE DELAY AT SLOPE 'LEAD 
TYPE OF SIG. COHo CENTRE AT PEAK PEAK OF INDICATORI 
( DA YS) (DAYS) ( RADS) ( DA YS) PHASE LEAD ( DAYS 
1 CONT 25. 9 - 78 39 2. 936 18. 6 4. 8 PHYS/0. 8 
1 PLAC 7.2 7.2 -- -- -- ---
2 CONT 21. 2 - 43 28. 3 2. 700 13 2. 8 HOOD/0. 5 
2 PLAC 17. 3 - 35 25.9 2. 482 10. 2 10.6 HOOD/1.7 
4 CONT 14.5 -102 26 -2.825 12 0. 2 HOOD/0.03 
4 PLAC 23. 9 - 72 35. 9 -2.980 16. 6 3.6 HOOD/0.6 
5 CONT 9.6 - 42 31. 5 3.073 15 ---
5 PLAC 3. 4 - 4 3. 7 -- -- -- ---
7 CONT 19 - 95 31 -2. 728 14 5. 2 HOOD/0. 8 
7 PLAC 11. 4 - 80 26. 6 3.076 1 3 7.2 HOOD/1.2 
8 CONT 16. 8 - 84 28. 0 2. 788 12. 5 9. 1 PHYS/1.5 
8 PLAC 21. 0 - 53 34. 9 -3.051 16. 9 4.6 PHYS/0. 8 
10 CONT --- -- -- -- -- ---
10 PLAC --- -- -- -- -- ---
11 CONT 20. 2 - 81 40. 5 -3. 050 19. 6 5. 5 HOOD/0.9 
11 PLAC --- -- -- -- -- ---
14 CO NT 19. 6 - 98 49. 0 3.037 23.7 0 ---
14 PLAC --- -- -- -- -- ---
1 5 CONT 29. 3 - 44.1 44. 1 2. 518 17. 6 8. 1 PHYS/1.3 
15 PLAC --- -- -- -- -- ---
16 CONT --- -- -- -- -- ---
16 PLAC --- -- -- -- -- ---
17 CONT --- -- -- -- -- ---
17 PLAC --- -- -- -- -- ---
18 CONT 20. 4 -104 34. 0 -3.078 16. 6 1 . 6 HOOD/0. 3 
Cont/-
1 37 
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18 PLAC --- -- -- -- -- ---
20 CO NT 29.3 - 88 44.1 2. 629 18. 4 7.0 HOOO/1.1 
20 PLAC --- -- -- -- -- ---
21 CONT 20. 7 - 34. 7 26.0 3. 128 12.9 6.2 HOOO/1.0 
21 PLAC 9. 5 9. 5 2. 714 4. 2 -- ---
25 CONT 21. 0 - 26. 3 21. 0 -2. 436 8. 2 9. 4 PHYS/1.5 
25 PLAC 14.4 - 17.9 17.9 3. 056 8. 7 6.2 HOOO/0. 9 
29 CO NT 19. 5 - 39.1 25.9 -2. 976 12.3 6. 0 HOOO/1.0 
29 PLAC --- -- -- -- -- ---
30 CONT --- -- -- -- -- ---
30 PLAC --- -- -- -- -- ---
32 CONT 8. 7 8. 7 -3. 030 4. 2 -- ---
32 PLAC --- -- -- -- -- ---
35 CONT 10. 1 10. 1 3. 131 5. 0 -- ---
35 PLAC 10. 8 - 14.8 14.8 -2. 364 5. 6 4.8 HOOO/0. 8 
36 CONT 17.0 17. 0 -2. 578 7.0 -- ---
36 PLAC 18.0 18.0 2. 051 5. 9 -- ---
37 CONT 21. 6 -130 32. 5 -2. 885 14.9 0. 7 HOOO/0. 1 
" " 13. 0 - 16.3 14.5 2.474 5. 7 1.2 HOOO/0. 2 
37 PLAC 10.6 - 47.4 23. 8 -3. 010 10. 4 24. 6 HOOO/3.9 
38 CO NT 5. 7 - 37.5 15. 0 -3. 088 7.36 9. 0 PHYS/1.4 
38 PLAC 8. 7 - 70 17.5 2.732 7.6 5.8 PHYS/0.9 
39 CONT --- -- -- -- -- ---
39 PLAC --- -- -- -- -- ---
44 CONT --- -- -- -- -- ---
44 PLAC 12. 6 - 15. 2 15. 2 1. 885 4. 6 0 ---
45 CONT 11. 4 -114 28. 5 2. 964 13. 4 0 ---
45 PLAC 8. 3 - 37.5 15. 0 2. 809 6. 7 ---
46 CONT 22. 0 - 27.5 27. 5 2. 370 10. 4 11. 4 PHYS/1.8 
46 PLAC --- -- -- -- -- ---
48 CONT --- -- -- -- -- ---
Cont/-
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48 PLAC --- -- -- -- -- ---
49 CONT 5.3 - 23.8 23.8 -3.049 11. 5 9 ---
49 PLAC --- -- -- -- -- ---
59 CONT --- -- -- -- -- ---
59 PLAC --- -- -- -- -- ---
8-3-3 Presence Of CYclicity In Control Cycles 
For 22 of the 30 subjects there was clear evidence for 
menstrual cycle congruent cyclicity in mood and physical 
symptoms (table 8-2) ie., subjects 1, 2, 4, 5, 7, 8, 11, 14, 
15, 17, 18, 20, 21, 25, 29, 36, 37, 38, 45, 46, 49, 50. For 
S32 and S48, there is marginal support for menstrual 
cyclicity in mood with the shortest period within an 
acce pt abl e range of val ues. but t he peak at a longer pe r i od. 
Menstrual cyclicity for physical symptoms in these subjects 
is supported. S35 shows the reverse pattern, with clear 
menstrual cyclicity for physical symptoms and the mood 
spectral density function overlapping with menstrual length 
periods but peaking at a shorter period of approximately 10 
days. 
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For five subjects, the pattern of cyclicity is not so 
clear. While showing significant menstrual length cyclicity 
in physical symptoms, SHI, S30- and S44 had significant mood 
symptom cyclicity at periods less than menstrual length. S16 
shows the reverse pattern, with menstrual cycle congruent 
cyclicity present for mood, but very short period cyclicity 
evi dent for physi cal symptoms. Whi Ie S39 showed no 
significant mood cyclicity within the menstrual range, she 
did so for shorter periods. The range of significant physical 
symptom cyclicity included menstrual cycle congruent periods, 
but the peak is displaced towards longer periods. 
If both mood and physical symptoms need to be cycling 
significantly at approximately menstrual cycle length, then 
22 out of the 30 subjects satisfy this requirement. If the 
requirement is for either to be cycling at around this 
period, then all are acceptable. 
No subject showed evidence of line spectra 
characteristic of deterministic cycles but the small number 
of cycles means this would be unlikely. However the broad 
peaks found are characteristic of probabalistic cycles. 
8-3-4 Retrospective Diagnosis 
The adequacy of retrospective self-report of menstrual 
cyclicity in symptoms is confirmed. All subjects showed 
evidence of this in the spectral analysis of the 
prospectively collected data during the control phase. 
8-3-5 Effect Of Treatment Expectations 
1 41 
Spectral density information suggests that 20 subjects 
were not greatly affected by the placebo preparation, which 
was given to alter expectations (S' s 2, 5, 7, 8, 16, 20, 21, 
25, 29, 30, 32, 35, 36, 37, 38, 44, 45, 46, 48, and 49). For 
these subjects there is clear evidence for continued 
significant cyclicity with periods congruent with the 
menstrual cycle. For subjects 4, 5, and 7, the peaks in the 
spectral density function were broader than previously 
observed. This probably reflected the fewer data points in 
placebo cycles for these subjects and the corresponding 
increase in bandwidth and decrease in sensitivity. Subjects 
35 and 36 showed the opposite pattern with the spectral 
density peaks narrower during the placebo condition. This 
again is most likely a reflection of the increase in number 
of placebo data points and narrower bandwidth used for these 
subjects. 
While having significant cyclicity in the range of 
menstrual cycle length, S's 4, 14, 15 and 17 showed shifts in 
peak spectral density value ie., S14 to shorter cycles for 
mood, S4 to longer cycles for mood and S's 15 and 17 to 
longer cycles for both mood and physical symptoms. Again the 
impact of variation in number of data points may well be 
responsible. 
Three subjects did not show evidence of mood related 
menstrual cyclicity in the placebo cycles, whereas they had 
in control cycles (S's 1, 10, and 39). 
Three subjects with control cycle physical symptom 
cyclicity, did not show evidence of this in the placebo 
cycles (S's 11, 18, and 50). 
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An alterative way of assessing the impact of the placebo 
treatment is by looking at the degree of coherence between 
the symptom types. This analysis is discussed in 8-3-6. 
8-3-6 Presence Of Other Than Menstrual Cyclicity 
Many of the subjects exhibited significant cycles with 
periods outside the range of the menstrual cycle (table 8-2). 
A very short cycle, period around 2.4 days, exists for S1' s 
mood scores unde r pI ace boo Mood cycl es wi t h a per i od of 
approximately 7 days were found in S's 10, 18, 20, 21, 36 and 
44 under control conditions and in S's 5, 7 , 18, 21, 29, 30, 
35, 44 and 46 under placebo. For physical symptoms, similar 
weekly cycles existed for S's 10, 16, 20, 21, 49 and 50 under 
control condi tions, and for Sf s 21, 49 and 50 under placebo. 
Longer cycles (which were still shorter than menstrual, ie., 
around 12 14 days) were found for mood inS' s 10, 25, 30, 32 
and 39 under cont rol condi t ions, and for S 16 unde r pI ac ebo. 
For physical symptoms 12-14 day cycles were evident in S' s 7 
and 32 under control conditions, and S' s 10 and 25 under 
placebo. 
8-3-7 Relationship between psychological and physical 
symptoms 
Seven subjects showed significant coherence between mood 
and physical symptoms for both control and placebo conditions 
143 
within the range accepted as being of menstrual significance 
(S' s 2, 4, 7, 8, 37, 38 and 45). Significant coherence 
between mood and physical symptoms, for control cycles, was 
found in S's 1,5,11, 14, 15, 18,213,21,29,46 and 49, but 
this relationship was lost under placebo. No significant 
relationship between mood and physical symptoms was found for 
S' s 113, 16, 17, 313, 39, 48 and 513. A significant relationship 
was found for periods shorter than those accepted as 
menstrual cycle-related for S' s 25, 32, 35 and 36 within the 
control cycles. This short period coherence continued under 
placebo condi ti ons for S' s 25, 35 and 36, but was lost in 
S32. S44 showed no significant coherence in control cycles, 
but developed a short period coherence during placebo 
trea t ment. 
8-3-8 Phase Relationships 
These were interpreted where significant coherence and 
spectral density cyclicity existed. Data series which meet 
these requirements, had phase values at peak frequencies, 
equivalent to a half cycle delay between mood and physical 
symptoms. This delay was calculated by dividing the phase 
value by 2'ITf, and applies to the one frequency. The 
resulting half cycle delay is a direct consequence of the 
opposite directions with which increasing severity is 
reflected in the devices constructed to measure the two 
domains. Therefore the two series approach synchrony. 
The slope of the phase plot over the range of 
significant coherence gives the lead/lag relationship, 
independent of frequency, when divided by 2'IT (Gottman, 
1981). This was able to be interpreted in 24 out of the 25 
coherent series. One series showed evidence of a curvilinear 
pattern over the range of significant coherence and so was 
not used. This analysis suggests that in sixteen of the 
series, mood leads by approximately one day. The remaining 
eight reflect physical symptoms leading with approximately 
the same delay. 
8-4 DISCUSSION 
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The utility of spectral analysis in directly assessing 
cyclicity was demonstrated. The lack of evidence for the 
presence of deterministic cycles is not suprising given the 
variation in length of the menstrual cycles used in the 
analysis. It is clear that if more than one cycle is studied 
to reduce the risk of chance covariation between symptoms and 
the menstrual cycle, then the probabalistic nature of the 
data has to be considered. The alternative of standardising 
cycle length creates additional assumptions about the pacing 
of hormonal events. 
The comparison between the analysis of variance approach 
and spectral analysis highlights the major strengths and 
weaknesses of the latter as a~ analytic tebhnique. The 
strengths come from the individual focus and the direct 
assessment of cyclicity. Frequently, the challenge is in 
selecting subjects who in fact have the disorder. The extent 
to which future symptoms are predictable determines the 
validity of conclusions able to be drawn from intervention 
studies. Having a control group is no safeguard against 
including nonsufferers, nor does it prevent both the control 
and treated groups showing decreases in severity which are 
direct results of inconsistent symptom expression. This is 
not to suggest that subjects who manifest variable symptom 
expression do not have PHS; rather these subjects add to the 
existing confusion, and so should not be included. In using 
spectral analysis three criteria could be used to select a 
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sub g r 0 up. Fir s t 1 y, c 1 ear me n s t r u a 1 c y c 1 i cit yin bot h mo 0 d 
and physical symptoms during the three control cycles is 
required. This produced 22 subjects in the present research. 
Secondly, subjects should not lose this cyclicity when 
treated with a placebo. This reduced the pool to 15 subjects. 
Thirdly, there should be significant coherence between the 
mood and physical symptom series. This further reduced the 
pool to 7 subjects. These are S' s 2, 4, 7, 8, 37, 38, and 45. 
These three requirements are demanding, but would give rise 
to a subject population of known dimensions. 
Another feature of the spectral analysis is the 
identification of significant cyclicities at periods shorter 
than the menstrual cycle. The weekly cycles give rise to 
speculation about the role of social events in determining 
negative symptoms. This is more difficult to explain with the 
approximately fortnightly cycles. However there are obvious 
limitations if symptoms are measured at a limited number of 
points during the cycle, particularly on one single 
occassion. It is possible that any choice of contrast period 
would be contaminated by such cycles. 
The requirement that the mood and physical symptom 
series show significant coherence over the range of 
frequencies associated with the menstrual cycle is the most 
contentious of the three selection criteria. The 
discrimination on the basis of what symptom type is of 
predominant interest is arbitrary and difficult to justify on 
any theoretical grounds. It is possible that subjects showing 
one category of symptom but not the other constitute a 
homogeneous subtype. However the advantage of the coherence 
requirement is that it provides a more general criterion of 
homogeneity and thus fits the broad definition of PHS. 
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The limitations of spectral analysis are twofold. 
Firstly the large number of data points required is a major 
problem. Even ,though the number of points available in the 
present analyses ranged up to 123, this is insufficient. The 
length of the menstrual cycle requires in excess of this to 
fully explore the potential of this technique. If the lack of 
response to placebo was dropped from the selection procedure 
suggested above, the baseline length is still considerable. 
Another feature of this is that none of the series had zero 
power at f=0. This is possibly the result of trend but little 
slope is evident, and the lack of order effects within the 
analysis of variance mitigate against this. An alternative 
explanation is that the limited number of data points results 
in poor discrimination at short frequencies. This raises the 
possibility that long seasonal cycles are present. Given the 
extended period of data collection this is possible. The 
usual method of removing seasonal trends is differencing, but 
this risks removing the short frequency cycles associated 
with the menstrual cycle. 
Secondly, spectral analysis does not provide a direct 
measure of severity. The series either show or fail to show 
significant menstrual cyclicity. This is a major 
disadvantage. Being able to detect a significant reduction in 
severity is useful in evaluating treatments. 
In light of the joint advantages and individual 
disadvantages, the use of both approaches to the analysis of 
Ion g i t u din a I d a t a, i s the mo stu s e f u 1. 
CHAPTER NINE - CONCLUSIONS 
This chapter presents a summary of the findings and an 
appraisal of the shortcomings in the two studies. Where 
appropriate l alternative procedures are identified and 
suggestions for future research are proposed. 
9-1 SUMMARY OF FINDINGS 
9-1-1 Retrospective and Prospective Recording 
Groups differing in retrospectively rated severity did 
not show significant variation in incidence. This was 
independent of whether incidence was calculated for 
mood-related or physical symptom-related PMS. It was also 
independent of which symptom type was present within any 
one cycle. These same groupsl differentiated according to 
retrospectively rated severity did show significant 
differences in severity of mood symptoms when this was 
recorded prospecti vely. Further l these between-group 
differences in mood severity w~re specific to the 
premenstrual phase and did not occur in relation to scores 
at mid-cycle. There were no similar significant differences 
found for physical symptom severity, 
The i n t e r vie w me a sur e SIt a ken at i n t e r vie won e I 
suggested that there was limited overlap between these 
measures and the subsequent symptom records. The most 
powerful predictor of these symptoms was the simple VAS 
rating of the previous month. The descending order from 
VAS1 to VAS6 suggests that accuracy could be a function of 
the amount of time being rated, The comparison between 
interview two and the symptom ratings from the previous 
three control cycles were similar l but showed a greater 
degree of overlap. This may have been function of increased 
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awareness of symptoms as a function of daily recording. 
Interview one and two overlap to the extent of 30% of 
the total variance, with the Steiner scales being 
predominant. Interview three ratings compared with symptoms 
in the placebo cycles showed no overlap, with the VAS1(3) 
predicting best. The consistency of the Steiner scales with 
respect to all but the symptoms in placebo cycles suggests 
these may have been a function of a more constant feature 
of the subjects' perceptions such as Ruble's(1977) 
stereotypic beliefs. 
9-1-2 Negative Expectations 
An attempt was made to counter negative expectations 
by inducing positive treatment expectations via a placebo 
preparation. This decreased the incidence of mood-related 
but not physical symptom-related PHS. Where PHS was defined 
as either of these symptom types being present, predictably 
the placebo had no significant effect. Placebo was 
associated with an increase in premenstrual mood and the 
relative between-group severity differences were preserved. 
There was also a premenstrual decrease in physical symptom 
severity during placebo administration. 
The interview two and three results showed no overlap. 
This supports the presence of a treatment effect and 
suggests that retrospective ratings are to some degree 
sensitive to actual events. 
The spectral analysis suggested 21 subjects .were 
unaffected, in the sense of retaining cyclicity during the 
administration of the placebo. Three subjects showed 
equivocal evidence of being affected, but this may have 
been the result of differing number of data points in the 
respective series. Three subjects showed an significant 
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effect on mood scores and while another three showed the 
same for physical symptom scores. Again this is in the 
sense of no longer showing evidence of significant 
cyclicity. With this technique it is difficult to quantify 
exact changes in severity. 
9-1-3 Statistical Analysis 
The use of an analysis of variance to detect changes 
in severity with treatment and the distribution of 
prospective symptom records with respect to retrospectively 
rated severity. was achieved best by using cycle phase as 
an independent variable. This produced two problems. 
Firstly, this style of analysis collapses across subjects 
thereby losing information about individual subjects. If 
there are good reasons for suspecting heterogeneity within 
subjects, this type of analysis is more difficult to 
interpret, especially where nonsignificant results are 
found. Secondl y, usi ng phase scores in t hi sway provi des 
only indirect evidence for cyclicity. It is possible by 
selecting different definitions of mid-cycle phase to 
either enlarge or minimise the amount of change found 
between it and the premenstrual phase. 
A spectral analysis does provide a direct estimation 
of significant cyclicity or its absence. It also detects 
other than menstrual cycles which could induce confounding 
in other analytic techniques. The ability of bivariate 
spectral analysis to provide both a measure of the linear 
relationship and phase between the two series is a 
strength, particularly in the absence of any theoretical 
rationale for treating the two symptom types entirely 
separately. The ability to analyse the data from an 
individual subject is also useful for selecting subjects 
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showing cyclicity as well as measuring treatment effects at 
this leve1. The limitations of this technique are twofold. 
Firstly, considerable resources are required to collect 
sufficient data on sufficient subjects and to perform the 
analyses. Secondly, while the height of the spectral 
density peak is half the square root of the amplitude at 
that frequency, it is not clear what relationship exists 
between amplitude and clinical severity. To this extent it 
is difficult to evaluate and quantify significant decreases 
in severity. 
9-1-4 Subject Selection 
Although retrospective evaluation of mood severity did 
bear a significant relationship to prospectively measured 
symptoms, this by itself is insufficient reason for 
selecting subjects, because this relationship characterised 
neither incidence nor physical symptoms. Incidence is 
particularly important in light of the consistency of 
symptom expression needed to adequately evaluate any 
treatment strategy. To select a homogeneous subject 
population the parameters that are a result of spectral 
analysis should be used. These are (1) significant 
cyclicity within the menstrual range but not outside of 
this, (2) coherence between mood and physical symptoms, (3) 
the absence of any placebo effect. Screening by means of a 
simple VAS rating of severity of symptoms over the previous 
month would reduce the number of subjects in the first 
instance. 
9-2 LIMITATIONS OF THE RESEARCH 
9-2-1 Subject Selection 
The subjects selected for inclusion represent a biased 
sample. Women prepared to keep daily records are likely to 
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be different from those who are not. The exclusion of those 
on oral contraceptives, while necessary, resulted in a less 
representative sample. No method of recruitment is ideal. 
That adopted in the present studies provided a sample of 
women who, during telephone interviews, convinced the 
interviewer that they suffered from PHS. Subjects were not 
required to be actively seeking treatment from General 
Practitioners or similar medical facilities. This raises 
questions concerning the seriousness of their disorder. 
However, most of the subjects were interested in treatment, 
and became involved in the sudies since they were not 
prepared to approach potentially unfriendly or neutral 
agencies to effect this. It is therefore difficult to gauge 
the actual severity of their symptoms. 
9-2-2 Daily Diary 
Although the daily diary was designed to collect 
prospective data, it in fact provided retrospective data, 
ie., the previous day. There w~s a considerable volume of 
data produced by the short term retrospective ratings used 
in the studies reported in this research. An alternative 
(between four and six ratings of current status each day) 
would have been impractical for both the subjects and 
researchers alike. In the interests of clarity the short 
term retrospective ratings have been referred to as 
prospective to distinguish them from the longer term 
retrospective ratings. 
Using a sample of nonsufferers of similar age to the 
experimental population, the mood VAS scores correlated 
significantly with a validated general mood questionniare 
(HAACL). However these mood scales had the following 
shortcomings: (1) subjects complained about the lack of a 
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suitable scale for rating irritability, The deliberate 
reduction in direct relationship between the mood 
dimensions and well publicised PHS symptoms may have been 
overdone, (2) The request to rate the previous day was 
rated as being too difficult on some occasions by some 
subjects. Considerable diurnal variation made one rating 
seem detached from reali ty for those subjects. (3) The 
sexual interest VAS was inappropriate. It rated change 
rather than level and so was not included in the daily 
summary scores. It was clear that some subjects either 
misunderstood the format of the scale or showed steadily 
increasing or decreasing levels of sexual interest over the 
entire study. 
The physical symptoms contained in the diary covered a 
smaller range of possibilities than for mood, and the type 
of scoring system was less flexible and may have been less 
sensitive to change. 
The daily diary was the sole method of measuring 
symptoms. This reliance upon subject self report has been 
criticised as being inadequate. This criticism comes 
largely from those who seek to explain the lack of 
correlation between self report and so called "objective" 
indices of behaviour. There are poor grounds for expecting 
other than this. For example, the lack of congruence 
between physiologically recorded and self reported levels 
of sexual arousal has been explained in terms of 
differences in the respective processes rather than 
Questioning the truthfulness of subjects. In the alcohol 
literature, where the behaviour under study is available to 
objective measurement, the accuracy of subject self report 
is verified (Sobell & Sobell, 1978), An alternative 
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strategy would be to gather confirmatory ratings from a 
spouse or close companion, as has been attempted with 
headache pain (Kazdin, 1977). The difficulties with this 
are; (1) there is a problem in determining which is 
veridical if the separate ratings do not correspond, and 
(2) there is some evidence to suggest that even close 
associates are not able to accurately determine mood state 
(Irwin et al., 1979). 
One unfortunate aspect of the scoring procedure 
adopted for the daily diary was the scoring of an increase 
in feelings of well being for mood and physical symptoms, 
in opposite directions. The visual interpretation of phase 
would have been enhanced if these had been in the same 
direction. 
9-2-3 Summary Scores 
The summation of all VAS scales into a single mood 
score was necessary to manage the considerable volume of 
data produced. However, this r'esults in minimising the 
position of a subject showing extreme variation on only one 
scale and little change upon the others. 
The use of menstrual days five to fourteen as the 
midcycle phase, was a large period in contrast to 
premenstrual scores. It is possible that in short cycles 
ovulatory disturbance was inadvertantly included whereas 
with long cycles this would not be the case. This could 
have induced a bias against long cycles if the ovulatory 
change was characterised by transient increases in mood. 
9-2-4 Length of Recording 
The ideal length of records is at least six cycles. 
Baseline and intervention would therefore extend over five 
to seven months. The consequences would be major advantages 
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for the statistical analysis particularly by aiding 
resolution in the shorter frequencies and assisting the 
discrimination of menstrual related cyclicity from longer 
periods or trend. It would also avoid the confusion arising 
as a result of inconsistent symptom expression across 
months. It does however induce potential seasonal 
variations and expose the subjects to many more social and 
psychological stressors, as well as being demanding thus 
potentially further biasing the final sample. 
9-3 SUGGESTIONS FOR FURTHER RESEARCH 
There are four major classes of further research 
needed. 
(1) The empirical investigation of subtypes, 
particularly the differentiation between 
irritability/hostility and predominantly 
depression/dysphoria as major symptoms. This would involve 
reducing the emphasis upon biological verses psychological 
subtypes that has been explicit in much previous research, 
and the instead increasing the emphasis upon accurate 
identification and the delineation of treatment-subtype 
interactions. 
(2) Implied in (1), but of critical importance is the 
need to improve procedures for identifying and selecting 
subjects, and the methods for analysing the prospective 
data. The procedures for subject selection, measurement and 
analysis, suggested by the research reported in this thesis 
would assist both the rational evaluation of treatments and 
the further exploration of subtypes. An additional method 
of analysis which is ideally suited to evaluating treatment 
effects is time domain modelling. The intensive analysis of 
multiple data series, involving a number of the biochemical 
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substances proposed as causative as well as prospective 
symptoms, could be usefully analysed using both frequency 
and time domain techniques. 
(3) Limitations in the execution of the research 
reported here suggest some smaller topics of interest. The 
importance of consistent expression of symptoms is 
reflected in the need to investigate accuracy of 
retrospective self report of incidence. It would also be 
valuable to investigate the relationship between 
self-reported symptoms and the reports of significant 
persons in the subjects' enviroment. This would also have 
implications for the debate over what degree of severity 
warrants treatment. 
(4) The development and evaluation of treatment 
derived from a psychological perspective, such as self 
management involving cognitive strategies, has not yet been 
attempted. This is consistent with the reduction of 
emphasis on the arbitrary distinction betwe~n psychological 
and biological symptoms suggested in (1) and could serve to 
highlight interrelationships. 
Ultimately the value of the research reported in this 
thesis will be determined by the degree to which it is 
used. As always, it marks a beginning rather than an end. 
15 § 
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Appendix 1 - Daily Diary 
Date NaI'Te: ••••••• """ •• " •• ".""".".",,.,,",, •• 
Weight today (before dressing) 
" .- " " " " " " " " " " " " . " " " " " " 
Did you take any pills or medicine in the last 4 days ....•..•••••.••••• 
If you did, what was the name of the medicine (or pill) ••••••••••...••• 
aIlCi the dose "" .. ""."".,,""""""" am the t~s taken "".,,"""",,""""""""""""" 
Below are sane statements concerning your feelings. Please put a cross 
at the position which closest to the way you felt. 
I Yesterday 1 
1 . H<.:IW happy were you? happy 
2. H<.:IW tired did you feel? exhausted 1...---. 
1 B 1 
W1happy 
energ~tic 
3. confident h I How confident did you feel? ope ess , 
4. very tense calm & rela..'{ed How tense or worried were you? ~j __________________________________________ ~ 
5. 
6. 
7. 
How did you towards other people? 
friendly 
I 
How difficult was it to concentrate? 
difficult 
! 
How easy was it to get things done? 
ea)'y 
8. was there a change in level of sexual interest? 
Decrease 
Next a:me sane questions. Please tick the correct box. 
(i) Did your period start? 
(ii) Did you have period pains? 
(iii) were you menstruating? 
Sate nnre questions. Please tick the box that applies best to you. 
(a) were your breasts te.ooer? 
(b) Did you feel bloated? 
(c) were you constipated? 
(d) Did you have a headache? 
(e) Did you have any food cravings? 
Finally is there anything else you would like to say about yesterday_ 
hostj.le 
Increase 
No 
Yes 
Severe 
Appendix 2 - Steiner Self Rating Scale 1 8~ 
SELF RATI'NG SCALE FOR PREMENSTRUAL TENSION SYNDROME 
Name: Date: 
-------------------------------------------
Instructions: The following questions are concerned with the way you feel or act today 
(or the way you felt or acted during the week). 
Please answer ALL questions by circling YES or NO as indicated. 
l. 
2. 
3. 
4. 
5. 
6. 
7. 
B. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
, 17. 
lB. 
19. 
• 20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
2B. 
29. 
30. 
3l. 
32. 
33. 
34. 
35. 
36. 
Do you find yourself avoiding same of your social commitments 
Have you gained 5 or more pounds during the past week? 
Is your co-ordination so poor that ~'ou are unable to use kitchen utensils, 
garden tools or unable to drive? 
Do you feel more angry than usual? 
Do you avoid family activities and prefer to be left alone? 
Do you doubt your judgement or feel that you are prone to hasty decisions? 
Do you feel more irritable than usual? 
Is your efficiency diminished? 
Do you feel tense and restless? 
Do you feel a marked change in your sexual drive or desire during the 
last week. (If YES, is it increased or decreased? 
Are your present physical symptoms causing so much pain and discomfort 
that you are unable to function? 
Have you recently cancelled previously scheduled social activities? 
Do you feel as if you were unable to relax at all? 
Do you feel confused? 
Do you suffer from painful or tender breasts? 
Do you have an increased desire for specific kinds of food (e.g.cravings 
for sweets, chocolate, etc.)? 
Do you scream/yell at family members' (friends, colleagues) more than usual? 
Are you "short-fused"? 
Do you feel sad, glocmy, and hopeless most of the time? 
Do you feel like crying? 
Do you have difficulty completing your daily household/job routine? 
Was there a marked change in your sexual drive with definite change in 
your sexual behaviour during the last week? 
Do you find yourself being more forgetful than usual or unable to 
concentrate? 
Do you happen to have more "accidents" with your daily housework/job (cut 
fingers, break dishes, etc.)? 
Have you noticed significant swelling of your breasts and/or ankles and/or 
bloating of your abdomen? 
Does your mood change suddenly without obvious reason? 
Are you easily distracted? 
Do you think that your restless behaviour is noticeable by others? 
Are you clumsier than usual? 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
Are you obviously negative and hostile towards other people? 
Are you so fatigued that it interferes with your usual level 
Do you tend to eat more than usual or at odd irregular hours 
Do you became more easily fatigued than usual? 
YES NO 
of functioning? YES NO 
(sweets, tDa9ks YES NO 
e c. YES NO 
Is your handwriting different (less neat than usual)? 
Do you feel jittery or upset? 
Do you feel sad or blue? 
Have you stopped calling or visiting some of your best friends? 
YES NO 
YES NO 
YES NO 
YES NO 
Below are two statements concerning premenstrual tension syndrome. please put a cross 
closest to the position you consider best describes your Symptoms. 
1. How severe were your P~IT symptoms this last month? 
absent __________________________ ~_________________ very severe 
2. How severe were your pm symptoms over the past six months? 
absent ______________ ~_____________________________ very severe 
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RATING SCALE FOR PREMENSTRUAL TENSION SYNDROME 
Name: Rater: __________ Date: _______ _ 
Cir~le the llOst appropriate score for each i tern: 
1. 
2. 
3. 
Irritability-Hostility (0-4) 
(Irritable, hostile, negative 
attitude, angry, short-fused, 
yelling & screaming at others) 
o. 
1. 
Not irritable. 
Doubtful, trivial. Not 
reported without direct 
questioning. . 
2. Mild, Occasional outbursts 
of anger and hostile 
behaviour. Spontaneously 
reported. 
3. Moderate, Irritable behaviour 
evident. Frequent outbursts. 
4. Severe. Affects llOSt inter-
actions between patient and 
significant others. 
Tension (0-4) 
(Tense, restless, jittery, upset, 
high-strung, unable to relax) 
o. Not tense. 
1. Doubtful, trivial. 
2. Mild. Reports occasional 
tension. 
3. 
4. 
Moderate. Tense, jittery, 
unable to relax. Restless 
behaviour evident. 
Severe. Constantly tense 
and upset. 
Efficiency (0-4) 
(Decreased efficiency, easily 
fatigued) 
O. No disturbance. 
1. Doubtful, trivial. 
2. Mild. Somewhat reduced 
efficiency . 
3. Moderate. Easily fatigued, 
4. 
gets much less done than usual. 
Severe. Fatigue causes serious 
interference with functioning. 
4. 
5. 
6. 
Dysphoria (0-4) 
(Dysphoric noOO, distinguish fran 
depression) 
O. Not dysphoric. 
1. Sanewhat blue, sad. Elicited 
only on direct questioning. 
2. Mild dysphoric and labile mood, 
spontaneously reported. 
3. Marked spontaneous emotional 
lability; occasional crying; 
feelings of loneliness. 
4. Severe, obvious and persistent. 
!tbtor Co-ordination ( 0-4 ) 
(Clumsy, prone to accidents, lowered 
llOtor co-ordination) 
O. No disturbance. 
1. Doubtful , trivial. 
2. Mild clumsiness, feels awkward. 
3 . Moderate. Frequent" accidents" . 
4 . Severe impainnent in llOtor co-
ordination, e.g. unable to 
write properly, sew, or unable 
to drive. 
Mental - cognitive functioning (0-4) 
(Forgetful, poor concentration, 
distractable, confused, lONered 
judgement) 
o . No disturbance. 
1. Doubtful, trivial. 
2. Mild. Slight forgetfulness 
and distractability. 
3. Moderate. Performance impaired 
by poor concentration, cognitive 
disorganisation, forgetfulness, etc. 
4. Severe. Marked deterioration 
in cognitive capacity, poor 
judgement, leading to 
regrettable decisions. 
cont/-
Appendix 3 continued:-
Eating habits (0-2) 
o . No change. 
1. Mild increase in food 
intake, eating at odd, 
irregular hours, lIDstly 
snacks and sweets. 
2. 
2. Obvious, marked increase. 
Uncontrollable cravings 
for sweets, chocolate, etc. 
Sexual drive and activity (0-2) 
O. No change. 
1. Mild but consistent increase 
or decrease in sexual 
drive, desire, libido. 
2. Marked change in sexual 
drive with definite change 
in sexual behaviour. 
Physical symptoms (0-4) 
(Painful or tender breasts; 
swelling of abdomen, breasts, 
ankles, or fingers; water 
retention; weight gain; 
headaches, low-back pain etc.) 
O. No physical symptoms. 
1. Doubtful or trivial. 
2. Mild. Sane symptoms, 
increased awareness of 
l::x:xlil y changes. 
3. l\bderate. Obvious changes 
and canplaints. 
4. Severe. Physical symptoms 
are incapaCitating. Pain 
and discanfort. Marked 
water retention and 
edema. Weight' gain lIDre 
than 5 lbs. 
10. Social impairment (0-4j 
(Avoidance of social activities 
and interactions with family, 
at hame, at work, at school, 
etc. ) 
O. No social impairment. 
l. 
2. 
3. 
4. 
Doubtful, trivial. 
Mild avoidance of social 
activity. 
l\bderate but obvious 
impairment of social 
activity, mainly noticeable 
at home and with family. 
Severe. Marked impairment 
of most social interactions 
including at work or 
school. Withdrawal, 
isolation. 
Total score: .............••. 
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Appendix 4 - VAS at Third Interview 
Treatment effectiveness: 
Overall 
I 
very effective 
First month 
Second month 
Third month 
Stress level (over last 3 months) 
very stressed 
Willingness to participate In future treatment trials 
I 
very happy to 
How distressing were your PMT symptoms 
First month 
Second month 
Third month 
Overall 
very 
I 
very 
I 
very 
very 
185 
not effective 
little stress 
, 
unwilling 
4 
not at all 
, 
not at all 
not at all 
~ 
not at all 
Appendix 5 
Mood and Physical Symptom scores for Control 
and Placebo Cycles for Each Subject 
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Appendix 7 - Consent Form 246 
PRINCESS MARGARET HOSPITAL 
TREATMENT TRIAL - PATIENT CONSENT FORM 
PROJECT TITLE: 
Investigation of the Premenstrual Tension Syndrome 
INVESTIGATORS: Dr M.G. Metaalf and aolleagues 
AIM OF TRIAL OF NEW TREATMENT OR INVESTIGATION 
To test a modified treatment for premenstrual tension. 
DESCRIPTION OF NATURE AND DURATION OF PATIENT'S INVOLVEMENT: 
During 3 menstrual ayales: 
1. to take a daily dose of pyridoxine in gluaose 
2. to keep a daily reaord of symptoms 
3. to aolleat a weekly speaimen of urine 
DESCRIPTION OF INCONVENIENCES OR HAZARDS WHICH MIGHT BE EXPECTED: 
Nil 
STATEMENT BY PATIENT: 
I have read the above and have had the opportunity for disoussion. I understand 
that the proaedures have been approved by a speaial hospital aommittee and that 
I may withdraw my agreement at any time. I understand that the treatment 
or investigation will be disaontinued immediately if any harmful effeats appear. 
I agree to take part in this study or trial of treatment. 
Signature of Patient Date 
Signature of Investigator 
